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 “An epigenetic trait is a stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence” (1). With this deϐinition, a ϐield of 
research is described that received greatly increasing attention in the last decade (2, 3). 
Because of the increase of efforts in the ϐield of epigenetics, a wealth of information has 
become available. Primarily, changes in epigenetic marks are associated with a change 
in chromatin condensation, altering the accessibility of genes for transcription factors. 
In this way, levels of gene expression are regulated, which is crucial for development 
of organisms and normal functioning of cells. Several processes fall under the term 
‘epigenetics’: whereas more and more is discovered about the functions of non-protein 
coding RNAs (4), nucleosome positioning and density (5) histone variants (6) and 
prions (7) in epigenetic regulation of gene expression, the most intensively investigated 
epigenetic mechanisms are DNA methylation and histone modiϐications. 
DNA methylation
In mammalian cells, cytosines, mainly when preceding guanines (CpGs), can become 
methylated at their C5 position through the action of DNA methyltransferases (Dnmt1, 
Dnmt3a and Dnmt3b) (8). Whereas Dnmt3a and Dnmt3b are known for executing de 
novo DNA methylation, Dnmt1 is taking care of maintenance of DNA methylation upon 
cell division. CpGs, the main target for DNA methylation in mammalian DNA are often 
present in clusters, called islands. More than half of the genes in vertebrates contain 
such CpG islands (9). If cytosines in CpG islands close to the transcription start site in 
promoters of genes are methylated, of which most is known, this is associated with 
gene silencing through several possible pathways (10). CpG methylation can hamper 
activating transcription factors from binding, the methylated CpGs can be bound by 
methyl binding proteins which recruit co-repressors, or the DNMTs recruit histone 
modifying enzymes, all leading to repression of gene expression. 
Importantly, this DNA methylation is reversible, which might be necessary to activate 
gene expression. Whereas DNA demethylation can occur passively by inhibiting the 
maintenance DNA methyltransferase subsequent to cell division, there is also evidence 
for active DNA demethylation, as reviewed in (11). Until recently it was not generally 
accepted that active DNA demethylation occurs in mammals, even though examples 
have been described of both global and locus speciϐic active DNA demethylation (11). 
For example, the interleukin-2 promoter-enhancer region is demethylated within 
twenty minutes upon stimulation in T lymphocytes. In this short time frame, passive 
DNA demethylation could not have occurred. In another example, the promoter of the 
brain-derived neurotrophic factor is demethylated in post-mitotic cells. Since post-




Although these evidences on active DNA demethylation caused a general acceptance 
of the phenomenon, the exact mechanism remains elusive. In the past years several 
potential mechanisms and associated candidate proteins have been suggested, as 
extensively reviewed (11, 12, 13, 14, 15, 16, 17). Currently, the most acknowledged 
possible pathway of active DNA demethylation is through oxidation of 5-methylcytosine 
to 5-hydroxymethylcytosine by Tet proteins (18, 19). 
Histone modiϐications
The human DNA, consisting of around 3 billion nucleotides comprising 20,000-
25,000 protein encoding genes, covers a length of about 2-3 meters in uncondensed 
state. Thus, for all of this to ϐit into the nucleus of cells in an organized manner, 147 
bp of DNA is wrapped around histone cores. 147 bp of DNA, together with the histone 
core and the interconnecting linker DNA is known as a nucleosome. The density of 
such nucleosomes thus regulates chromatin condensation, also important for gene 
expression regulation. The histone core octamer of nucleosomes consists of two 
dimers of histone H2A and H2B, binding a tetramer consisting of two copies each of 
histone H3 and H4. Importantly, each histone monomer has a protruding N-terminal 
tail which can be posttranslationally modiϐied. Several types of such modiϐications have 
been observed, including methylation, acetylation, phosphorylation and ubiquitination 
(20). Depending on the exact amino acid residue modiϐied but also on the quantity 
of modiϐication marks (up to three methyl groups can be added) and the type of 
modiϐication, such posttranslational modiϐications have been associated with repressed 
or activated genes (21). A nomenclature has been created for describing this list of 
histone modiϐications. First the histone of which the tail is modiϐied is named, then the 
amino acid residue that is modiϐied, followed by the modiϐication and the amount of this 
posttranslational modiϐication that is present (22). For example H3K27me3 represents 
trimethylation of lysine 27 of histone 3. Variants of the histones increase the complexity 
of gene expression regulation even more, executing a variety of inϐluences on gene 
expression (6).
For almost every speciϐic modiϐication there is an enzyme in charge (or more than 
one). Moreover, even for the speciϐic addition or removal of the ϐirst, second or third 
methyl group on one histone tail residue different enzymes can be needed. This list 
of enzymes responsible for inducing (writers) or removing (erasers) posttranslational 
histone tail modiϐications is still extending (23).
Furthermore, there are ‘readers’ that bind to speciϐic histone modiϐications (24). It is 
suggested that these ‘reader’ proteins recognize speciϐic histone modiϐications through 
e.g. their bromodomains or chromodomains and subsequently inϐluence gene expression 




activity but merely recruit enzymes to execute the effect. This suggests the presence of a 
certain histone code, indicating that (combinations of) histone modiϐications determine 
the state of gene expression (25, 26). However, further investigation is necessary to 
determine whether epigenetic marks are indeed instructive for gene expression or if 
they are merely a consequence (27, 28). 
EPIGENETICS IN DISEASE
In the normal situation, epigenetic regulation is especially important in 
development, establishing diversity in cellular phenotypes of an organism despite the 
fact that each cell type has the same genotype (29, 30). In later stages of development, 
the inheritability of epigenetic marks ensures maintenance of the gene expression 
regulation and thereby the phenotype of cells after cell division (31). Interestingly, 
there is also evidence for chromatin to escape the resetting of the epigenetic state in 
the germline, causing transgenerational inheritance (32, 33, 34). This transgenerational 
epigenetic inheritance seems less likely to occur at a broad scale but is probably 
important for e.g. the repression of retrotransposons (33). Recent indications imply that 
transgenerational inheritance of gene expression regulation is likely not so much caused 
by DNA methylation and histone modiϐications as it is by RNA-mediated pathways (33).
However, whether received from a parent or induced by environmental factors, 
errors can occur in epigenetic mechanisms, causing unwanted changes in epigenetic 
marks. Ultimately, such epimutations can lead to aberrant gene expression silencing or 
activation. In addition to the long known genetic mutations, many diseases have now 
been associated with epimutations (35, 36). The research into the role of epigenetics 
in diseases has mainly focused on cancer, where e.g. aberrant silencing of tumor 
suppressor genes causes uncontrolled cell growth (3, 37, 38). Interestingly, as it is now 
known that epigenetic modiϐications play a role in diseases like cancer, the epigenetic 
marks are currently used and developed as diagnostic or prognostic markers (39, 40, 
41). Importantly, epigenetic marks are reversible (42), which provides potential for 
therapeutic intervention. Indeed, various epigenetic therapies have been developed to 
inhibit enzymes involved in DNA methylation and histone modiϐications (42, 43). Thus 
far, mainly inhibitors of DNA methyltransferases and histone deacetylases are in use, 
but inhibitors of other epigenetic enzymes are in development as well (43). Some of 
the DNMT and HDAC inhibitors have been FDA approved and are currently used in the 
clinic for treatment of hematological malignancies (42, 43). Recently, progress has been 
achieved in treatment of solid tumors with epigenetic drugs (44). 
Despite these successes, risks and downsides of these drugs have been suggested as 
well (45, 46, 47). The major risk of epigenetic drugs is that inhibition of the epigenetic 




inducing expression of genes that should remain silenced (Fig. 1a) (48). In addition, 
histone modiϐiers often affect non-histone proteins as well, so upon inhibition of 
these histone modifying enzymes, other processes are affected too (49, 50). Another 
disadvantage is that the currently FDA-approved epigenetic drugs are designed to 
upregulate the expression by acting against silencing epigenetic processes and will 
thus not be applicable to downregulate aberrantly expressed genes. Furthermore, 
whereas the inhibition of DNA methylation by epigenetic drugs is beneϐicial for 
upregulation of, for example, expression of a tumor suppressor gene, the stability 
of the genome is endangered. To be exact, genome-wide DNA hypomethylation 
causes DNA recombination, resulting in instability of the genome (51). Moreover, 
the FDA-approved drugs inhibit epigenetic enzymes and upon clearance of the drug 
the unaffected endogenous epigenetic marks will likely recruit the recovered target 
enzyme. Consequently, the initial prevention of the epigenetic mark will be reset and/
or remaining marks could recruit repressive machinery. 
The temporary nature of the effect of current epigenetic drugs also applies to 
gene-speciϐic approaches like siRNA (degradation of mRNA) and cDNA (introduction 
of the gene of interest). siRNA has to be delivered repeatedly because of the constant 
production of mRNA. Introduction of cDNA into cells only results in expression of this 
one isoform of the gene of interest, causing problems in gene function (52). In addition, 
depending on the promoter used, the gene is expressed in abnormal concentrations. 
Another approach for gene-speciϐic gene expression modulation is Epigenetic Editing.
EPIGENETIC EDITING
In this thesis, the potentials of Epigenetic Editing were investigated. Epigenetic 
Editing is the gene-speciϐic rewriting of epigenetic marks in order to modulate 
expression of endogenous genes (53). This approach has the potential to adverse all 
of the disadvantages of the current epigenetic drugs as mentioned above (Fig. 1b). The 
principal concept of Epigenetic Editing is the fusion of a gene speciϐic DNA binding 
domain to an epigenetic effector domain, thereby forcing presence of the epigenetic 
effector domain on the transcription start site of the gene of interest (Fig. 2). The 
targeted writer or eraser of epigenetic marks can subsequently rewrite the epigenetic 
marks, ultimately leading to gene expression modulation.
The main advantage, obviously, is the gene-speciϐicity of the approach (Fig. 1b), 
caused by engineering DNA binding domains that recognize speciϐically the gene 
of interest. Using such DNA binding domains enables the targeting of virtually any 
(currently undruggable) gene. Furthermore, the (combinations of) epigenetic effector 
domains will cause a change in epigenetic marks, which can be inherited upon cell 




Figure 1. Epigenetic editing is gene-speciϐic
In (A), gene-expression status of tumor suppressor genes, oncogenes and ‘irrelevant’ other genes is 
schematically represented in the healthy situation, in cancer and upon treating cancer cells with (genome-










fused to the DNA binding domain, both up- and downregulation can be envisioned. 
Importantly, the epigenetic interference will lead to expression or repression of all 
isoforms of a gene and expression will be regulated by the natural gene expression 
regulation mechanisms. Another advantage is the targeting of only two alleles of a 
gene, whereas e.g. siRNA needs to act against big amounts of constantly produced RNA. 
In addition to the advantages for using Epigenetic Editing as a therapeutic approach, 
Epigenetic Editing is of interest for investigating fundamental epigenetic questions, for 
example related to cause and consequence of epigenetic marks with respect to gene 
expression (27, 28).
DNA binding domain
For gene-speciϐicity, engineerable DNA binding domains like zinc ϐingers, triple helix 
forming oligonucleotides (54) and TALe domains (55) can be used. In this thesis, zinc 
ϐingers were used, which are found in many natural transcription factors and can be 
engineered to recognize any target sequence of interest (56). One zinc ϐinger recognizes 
three to four base pairs of DNA and a table has been created to identify the zinc ϐinger 
needed to target the triplet of interest (56). Using these modular building blocks (57), 





Depending on the epigenetic marks at the gene of interest and the desired effect, 
many epigenetic enzymes serve as interesting candidates for the modulation of target 
gene expression by fusion to zinc ϐingers. To repress gene expression, enzymes that 
methylate DNA or induce repressive histone modiϐications like H3K9me3 or H3K27me3 
are of interest to fuse to the DNA binding domain, whereas enzymes removing H3K4me3 
or histone acetylation (associated with active genes) could also lead to repression of 
gene expression. To re-activate epigenetically silenced genes, enzymes that perform the 
reverse process can be fused to DNA binding domains. Thus, DNA demethylases or e.g. 
an H3K27 demethylase or a histone acetyltransferase are of interest to fuse to DNA 
binding domains for re-activation of gene expression.
Figure 2. Epigenetic Editing 
Here, the general concept of Epigenetic Editing is schematically shown. A represents the gene-speciϐic 
DNA binding domain, B represents the epigenetic effector domain. Arrows show the writing or erasing of 
epigenetic marks by the fusion protein. (see chapter 2 for more detailed explanation)
recognizing 18 base pairs, from a mathematical point of view a unique address in the 
human genome can be targeted (58). In this way, also the zinc ϐingers recognizing the 
EpCAM promoter, which were used in this thesis, have been engineered (59).
Engineering and testing of zinc ϐingers can also be performed using a zinc ϐinger 
library (60), combined with further optimization (61). The library consists of zinc 
ϐinger proteins fused to a gene expression modulating domain. Thus, the binding zinc 
ϐinger can be traced back by screening for an effect on gene expression of the gene of 
interest. The ICAM-1 zinc ϐinger used in this thesis has been selected in this way and 
further optimized (61).
Much progress has been achieved so far using engineered zinc ϐingers. In fusions 
to transient transcriptional activation domains or nucleases (62) (for gene correction 
purposes) zinc ϐingers have entered clinical trials. Moreover, in fusion to certain 









AIM AND OUTLINE OF THIS THESIS
The overall aim of this thesis is to identify potent writers/erasers of epigenetic 
marks to gene-speciϐically induce expression of epigenetically silenced genes by 
rewriting their epigenetic signatures. For achieving this aim, two questions need to 
be answered; (1) does targeting of the candidate (domain of the) epigenetic enzyme 
result in gene-speciϐic targeted removal of repressive epigenetic marks or induction of 
epigenetic marks associated with active genes and (2) does this subsequently result in 
achievement of re-activation of gene expression.
In chapter 2, previously reported efforts on targeting epigenetic enzymes to 
predetermined sites are reviewed. As described in chapter 2, successful induction 
and removal of epigenetic marks has been achieved by sequence-speciϐic targeting of 
various epigenetic enzymes. This sequence-speciϐic targeting is targeting by fusion to a 
sequence-speciϐic DNA binding domain which is not gene-speciϐic. In addition, several 
of such targeting studies show activation or repression of target gene expression. 
Importantly, few studies report efϐicient gene-speciϐic repression of endogenous genes 
through Epigenetic Editing (63, 64, 65) However, no reports on Epigenetic Editing 
to gene-speciϐically induce gene expression have been published as far as known. In 
addition to the description of effects on epigenetic and gene expression level, in chapter 
2 factors are distilled from the reported studies that are likely to be of inϐluence on the 
efϐicacy of Epigenetic Editing. 
To identify potent enzymes to achieve re-activation of epigenetically silenced genes, 
several experimental set-ups have been used to screen epigenetic enzymes (mainly 
putative DNA demethylases) for their effect on epigenetic marks and gene expression 
in chapter 3. In addition to analyzing genome wide effects upon overexpressing the 
epigenetic enzymes and the use of cotransfection studies to assess untargeted and 
targeted effects of the enzymes, cell systems were used with large integrations of 
repeats of DNA binding domain recognition sites. This large amount of LacO site 
repeats, to which the LacR DNA binding domain can bind, is an interesting system to 
screen for the effect of targeted epigenetic enzymes. First of all, the large repeat of LacO 
sites ensures the presence of a large amount of LacR-targeted epigenetic enzyme in the 
same region. Moreover, the repeats are integrated within the genome of mammalian 
cells, more closely resembling the natural situation of chromatin in a repressed state 
than plasmids.
Towards gene-speciϐic and endogenous targeted effects, in chapter 4 and chapter 
5, the endogenous epigenetic environment of the EpCAM and ICAM-1 gene were 
determined, respectively. Furthermore, the feasibility of re-activating the genes through 
epigenetic mechanisms is assessed using epigenetic drugs. As such, these studies 




epigenetic marks. In chapter 4 the molecular epigenetic marks playing a role in 
regulation of EpCAM expression in ovarian cancer cells are determined. In chapter 5, 
previously suggested epigenetic silencing of ICAM-1 expression in ovarian cancer cells 
is conϐirmed for our panel of cell lines. Subsequently, it is investigated in this chapter 
whether Artiϐicial Transcription Factors, consisting of ICAM-1 speciϐic zinc ϐingers and 
the transient activation domain VP64 (four copies of the viral protein VP16), are able to 
induce gene-expression from the silenced locus. Furthermore, the effect of gene-speciϐic 
induction of ICAM-1 expression on tumorigenicity is investigated. 
In the ovarian cancer cells used in chapter 4 and 5, we showed that the EpCAM 
and ICAM-1 genes are epigenetically silenced. In addition, validated zinc ϐingers binding 
these genes are available (59, 61). Therefore, the combination of these genes and cell 
lines is an interesting model system, uniquely suited to investigate approaches to 
induce expression of epigenetically silenced genes through Epigenetic Editing. Thus, in 
chapter 6, we attempted to induce expression of the epigenetically silenced EpCAM and 
ICAM-1 genes in ovarian cancer cells through Epigenetic Editing by targeting putative 
DNA demethylases or histone modifying enzymes to the target genes. 
In chapter 7, a general discussion of the results obtained in this thesis follows. In 
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Despite signiϐicant advances made in epigenetic research in recent decades, many 
questions remain unresolved, especially concerning cause and consequence of epigenetic 
marks with respect to gene expression modulation. Technologies allowing the targeting 
of epigenetic enzymes to predetermined DNA sequences are uniquely suited to answer 
such questions and would provide potent (bio)medical tools. Towards the goal of gene-
speciϐic gene expression modulation by overwriting epigenetic marks (Epigenetic 
Editing), instructive epigenetic marks need to be identiϐied and their writers/erasers 
should then be fused to gene-speciϐic DNA binding domains. The appropriate epigenetic 
mark(s) to change in order to efϐiciently modulate gene expression might have to be 
validated for any given chromatin context and should be (mitotically) stable. Various 
insights in such issues have been obtained by sequence-speciϐic targeting of epigenetic 
enzymes, as is presented in this review. Features of such studies provide critical aspects 
for further improving Epigenetic Editing. An example of this is the direct effect of the 
edited mark versus the indirect effect of recruited secondary proteins by targeting 
epigenetic enzymes (or their domains). Proof-of-concept of expression modulation of an 
endogenous target gene is emerging from the few Epigenetic Editing studies performed. 
Apart from its promise in correcting disease associated epi-mutations, Epigenetic 
Editing represents a powerful tool to address fundamental epigenetic questions.
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INTRODUCTION
Epigenetics is gaining momentum in nearly all biomedical research ϐields, 
and substantial knowledge of the epigenetic marks (e.g. DNA methylation and 
posttranslational histone modiϐications) and enzymes involved in reading, writing 
and erasing of such marks have been obtained (1, 2, 3, 4, 5). The majority of the data 
reported so far, however, does not provide insights in e.g. the relative importance of the 
marks with regard to gene expression control, nor in the order of events. In general, the 
performed studies tend to be descriptive and epigenetic questions related to cause or 
consequence effects of epigenetic marks with respect to gene expression modulation 
are under debate (6, 7, 8). In light of the fact that such fundamental questions have only 
been addressed in a few studies, including (9, 10, 11), targeting epigenetic enzymes to 
particular chromatin landscapes will provide useful insights. This review sets out to 
summarize the outcome of targeting approaches with respect to the effect of epigenetic 
writers and erasers on the chromatin state and/or on gene expression (Figure 1 and 
tables). 
The general principle of DNA-sequence-speciϐic targeting systems is the fusion 
of (a part of) an epigenetic enzyme to a DNA binding domain (DBD) to enforce the 
presence of this effector domain on a particular DNA sequence (Figure 1). This target 
DNA sequence can be located within an oligonucleotide, a plasmid or integrated in a 
particular chromatin environment in the genome of a cell. In addition to the induced 
epigenetic changes, the effect of targeting epigenetic enzymes on gene expression can 
be assessed by measuring gene expression levels of (reporter) genes that lie in close 
proximity of the DBD recognition site. Most of the reported targeting efforts make use 
of non-mammalian DBDs and (multiple repeats of) their speciϐic recognition sequences 
including the yeast Gal4-UAS system (12), the prokaryotic Tet Repressor (TetR)-Tet 
Operator (TetO) (13), Lac Repressor (LacR)-Lac Operator (LacO) (14, 15) and the 
LexA repressor-LexA operator system (16). Additionally, some mammalian systems 
have been exploited to target enzymes to native endogenous chromatin sites, like the 
Methyl Binding Domain (MBD) of MeCP2 to target enzymes to genomic sites consisting 
of hypermethylated DNA (17, 18), the DBD of Mixed Lineage Leukemia (MLL) to force 
epigenetic enzymes to reside on endogenous MLL target genes (19, 20) and the DBD of 
NFκB to affect NFκB targets (21).
All of the above mentioned systems, however, are somehow limited with regard to 
addressing biologically relevant questions, because of the need to introduce foreign 
DBD recognition sites in the host cells, or because they are not speciϐically targeting 
one unique site in the genome, but multiple endogenous target sites of the DBD. To 
speciϐically bind one genomic address, as explored in Artiϐicial Transcription Factors 




(ZF) proteins (23), Triplex Forming Oligos (TFOs) (24) and the recently described TALE 
domains (25). Indeed, with the recent developments in the ϐield of genome editing 
(where nucleases are fused to sequence-speciϐic ZF proteins to introduce site-speciϐic 
DNA damage: Methods of the Year 2011 (26)), the targeting of epigenetic editors 
(writers or erasers) to a speciϐic gene has come within easy reach.
Figure 1. Targeted rewriting of epigenetic marks
Schematic ϐigure, showing the general concept of targeting epigenetic enzymes. In the middle an example of 
a certain locus harboring a DNA binding domain (DBD) recognition site (black triangle) is shown. Lollypops 
represent either unmethylated (open) or methylated (ϐilled red) CpGs. Histones (yellow circles) and their tails 
(orange) are also represented. Histone tails can be posttranslationally modiϐied and as such are associated 
with a repressed chromatin state (represented by the ϐilled black dots), or with an active chromatin state 
(represented by open black circles). The upper and lower ϐigure show the induced change in gene expression 
by targeting a DBD fused to an epigenetic enzyme involved in changing the epigenetic composition (histone 
modiϐications or DNA methylation), thereby causing gene activation (top) and repression (bottom). In the 
epigenetic enzymes, CD=catalytic domains and RD=recruiting domains are indicated. Black arrows show the 
action of the CD of the epigenetic enzymes, dashed arrows show the possible recruitment of other proteins or 
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The effective binding of the (gene-speciϐic) DBDs to various euchromatin and 
heterochromatin targets has been shown by fusing the DBDs to transcription activating 
or repressive domains (VP64 or SKD, respectively), which recruit other proteins to 
induce (27) or repress (23) target gene expression. Despite their success (22, 23, 28), 
ATFs are likely to function only transiently and gene-speciϐic overwriting of epigenetic 
marks by targeting epigenetic enzymes or domains thereof (Epigenetic Editing) might 
provide advantages with respect to long-term modulation of gene expression. Apart 
from obtaining sustained gene expression modulation, other advantages of Epigenetic 
Editing include upregulation by allowing natural expression mechanisms to occur, as 
opposed to mere overexpression as obtained by gene therapy or ATFs. Moreover, the 
approach of Epigenetic Editing is uniquely suited to investigate functions of epigenetic 
writers and erasers and to elucidate consequences of epigenetic marks at any given 
chromatin environment, providing insights in gene expression regulation mechanisms. 
In this review, an overview of studies on sequence-speciϐic and the few gene-speciϐic 
targeted epigenetic editors will be presented. Also, some points from these studies 
will be highlighted that will further improve gene-speciϐic Epigenetic Editing efforts. 
Although essential information on chromatin behavior has been obtained by targeting 
epigenetic readers as well, this review will only focus on direct modulation of epigenetic 
marks by the implicit targeting of writers and erasers.
GENE EXPRESSION MODULATION WITH TARGETED EPIGENETIC EDITORS
A substantial amount of studies on targeting epigenetic enzymes have provided 
strong indications that epigenetic editors can be targeted to obtain a change in 
gene expression. These studies, as discussed in this review, have been using diverse 
experimental designs ranging from oligonucleotides to endogenous genes in the 
natural chromatin context. Thus far, the observed effects of targeted epigenetic 
enzymes (including histone modifying enzymes) have been mainly obtained by co-
transfection experiments. Such experiments more closely resemble the endogenous 
situation than test-tube oligonucleotides experiments, since the fusion proteins (and 
their target plasmid) encounter endogenous factors that might play a role, or are even 
required, in changing essential epigenetic marks and/or in obtaining gene expression 
modulation. However, the use of cotransfections to analyse the effects of targeted 
histone modiϐiers is subject of debate. Whereas it has been reported that plasmids are 
not suitable for establishing the effects of targeting histone modifying enzymes because 
of the lack of chromatinization (29), others show by ChIP that a molecular effect of 
targeting histone modifying enzymes can be observed, indicating that histones can get 
associated with the plasmid (30, 31). These latter studies conϐirm nuclease-digestion 




34). More informative data, however, can be derived from targeting epigenetic editors 
to exogenous sites (usually including a reporter gene) integrated in the chromatin 
context of cells. Although this approach is also artiϐicial and integrated sites are more 
susceptible to epigenetic silencing, it provides insights in the effect of induced changes 
on the chromatin context and is suitable to address heritability issues. True Epigenetic 
Editing, where a single endogenous gene is targeted, obviously provides the most 
relevant information and the few studies published so far will be discussed in more 
detail.
As described below, although not all of the targeting studies describe effects on 
both molecular epigenetic level and gene expression modulation, some (including the 
Epigenetic Editing studies) clearly indicate the causal relationship between the rewritten 
mark and gene expression modulation. Because of differences in experimental design 
(such as the type of DNA binding domain or design and expression of the construct) it is 
difϐicult to compare efϐicacy of targeted gene expression modulation between studies. 
It is tempting to speculate that an absence of effect on gene expression upon inducing 
a change in one epigenetic mark can be explained by the native chromatin context, 
as exempliϐied by the protection of DNA for CpG methylation when histone 3 lysine 
4 is methylated, which thus might prevent spreading (35, 36, 37). Other marks that 
remain present in the chromatin context of the targeted gene might recruit enzymes to 
restore the initial epigenetic proϐile. In this regard, it is currently unclear if more than 
one mark needs to be changed to facilitate an effective change in gene expression in 
the endogenous situation. Furthermore, the change of more than one epigenetic mark 
could very well be required for heritability of the effect, which would be of importance 
for therapeutic approaches in particular. Nevertheless, as described in this ϐirst part, 
promising results have been obtained by the active change of just one epigenetic mark 
and approaches to further improve Epigenetic Editing arising from such studies will be 
discussed in the second part.
Downregulation of gene expression via rewriting of epigenetic marks
In general, targeted epigenetic silencing has advantages over siRNA approaches, 
which are currently widely exploited for various clinical phenotypes, as reviewed in 
(38), but which are generally transient and suffer from target-independent effects (39, 
40). An alternative (synergistic) approach to downregulate the expression of a gene of 
interest is by Artiϐicial Transcription Factors, which might proof efϐicient as only two 
copies of DNA need to be targeted in every cell, as opposed to numerous continuously 
produced mRNA molecules. Although signiϐicant repression has been achieved for 
various endogenous genes by fusions of ZFs to the KRAB domain (23, 28), the KRAB 
domain does not have enzymatic activities by itself and therefore does not directly 
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interfere with the epigenetic context at the target site. In this respect, direct targeting 
of epigenetic enzymes to endogenous target sequences (Epigenetic Editing) is more 
relevant, both for biological questions as well as for the potential use of Epigenetic 
Editing as a therapeutic approach in the future. In this section, studies on repressive 
effector domains targeted to actively interfere with epigenetic marks in order to repress 
gene expression are discussed.
Targeted DNA methyltransferases 
DNA hypermethylation, especially around the transcription start site and exon 1 (41, 
42), is strongly associated with inactive genes. Moreover, DNA methylation is in principle 
faithfully inherited during mitosis, and has been reported to serve as a strong molecular 
mark for gene silencing memory (43, 44, 45). Therefore, to permanently downregulate 
the expression of a gene, targeting DNA MTases is an obvious choice. Some alternative 
gene-speciϐic technologies to induce DNA methylation have been described, including 
RNA-directed (46) and methylated oligo-induced (47) methylation, but the general 
applicability of such approaches to silence any gene of interest is unclear. Nowadays, 
DBDs can be engineered to speciϐically bind virtually any gene (22, 23) to target 
transcriptional repressors to these genes, subsequently decreasing gene expression. 
Indeed, upon fusion of such engineerable DBDs to the KRAB domain, effective reduction 
of oncogene expression (resulting in reduced tumorigenicity) was shown (28). Thus, 
fusion of DNA MTases to such domains offers an appealing approach for inducing 
inheritable gene silencing. In fact, DNA MTases have been extensively studied in fusions 
to ZFs (Table 1), as also reviewed in (48). 
Indeed, upon targeting by fusion to gene-speciϐic (ZFs or TFOs) or sequence-speciϐic 
(Gal4) DBDs, both the prokaryotic DNA MTases M.SssI, M.HhaI and M.HpaII as well 
as the catalytic domains (CDs) of the mammalian enzymes mDnmt3a and mDnmt3b 
showed efϐicient preferential DNA methylation of target sites in oligonucleotides 
(49, 50, 51, 52, 53) or on reporter plasmids (30, 50, 52, 53, 54) and when assessed, 
the targeted DNA methylation upon cotransfections was correlated to repression of 
reporter gene expression (Table 1). The ability of a ZF fused to a prokaryotic DNA MTase 
to cause preferential DNA methylation at an endogenous mammalian target site was 
observed for M.SssI in the context of yeast chromatin (55). Noteworthy, the ZF binding 
site itself was not methylated, indicating protection from direct DNA methylation by 
the ZF binding. As yeast cells have no endogenous DNA methylation system, targeting 
speciϐicity can be easily investigated. In this respect, this yeast study –as conϐirmed in 
some of the other studies (49, 52, 55)– revealed additional aspeciϐic background DNA 
methylation, which will be further discussed in ‘TOWARDS SPECIFIC GENE EXPRESSION 




To increase speciϐicity of the targeted DNA methylation by prokaryotic enzymes, 
ZFs were fused to less active mutants of these prokaryotic DNA MTases (M.HhaIQ237G 
and M.HpaIIF35H, see also ‘TOWARDS SPECIFIC GENE EXPRESSION MODULATION ǧ The 
effector domain’) (52). In contrast to ZF-M.HhaIQ237G, ZF-M.HpaIIF35H was able to induce 
DNA methylation on its target site, integrated in the bacterial genome. Moreover, 
when targeting a site integrated in the mammalian genome, ZF-M.HpaIIF35H could 
induce targeted DNA methylation as well as downregulation of the reporter gene (56). 
Interestingly, the histone modiϐication state of the ZF target site accordingly changed 
into a repressive state, as an enrichment of H3K9me2 and a reduction of H3K4me3 
was observed at the site of the integrated reporter gene where DNA methylation was 
induced (56). This indicates that active change of one epigenetic mark (in this case DNA 
methylation) can cause a cascade of changes, which might reinforce the repressive state 
of the chromatin at the target gene. Such a reinforced repressive chromatin state could 
explain the observation of remaining DNA methylation at the target site after several 
cell passages. Moreover, the stable DNA methylation state was associated with stable 
reporter gene repression at least up till 17 days after the expression of ZF-M.HpaIIF35H 
was no longer detected at both the RNA and protein level (at 6 or 7 days after transfection 
respectively) (56). This sustained DNA methylation and repression of gene expression 
is indicative of the DNA methylation induced by ZF-M.HpaIIF35H being inherited through 
cell divisions. This study thus provides proof-of-concept that targeted DNA methylation 
Table 1. Targeted DNA methylation editors
: no effect, n.a.: not assessed, : effect reported, : downregulation, : upregulation
DBD; DNA binding domain, EGE; Epigenetic Editing, GEM; Gene expression modulation, ZF; Zinc Finger, TFO; 
Triple helix Forming Oligo.
Enzyme DBD Target EGE GEM References
ǤSss 	 ǡȋȌ 9 ǤǤ ȋͶͻǡͷͷȌ
	 ȋȌ 9 ǤǤ ȋͷͲȌ
ǤHha 	 ȋȌ 9 ǤǤ ȋͷͳǡͷʹǡͷ͵Ȍ
 9 ǤǤ ȋͷʹǡͷ͵Ȍ
ȋȌ 8 ǤǤ ȋͷʹȌ
ǤHpa 	 ǡȋȌ 9 ǤǤ ȋͷͳǡͷʹȌ
ȀȋȌ 9 ǤǤ ȋͷʹȌ
ȋȌ 9 È ȋͷʹǡͷ͸Ȍ
͵	 
Ͷ ȋȌ 8 È ȋ͵ͲȌ
͵ 
Ͷ ȋȌ 9 È ȋͷͶȌ
	 ȋȌ 9 È ȋͷͶȌ
	  9 ǤǤ ȋͷͶȌ
͵ 	  9 ǤǤ ȋͷͻȌ
ȋȌ 9 È ȋ͸ͲȌ
͵ 
Ͷ  9 È ȋͷͶȌ
ͳ 
Ͷ ȋȌ ǤǤ È ȋͻ͵Ȍ
ͷǦ
 ȽǦ ȋȌ 9 Ç ȋͻ͸Ȍ
 ȋȌ ǤǤ 8 ȋͻ͹Ȍ

 	Ɉ ȋȌ 9 Ç ȋʹͳȌ
͸Ͷ 	 ȋȌ 9 Ç ȋͻͺȌ
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can be exploited for sustained gene repression. 
Compared with prokaryotic MTases, mammalian DNA MTases, i.e. Dnmt1, 3a and 3b, 
display several advantages when considered for use in targeted DNA methylation of the 
mammalian genome: Although, like M.SssI, mammalian DNA MTases can methylate all 
CpG sequences without any further sequence-restrictions, the low catalytic activity of 
the mammalian enzymes (57) might better allow restriction of methylation to targeted 
CpGs by fusion to DBDs. In addition, since being mammalian, the MTase activity is 
probably not inϐluenced by DNA-histone interactions that theoretically might hamper 
the prokaryotic DNA MTases, as these originate from histone-less organisms (58). 
Moreover, mammalian enzymes are more likely to recruit other mammalian proteins 
important for reinforcement of transcriptional repression. This is nicely exempliϐied by 
the Gal4-mDnmt3a full length cotransfection study (Table 1): although no detectable 
DNA methylation was induced at the target region by this construct, repression of 
reporter gene expression was observed (30). Recruitment of endogenous co-factors 
has been observed for this and several other epigenetic effector domains and will be 
discussed later. Last but not least, the domain will evoke less immunogenicity since it is 
less foreign to the organism.
The ability to cause preferential DNA methylation at a cellular target site was 
observed for a ZF fused to hDnmt3a CD, targeting mitochondrial DNA (59). In this study, 
23% of the clones analyzed by bisulϐite sequencing showed preferential methylation at 
the cytosine directly adjacent to the ZF binding site (59). Another interesting parameter 
that can and has been addressed in this study is spreading of the epigenetic mark, which 
was observed within a region of at least 120 bp surrounding the ZF target site (59). In 
another study, where DNA methylation was targeted to successfully methylate viral DNA 
upon cellular infection, spreading up to 380 bp on either site of the DBD recognition site 
has been observed (54). However, it is not directly clear whether the observed induction 
of distant DNA methylation in these studies is truly because of spreading or because of 
the ϐlexibility of the targeting construct or the target DNA. 
 Only very recently, the ϐirst gene-speciϐic ZF-targeted DNA methylation was 
reported in the nuclear chromatin context for the tumor suppressor gene MASPIN and 
the oncogene SOX2 (60). Upon this Epigenetic Editing approach, via targeting the CD 
of Dnmt3a to the promoter of the MASPIN gene, the most pronounced targeted DNA 
methylation (of 50%) occurred for two target CpGs. However, differential positioning 
of the induced DNA methylation was obtained. The targeted DNA methylation was 
sufϐicient to efϐiciently downregulate MASPIN expression, with up to 90% repression 
observed in single clones. Efϐicient repression without dense DNA methylation is in line 
with other observations, like for p53 where induced DNA methylation of a single speciϐic 




MASPIN downregulation was stably inherited: up to 50 days post-infection, when the 
expression of the ZF-Dnmt3a CD fusion was barely detectable, gene expression was 
still repressed. Moreover, treating cells at this time point with the DNA methylation 
inhibitor 5-azadeoxycytidine released the repression, indicating that the induced 
DNA methylation is still present. Indeed, methylation patterns remained similar to 
the patterns observed soon after transductions. Furthermore, knockdown of UHRF1 
expression, a protein involved in DNA methylation maintenance, caused signiϐicant re-
expression of MASPIN. The ϐindings were extended to the oncogene SOX2, which could 
also be efϐiciently repressed upon targeting Dnmt3a CD to its promoter by fusion to 
another ZF. By making use of a doxycycline inducible promoter, expression of the ZF-
Dnmt3a CD could be cleared after 48 hrs, allowing the cells to recover from repression. 
Interestingly, the cells did not recover cell proliferation, again indicating heritability of 
the repression. Studies like these indicate the beneϐit of using Epigenetic Editing over 
targeting the KRAB domain.
Targeted repressive histone modifying enzymes
As an alternative (or synergistic) approach to the introduction of DNA methylation 
at transcription start sites, repression of gene expression can be achieved by targeted 
modiϐication of histone tail residues. In this respect, chromatin that has a repressive 
composition is known to be covered by histone H3K9 methylation, exhibiting a 
chromatin state that is proposed to be able to spread its epigenetic composition for 
instance via Heterochromatin Protein 1 (HP1)-induced heterochromatinization (62, 
63). As such, H3K9 MTases (such as Setdb1, G9a and Suv39H1/SU(VAR)3-9) are of 
interest to fuse to DBDs for repression of target gene expression. Furthermore, histone 
H3K27 methylation represents a chromatin state related to Polycomb group protein 
(PcG) regulated genes that become stably silenced during differentiation and cell fate 
determination, which makes an H3K27 MTase (like Ezh2 or vSet) another interesting 
candidate for targeted repression of gene expression. Indeed, H3K9, H3K27 and 
H3K36 MTases (Set2 and Smyd2) as well as an H3K4 demethylase (LSD1) have been 
targeted leading to gene repression in all cases where gene expression was assessed 
(Table 2a). Interestingly, lysine residues like H3K9 and H3K27 can be either acetylated 
or methylated, and deacetylation of acetylated histone lysine residues is required 
before the induction of histone methylation on these lysine residues can take place 
(64). It has long been thought that because acetylation neutralizes the positive charge 
on the histones, this modiϐication facilitates the open conϐiguration of the chromatin 
at actively expressed regions in the chromatin (65, 66). Indeed, hypoacetylation is 
found at promoter sites of genes with low or no expression levels, whereas acetylated 
histone tails are mainly associated with active genes (64, 67). In addition to this ‘charge 
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hypothesis’, acetylation also recruits protein complexes (including chromatin ‘readers’) 
by changing the histone modiϐication composition of the chromatin (68, 69). Thus, to 
silence genes through Epigenetic Editing, the HDACs are among the candidate enzymes 
to be targeted. HDACs of class I (HDAC1, 2 and 3) as well as the sirtuin SirT1 (NAD+ 
dependent, class III) have been targeted in cotransfection studies using the Gal4 or 
LexA DBD and indeed reduced gene expression (Table 2a).
Although promising, most studies were not intended to assess the actual induction of 
the histone mark and no conclusions can be drawn from these studies regarding causal 
relationships between histone marks and gene expression. In contrast, the anticipated 
targeted change of histone modiϐications was assessed and reported for Setdb1 (30) 
upon cotransfections and for Sirt1 (70), LSD1 (71), G9a (72) and Ezh2 (73, 74) targeted 
to integrated target sites (Table 2a). Accordingly, these changes in epigenetic marks 
were associated with repression of gene expression.
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Table 2a. Targeted activating histone modifying enzymes
: no effect, n.a.: not assessed, : effect reported
Aka; also known as, DBD; DNA binding domain, EGE; Epigenetic Editing, GEM; Gene expression modulation, 
ZF; Zinc Finger.
Interestingly, targeting of Gal4 fused to Sirt1 (70), G9a (72) and Ezh2 (73) to 
integrated target sites, caused other changes in histone marks in addition to the ones 
anticipated, as also described for targeted DNA methylation. This again might indicate 
that the change of one mark can induce a cascade of changes in chromatin modiϐications 
which probably reinforces the repressed state and might also add to the persistence 
of repression. Indeed, mitotically inherited repression of target gene expression was 




the Gal4-Ezh2 fusion protein in human cells (73), associated with both the anticipated 
H3K27 methylation and additional H3K4 demethylation. In a murine study, Gal4-Ezh2 
did not change other marks than H3K27 methylation (74). In fact, although targeting 
Ezh2 was shown to recruit Dnmt3a to the integrated target site, no DNA methylation 
was observed and permissive chromatin marks (H3K4me2, H3Ac) remained present. 
The absence of DNA methylation, despite the presence of Dnmt3a, might be explained 
by the presence of H3K4 methylation, as this mark seems to prevent DNA methylation 
(35, 36, 37) and as such might need to be removed by a speciϐic histone demethylase 
before repression of gene expression can take place. In this respect, targeting of TetR-
LSD1 to an artiϐicial chromosome resulted in demethylation of H3K4Me3 (without 
affecting H3K9/K27 methylation) and induction of gene expression (71). However, 
in another study, targeting of Gal4-LSD1 to a target integrated in mammalian cells, 
with the aim to allow DNA methylation to be induced upon targeting of Ezh2, was not 
successful (74). It might be that this discrepancy is caused by the chromatin context of 
the artiϐicial chromosome where LSD1 was targeted to by fusion to TetR, which made it 
easier to reach the target or to affect the histone modiϐication levels. However, since the 
experimental designs were so different, it is difϐicult to compare the two studies.
The crosstalk between histones and DNA methylation (75, 76) has also been 
described for other histone marks than H3K4 methylation. In this respect, the Histone 
Methyl Transferase (HMT) G9a, which induces H3K9 methylation, HP1 binding, local 
heterochromatin formation and gene silencing, can also recruit DNA MTases Dnmt3a 
and 3b which catalyze de novo DNA methylation (77, 78). Similarly, in addition to loss of 
H3K9 methylation at major centromeric satellites in Suv39h knock-out embryonic stem 
cells, also a decrease in Dnmt3b dependent CpG methylation has been observed (79). 
Targeting of such writers might thus result in efϐicient repression of gene expression. 
Indeed, gene-speciϐic ZF-targeted histone modiϐications result in repression of a target 
gene in the endogenous chromatin context by targeting G9a/Suv39H1 or a histone 
deimination domain (29, 80). Targeting of G9a or Suv39H1 by fusion to a three-ϐinger 
ZF designed to bind the gene of interest (VEGF-A), provides the ϐirst example of ZF-
mediated Epigenetic Editing of an endogenous gene (29). This VEGF-A ZF, when fused 
to a transcriptional activation domain like Viral Protein 16 (VP16) of HSV, caused 
upregulation of endogenous VEGF-A expression (81) and has been further investigated 
in phase II clinical trials after fusion to the activator p65. Despite a lack of improved 
therapeutic effect over placebo treatment (82), these efforts demonstrate the feasibility 
of targeting genes in a clinical setting by ZFs. Swopping the transcriptional activation 
domain with the catalytic C-terminal domain of H3K9 MTase G9a (N-terminal 828 
amino acids (aa) removed) or with smaller N-terminal deletions (Δ75aa, or Δ148 
aa) of Suv39H1, caused induction of at least H3K9me2 as well as repression of the 
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endogenous target gene (29). The effect of the H3K9 MTases (inducing the anticipated 
mark and repressing gene expression upon targeting) was validated by us for another 
endogenous gene by fusing the enzymes to another ZF (83). For VEGF-A, increased 
levels of H3K9me2 were observed throughout the investigated region, up to 900 bp 
away from the ZF binding site upon targeting either Suv39H1 (Δ75 aa N-terminal) or 
the CD of G9a (29). This indicates that the targeting of an H3K9 MTase enables the 
activation of an endogenous mechanism spreading the H3K9 methylation marks and 
thereby reinforcing repression. Interestingly, in this study and the one with targeted 
deimination by Cuthbert et al. (80), the targeting construct was delivered to the cells via 
transient transfection of an expression plasmid, whereas the only other example of true 
endogenous Epigenetic Editing delivered the construct virally (60). Unfortunately, the 
observed effects were not followed in time, which would have been interesting because 
prolonged effects would indicate that the targeted induction of the mark is mitotically 
inherited.
Induction of gene expression via rewriting of epigenetic marks
Also for induction of gene expression, to reactivate epigenetically silenced genes 
(for example tumor suppressor genes in cancer), there is a variety of possibilities. The 
achievements obtained by targeted DNA demethylation, locus-speciϐic addition of acetyl 
groups to histone tail residues, methylation of H3K4 or H3K79 and demethylation of 
H3K9 or H3K27 will be discussed in this part (see Table 1 and Table 2b).
Targeted ‘DNA demethylases’
To achieve long term re-expression, it seems apparent that the removal of DNA 
methylation is an important step, at least from around the transcription start site and 
exon 1 of the target gene (41, 42). However, until quite recently it was not generally 
accepted that active DNA demethylation occurs in mammals, even though examples had 
been described of both global and locus-speciϐic active DNA demethylation, as reviewed 
in (84). In this respect, straightforward mammalian effector domains to obtain targeted 
DNA demethylation are not available. Now that the concept of active DNA demethylation 
in mammals is increasingly accepted, efforts to identify mammalian proteins associated 
with the process of active DNA demethylation resulted in interesting candidates for 
targeted removal of DNA methylation marks as reviewed in (84, 85). In fact, several 
mechanisms and proteins were described to be associated with DNA demethylation. 
In plants, enzymes involved in DNA demethylation are relatively well established. 
Repressor of silencing 1 (Ros1), Demeter (DME) and Demeter-like proteins (DML2, 
DML3) are unambiguously associated with active DNA demethylation via base excision 




have been shown to function in a mammalian setting (29), no efforts were reported on 
expressing or targeting the plant CpG demethylation enzymes in mammalian cells. 
Potential mechanisms of active DNA demethylation in mammals, for which some 
indications have been described, are (1) direct removal of the methyl group, (2) 5meC 
glycosylation followed by BER (like in plants), (3) deamination followed by mismatch 
repair and (4) nucleotide excision repair (84, 88). However, most of these mechanisms 
are still under debate. One mechanism that is now increasingly accepted to play a role 
in DNA demethylation is oxidation of 5-methylcytosine to 5-hydroxymethylcytosine 
(5hmC) by the Tet enzymes. The biological role of 5hmC itself is not fully known yet. 
However, the 5hmC mark has been associated with active genes (89), speciϐically 
at the promoter (90) but also in the gene bodies (91, 92). Similarly, ChIP-seq studies 
demonstrated Tet1 to be present on genes occupied by H3K4me3 (active), H3K27me3 
(inactive) or both (bivalent domains) and promoter activity can not be predicted by 
Tet1 binding (93). For Epigenetic Editing purposes, it is noteworthy to mention that 
5hmC has been proposed to be an intermediate in the active DNA demethylation 
pathway (94). Consistent with this, intermediates that might be formed in the process 
of converting 5hmC to be eventually replaced by an unmodiϐied cytosine were detected 
recently (95).
Interestingly, upon targeting of Tet1 to ϐive Gal4-binding sites integrated in 
mammalian cells, repression of the targeted integrated reporter gene was observed 
(93). Also recruitment of Sin3a, a protein that is part of a transcriptional repression 
complex could be detected. Unfortunately, this targeting study did not investigate 
effects on the DNA methylation status of the CpGs of the targeted site. In addition, Tet1 
was not targeted to hypermethylated (inactive) genes, so its effects on gene expression 
in a heterochromatin context are currently largely unknown. 
As also suggested in one of the many reviews about DNA demethylation (88), 
targeting candidate DNA demethylases of the proposed possible pathways to speciϐic 
genes in different chromatin contexts will provide more insights into the enzyme or 
enzymes that can truly actively demethylate methylated CpGs. However, only a few 
studies have employed targeting of potential DNA demethylases so far, of which one 
not even intentionally: Upon overexpression of 5-MCDG, presently known as Thymine 
DNA Glycosylase (TDG), the protein associated with the retinoid receptor RXRα (96). A 
reporter transgene was bound by this receptor and (consequently) DNA demethylation 
and upregulation of the expression of this gene were observed. Interestingly, TDG 
was recently fused to the DBD of NFκB, which also led to some DNA demethylation 
of endogenous NFκB target genes and an increase in target gene transcription (21). 
Contrastingly, in another study, aiming to prevent silencing, no effect on the expression 
of an integrated target gene was seen upon stable transfection of LexA-MCDG in 
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mammalian cells (97).
Alternatively, a ZF targeting study in mammalian cells reported on DNA demethylation 
induced by targeting a transcriptional activator (VP16-tetramer; VP64) to an endogenous 
gene (98). Effectively, a gene-speciϐic upregulation of gene expression of 25- to 125-fold 
on mRNA level was achieved, associated with DNA demethylation of up to 70% of the 
targeted CpGs. Although it might be suggested that the DNA demethylation is a secondary 
effect of the VP64-induced transcription, the precise location of demethylation, which is 
strictly determined by the orientation of the effector domain, would argue against this. 
Still, it needs to be further investigated whether the DNA demethylation is due to active 
DNA demethylation by VP64 or its recruited proteins, or whether the effect is merely 
a consequence of steric hindrance by recruited protein complexes preventing Dnmt1 
from copying methylation to the daughter strand upon cell division. In plants, transient 
transfection of gene-speciϐic ZFs fused to VP64 even resulted in heritable (at least two 
subsequent generations) activation of gene expression of the targeted gene (99). The 
sustained effect observed here might also be associated with epigenetic changes like 
DNA demethylation, although this was not addressed in the speciϐic study. 
Targeted activating histone modifying enzymes
Although DNA methylation provides a powerful silencing memory, it is not necessarily 
a lock for gene expression and many genes have been found to be upregulated despite 
their DNA hypermethylation status after treatment of cells with HDAC inhibitors 
as described in (43) and references therein. Thus, instead of (or in addition to) DNA 
demethylation, gene-speciϐic removal of repressive histone marks and/or induction of 
activating histone marks might achieve efϐicient and lasting upregulation of target gene 
expression. Histone modifying enzymes that are likely to be of interest for obtaining 
targeted activation of gene expression are histone acetyltransferases (HATs; such as 
p300, P/CAF, CBP and GCN5) and histone methyltransferases methylating histone tail 
residues H3K4 or H3K79 (for instance Meisetz and Ash1 or Dot1/Dot1L, respectively). 
Several ‘activating’ histone modifying enzymes have been targeted to predetermined 
target sites (see Table 2b for an overview) within reporter plasmids, integrated within 
host genomes or to endogenous target sites by using the endogenous DBDs MLL or 
MBD. 
Irrespective of the context of the target gene, upregulation of gene expression was 
seen for most of the activating histone modifying enzymes that were targeted (p300, P/
CAF, CBP, GCN5, Meisetz, Ash1 and Dot1). Since most cotransfection studies intended to 
examine the role of coactivators, molecular chromatin marks were generally not studied 
(and if so, to a low extent). Importantly, the one cotransfection study that assessed 




modifying enzyme indeed showed an increase in acetylation by targeted p300 (31). 
Interestingly, despite using the same DBD, different genes can be affected when 
(domains of) other enzymes are fused. Namely, when the HAT domain of CBP in a 
fusion of CBP to MLL was exchanged for the HAT domain of either P/CAF or GCN5, 
other genes seem to be upregulated than with the CBP HAT domain, since different (less 
differentiated) cell surface markers are expressed (20). Thus, this indicates that the 
various HATs each have their own substrates and/or that depending on the chromatin 
context different functional effects are induced.
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Table 2b. Targeted activating histone modifying enzymes
: no effect, n.a.: not assessed, : effect reported
Aka: also known as, DBD; DNA binding domain, EGE; Epigenetic Editing, GEM; Gene expression modulation, 
ZF; Zinc Finger.
Whereas writing activating marks seems to be effective, removal of repressive 
marks could also be of interest for activation of genes. In fact, although (tri)methylation 
marks were long thought to be relatively stable, various enzymes have now been 
described to actively remove these methylation marks (100, 101). To actively remove 
the repressive H3K27me3 mark, UTX (102, 103) and JMJD3 (104) could be explored in 
targeting studies, but to the best of our knowledge no such studies have been reported 
to investigate the effect of removal of this particular mark. However, other histone 
demethylases, demethylating H3K9 and/or H3K27me2 (JMJD2D or KIAA1718) have 
been studied in a targeted fashion and removal of the marks was indeed demonstrated. 
Targeting of JMJD2D to methylated endogenous genes by fusion to the MBD of MeCP2 
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only resulted in the intended reduction in H3K9me3 at the analyzed MLH1 gene, no 
changes in H3K9me2 or DNA methylation levels were observed (17). Upon analyzing 
the effect on gene expression for this target gene, it appeared that demethylation of 
H3K9me3 was not enough to induce gene expression (17). Likewise, for another target 
gene that was assessed (GSTP1), no induction of gene expression could be shown. 
Molecular marks were not analyzed for this gene. The lack of upregulation despite the 
change in H3K9 methylation might be explained by the fact that no other (assessed) 
marks changed. In contrast, targeted KIAA1718 (which did cause upregulation of gene 
expression) showed an increase of H3 acetylation levels, in addition to the expected 
decreased level of H3K9me2 (105). 
Another example of additional histone modiϐications changing was observed 
when targeting drosophila Ash1. Not only H3K4me2 levels decreased, H3K9me2 and 
H4K20me2 marks were increased at a stably integrated reporter gene in Drosophila S2 
cells (106). However, the induction of H3K9me2 and H4K20me2 is a known function 
of dAsh1 in addition to the H3K4 methylation. Interestingly, despite the additional 
induction of the two marks that are associated with gene inactivity (H3K9/H4K20 
methylation), upregulation of the reporter gene expression was still observed. The 
human homolog of Ash1 was not able to change gene expression upon targeting (97). 
Nevertheless, this is in line with ϐindings that human Ash1 does not methylate H3K4, 
but can only mono- and di-methylate H3K36, which might be insufϐicient for gene 
expression modulation (107).
As becomes clear from Table 2b, only a few studies addressed the effect of targeting 
the ‘activating’ enzymes both on modulation of the histone marks as well as on gene 
expression, whereas others were not intended to assess both. Studies investigating 
both of these features can give some insights on whether the cause of activation is the 
induction of the anticipated mark or merely recruitment of other regulatory proteins 
(6, 7). From the studies reported so far, indications can be distilled that the anticipated 
change in histone modiϐication by targeting of p300 (31), Ash1 (106), Dot1L (19), JMJD2D 
(17) and KIAA1718 (105) indeed led to increase in gene expression of the targeted 
gene. However, only studies including the targeting of a catalytic inactive counterpart of 
the domain can ϐirmly indicate a causative relationship between mark and expression 
regulation and such studies have been performed for DNA methyltransferases (54, 59, 
60), Meisetz (108), dAsh1 (106), vSet1 (109), Suv39H1 (29) and G9a (72) as will be 
described below.
TOWARDS EFFICIENT TARGETED GENE EXPRESSION MODULATION
From the above, one can conclude that targeting epigenetic enzymes is a feasible 




the effect of edited epigenetic marks. Various reports also demonstrate that targeting 
epigenetic writers or erasers indeed affect gene expression levels, and some studies 
touched upon the chromatin context requirements. So far, three papers on gene-speciϐic 
Epigenetic Editing have been published, describing the targeting of an epigenetic writer 
to an endogenous locus through fusion to a gene-speciϐic DNA binding domain (29, 
60, 80). Indeed, in these studies gene expression was affected, with some indication of 
spreading of the H3K9me2 mark (29) or mitotic stability of targeted DNA methylation 
(60). Despite successful attempts on rewriting epigenetic signatures to modulate gene 
expression, the studies summarized above indicate that many issues remain to be 
clariϐied for this approach to become robust. In this respect, questions to be addressed 
include: a) which epigenetic mark or combination of marks needs to be induced/
removed in order to efϐiciently interfere with gene expression (given a particular 
chromatin context); b) is the edited mark mitotically stable or will the native epigenetic 
marks be restored upon removal of the editor; c) what is the inϐluence of the chromatin 
landscape in determining the outcome. Depending on the envisioned epigenetic change, 
the most optimal effector domains need to be engineered to selectively, yet efϐiciently, 
execute its activity speciϐically at the targeted site. Some of the studies summarized by 
us (see Tables) did address such efϐiciency and speciϐicity issues in more depth and will 
be discussed below.
Direct gene expression modulation: catalytic activity important
It is subject of a hot debate whether epigenetic marks are the drivers of gene 
expression regulation or merely associated with expression status (6, 7, 8). Indeed, 
for some enzymes, targeting studies have shown that introducing mutations in the CD 
or removal of this domain has little or no effect on the induction of changes in gene 
expression compared to the effect of their larger or full length counterpart proteins. 
This indicates that not in all cases catalytic activity of the targeted enzyme is important 
for an effect on gene expression. Obviously, different studies target the effectors to 
different chromatin and cellular contexts, and this context will signiϐicantly inϐluence the 
outcome (as described for HATs below). Moreover, differences might also be explained 
by a variation in expression levels or nuclear entry of the constructs, but this was not 
addressed in most studies. Despite the fact that it is difϐicult to distill general rules 
from the limited amount of studies done so far, some evidence exists that, in particular 
cases, induction of the mark itself is likely to be sufϐicient to initiate gene expression 
differences. 
In this respect, targeting of the CDs of Dnmt3a (murine: aa 598-908, human: aa 
592-909) and Dnmt3b (murine: aa 557-859) was sufϐicient to cause targeted DNA 
methylation and repression of gene expression, whereas targeting of catalytically dead 
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mutants had no effect on expression levels (54, 59, 60). Also with respect to H3K4me3, 
replacing a Glycine residue with an Alanine residue at aa position 278 in the catalytic 
PR/SET domain (aa 246-365) completely abolished the activating potential of Gal4-
targeted Meisetz (108). Similarly, mutating the HMTase domain (E1357K or N1458I) 
of drosophila Ash1 prevented the increase of H3K4 methylation at the target site, and 
subsequently eradicated the activation of gene expression, as opposed to the wildtype 
enzyme (106). With respect to the repressive mark H3K27me3, creating a catalytic 
mutant by changing one aa of the Set domain of the H3K27 MTase vSet (Y105A or 
Y105F) was sufϐicient to prevent the decrease in reporter gene expression which was 
observed upon targeting the wildtype enzyme (109). Also for SUV39H1, the repressive 
activity of a construct -where the N-terminal 76 aa of the enzyme were deleted- was 
completely abolished by mutating the catalytic activity (29). In case of Gal4-G9a, a 
ΔSet construct could not induce H3K9 methylation and subsequently had no effect on 
gene expression (72). Vice versa, targeting truncated constructs including the HMT 
activity (aa 210-1202 (72)) of the HMTase G9a and even a domain as small as aa 829-
1210 (29) were able to induce H3K9 methylation, and both targeted constructs could 
efϐiciently downregulate target gene expression. In general, these studies provide strong 
indications that epigenetic marks can be instructive in gene expression regulation.
Indirect gene expression modulation: recruitment of secondary enzymes by 
epigenetic editors
 Next to enzymes which seem to rely solely on their catalytic activity for gene 
expression modulation, other enzymes have been described to possess efϐicient gene 
expression modulating activity despite absence of (or mutations in) the CDs. For 
example for Dot1, the H3K79 MTase from yeast, two mechanisms of derepression can 
be elucidated, a CD-dependent and a CD-independent mechanism of action. The CD-
dependent mechanism was conϐirmed by targeting of only a small part (aa 172-582: 
including the HMT domain) of Dot1, which was still able to derepress a target gene 
integrated in the yeast genome, with similar efϐiciency as full length Dot1 (110). On 
the other hand, targeting of only the N-terminal part (1-237 aa, not including the 
HMT domain) of Dot1 also induced derepression of gene expression, thus via a CD-
independent mechanism. Whereas the CD-dependent mechanism works via reducing 
the binding of Sir proteins (yeast homologs of the mammalian sirtuin HDAC proteins) 
to the target through methylation of H3K79, the recruitment of the HAT Gcn5 appears 
to be required for the CD-independent mechanism. In addition, the N-terminal domain 
seems to function in positioning the gene away from the nuclear envelope (where 
heterochromatin normally localizes). Similar effects were observed with hDot1L for 




model system (110). Although aa 1-430 shows the best effect (better than 1-340), 
aa 318-430 on its own has no effect. Interestingly, when a truncated part of hDot1L 
(aa 1-670, including the HMT domain) was investigated in a fusion to MLL (111), less 
efϐicient induction of H3K79 methylation was observed when compared with MLL-
AF10, which supposedly recruits the full length endogenous Dot1L, conϐirming that 
other domains of Dot1L are required for full activity. Therefore, these reports provide 
an example of an effector domain containing functional domains apart from the CD 
which also play a role in achieving gene expression modulation.
Similarly, mutating the active site of SirT1 did not abolish all repressive activity. 
Moreover, deletion of the N-terminal 268 aa (which does not affect the HDAC domain) 
diminished the repressive effect of SirT1, compared to the full length enzyme (70). This 
observation might be explained by the fact that the missing part was shown to recruit 
histone H1b, which has been associated with heterochromatin. Likewise, a fusion of 
TetR to a catalytically inactive mutant of LSD1 (K661A) was still active, resulting in 
reduction of H3K4me2 levels at the target site, be it after longer exposure of the target 
site to the mutant enzyme than for the wildtype (71). The authors suggested that the 
observed decrease in H3K4me2 levels was a secondary effect due to induced repression 
of transcription; recruited repressor proteins might in turn recruit the wild type LSD1. 
Also for Set2, the histone MTase activity can only explain part of the repression, since 
two mutations (R195G and C201A) in the CD of this H3K36 MTase both did not abolish 
repression completely (112). It might be that a substantial part of repression by Set2 
lacking the active Set-domain is caused by the remaining ability to recruit HDACs, as an 
association was reported for another H3K36me2 MTase, Smyd2, with HDAC1 and Sin3A 
(113).
Despite the indications described above that catalytic activity is (at least partially) 
responsible for the observed effects on gene expression, examples exist of efϐicient gene 
expression modulation by targeting enzymes without CDs and/or catalytic activity. 
Illustrative here is an example of Dnmt3a: although the CD is known to result in DNA 
methylation and gene repression, the targeting of the full length murine Dnmt3a to a 
reporter plasmid did not result in DNA methylation (30). Despite this lack of detectable 
induced DNA methylation, repression of reporter gene expression was observed and, as 
demonstrated by ChIP, proteins with repressive functions, including Setdb1 and HDAC1, 
were recruited to the promoter site. Thus, in this case, it seems that silencing of the 
reporter gene was not caused by DNA methylation through mDnmt3a, but indirectly by 
recruitment of other repressive proteins. Since the observed repressive complex was 
also formed on endogenous promoters of hypermethylated genes, as demonstrated 
by ChIP-reChIP, this study underlines the power of targeting mammalian proteins to 
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initiate a natural repressive cascade in the mammalian context. 
Regardless of the indirect effect on gene expression, the editing of a mark might 
be an absolute requirement in order for the intervention to be mitotically stable. This 
is exempliϐied by a targeting study in which an Ezh2-mutant lacking its catalytic Set 
domain still efϐiciently repressed transcription to 10% of the control level (73). As 
the Gal4-Ezh2 ΔSet fusion protein was not associated with an increase in H3K27me3 
levels at the target site, the repression by the ΔSet mutant of Ezh2 might be caused by 
sterical hindrance through recruitment of binding partners of the Polycomb repressive 
complex (PRC2) such as EED and Suz12. Conϐirming this hypothesis, targeting EED to 
the reporter, using the same system, resulted in gene silencing to 30% of the control 
level. Moreover, the repressive effect is no longer observed upon clearance of the 
inducible expression of Gal4-Ezh2 ΔSet. This transient effect is in striking contrast to 
the effect obtained by targeting wildtype Ezh2 which showed both induction of H3K27 
methylation and prolonged repression of reporter gene expression. Most likely, the 
introduction of H3K27me3 and the subsequent cascade of events, not achieved by the 
Gal4-Ezh2 ΔSet fusion protein, are essential for obtaining sustained repression. 
Theoretically, the presence of certain (recruiting) domains within the effector 
domain can decrease the efϐiciency of the targeted enzyme by causing the effector 
domain to be captured by endogenous proteins before reaching the intended target 
site. This was suggested to explain the failure to repress endogenous reporter gene 
expression by targeting full length H3K9 MTase Suv39H1 in fusion to a ZF (29). The 
intact HP1 interaction domain might be captured by endogenous HP1 proteins in 
heterochromatin, thereby preventing the fusion protein from reaching its target. 
Deletion of the N-terminal (HP1 interaction domain containing) 76 aa or 149 aa did 
result in efϐicient histone methylation and gene repression of a gene in the chromatin 
context in a ZF-targeting study (29). Even though the deletion construct could not recruit 
HP1 directly because it lacked the HP1 interaction domain, H3K9me2 was observed as 
far as 1 kb upstream of the ZF binding site, which suggests that some spreading did 
occur. This spreading was mediated by the enzymes recruited by the induced mark itself 
and not indirectly through recruitment of other proteins by the targeted enzyme, as a 
catalytic mutant did not demonstrate any enrichment in the methylation marks at this 
upstream region. Despite the successful repression induced by the truncated Suv39H1, 
inclusion of parts of the N-terminal domain might help to reinforce the repressive effect 
as targeting of only this domain (aa 1-195) resulted in equally efϐicient repression of 
reporter gene expression compared to targeting of full length Suv39H1 in another study 
(114). Apparently, in the latter co-transfection study no capturing effect by endogenous 
HP1 was observed for Gal4-Suv39H1, as the full length could efϐiciently repress 




SU(VAR)3-9 (of which the ϐirst 155 aa are lacking in the human homolog Suv39H1) 
rendered the Gal4 fusion protein ineffective in a co-transfection study compared to its 
full length, even though this N-terminal part does not contain the Set domain (115). For 
the full length enzyme, the strong repressive effect was severely reduced after addition 
of an HDAC inhibitor, which conϐirms a role for the interaction of the N-terminal domain 
with the HDAC RPD3.
The most extensively studied protein with respect to effects of different domains 
is the HAT p300 (see Figure 2), where at least three domains seem to inϐluence gene 
expression levels. Targeting aa 964-1922 of p300, which includes the HAT domain, by 
fusion to Gal4 is sufϐicient to result in activation of reporter gene expression in one 
study (116), but not in another (117). Also, targeting of a similar but somewhat smaller 
HAT-containing domain of p300 failed to induce endogenous target gene expression 
in an MBD targeting study (18). Interestingly, in these latter two studies, p300 fusion 
constructs without the HAT domain (Δ242-1737 (117) and Δ1472-1522 (18)) could 
induce activation of gene expression, even to a higher extent than the full length 
protein. These p300 deletion constructs both contain the N-terminal and the C-terminal 
activation domains, known to form ‘enhanceosomes’, which might explain the observed 
effects. Indeed, targeting of only the N-terminal (aa 1-596, but not aa 1-242) or the 
C-terminal domain (aa 1737-2414) induced expression, again outperforming the 
full length fusion construct (117). Differences between effects of similar domains in 
different studies, however, are observed and might be explained by the location of 
the targeted sites (as will be discussed in the part ‘Towards speciϔic gene expression 
modulation – The DNA binding domain’). In this respect, in another study, targeting of 
only the activating N-terminal 1-596 domain, by fusing it to the MBD of MeCP2, could 
not induce expression of endogenous methylated genes (18). Of course there are many 
other factors in addition to the location of the targeted site that are likely to play a role 
in the observed differences in effects caused by similar domains of the p300 protein. 
For example, the differences in cell lines and constructs (in particular the DNA binding 
domains) could determine the controversial outcomes. However, within every study 
some domains of the p300 protein did show an activating effect, indicating that the 
experimental set-up was available for effective gene expression modulation to occur by 
targeted HATs.
Also for CBP, targeting of only the HAT domain and the CBP2 domain (aa 1099-1877) 
results in gene activation to a higher extent than the full length enzyme (118). Deletion 
of aa 1458-1475 within the HAT domain eliminated the activating effect of the histone 
acetyltransferase, even when the CBP2 domain is present. The removal of the CBP2 
domain -while leaving the HAT domain intact- resulted in a slightly decreased activating 
potential. This decrease in activating potential might be explained by the CBP2 domain 
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containing a number of binding sites for co-activators, although targeting of only the 
CBP2 domain did not result in an activating effect (118).
In conclusion, for some epigenetic enzymes gene expression modulation is 
caused through the direct writing or erasing of epigenetic marks, whereas for others 
recruitment of co-activators or repressors determines functional outcome. However, to 
achieve efϐicient, sustained effects (mitotic heritability), the actual editing of epigenetic 
marks seems warranted.
target gene in all targeting studies reviewed here. The activating domains are shown above and the non-
activating domains below the full length protein. In green and red, respectively, the bromodomain and the 
HAT domain of p300 are indicated according to a conserved domain search on the NCBI website. Blue dashes 
in the full length protein show the positions of the commercially available ‘HAT domain’ of p300 (Millipore). 
Numbers indicate amino acid positions. Black dashed lines represent a part of the enzyme deleted in the 
middle of a protein. References are indicated by the pattern of stripes within the domain box as explained in 
the legend. The table at the right side indicates whether the N-terminal activation domain, HAT domain and/
or C-terminal activation domain are present in the related construct. Light blue colou r ed domains were 
more active than the full length enzyme upon comparison within one study. Thin dotted lines connect two 
equal domains with different outcomes.
Figure 2. Targeted gene-expression regulation capacity by 
various domains of p300
This ϐigure gives an overview of the domains of p300 that were 
targeted by fusion to a sequence-speciϐic DNA binding domain. 
Full length protein actively upregulated the expression of the 
TOWARDS SPECIFIC GENE EXPRESSION MODULATION
The effector domain
Thus, targeting epigenetic enzymes or domains thereof, can induce efϐicient 




importance for general applicability of the approach is the locus speciϐicity of the 
targeted approach. As exempliϐied by Gal4-targeted Drosophila Ash1, the targeting of 
domains does not necessarily ensure site speciϐic effects. The natural Ash1 target gene 
Ubx, which normally is not expressed in the experimental model used, was re-expressed 
as well in addition to the intended targeted reporter gene (106). The re-expression of 
Ubx upon expression of Gal4-Ash1 was accompanied by induction of H3K4, H3K9 and 
H4K20 methylation at this endogenous site as also observed for the intended integrated 
target site. Apparently, the Gal4 DBD was not strong enough to prevent binding of Ash1 
to the Ubx gene. In this line of reasoning, it is also important to realize that certain 
epigenetic enzymes, such as HATs and HDACs were shown to have an effect on non-
histone proteins such as transcription factors (119, 120), which might inϐluence the cell 
biological outcome.
Similarly, targeting of DNA methyltransferase M.HhaI and M.HpaII fused to a four-
ϐinger ZF resulted in methylation of their coding plasmids in bacteria although these 
were devoid of ZF binding sites (52). In addition, background methylation was reported 
for M.SssI (49, 55). Contrastingly, the enzyme only efϐiciently functioned on naked 
DNA when tethered to the DNA; efϐicient methylation was observed for ZF-M.SssI for 
oligonucleotides containing the ZF binding site, but not for oligonucleotides without the 
ZF binding site (49). Although the afϐinity of M.SssI itself for DNA was decreased upon 
fusing the enzyme to zinc ϐingers, it still seems to be too high to allow its site of action 
to be restricted by DBDs (49). Namely, similar methylation efϐiciencies were observed 
for targeted versus untargeted M.SssI in yeast cells, for a non-ZF target locus as well as 
for the targeted locus (55). Such off-target effects underline the need for MTases strictly 
functioning at the predetermined target. 
A promising way to diminish off-target effects of epigenetic enzymes in targeted 
fusion proteins is to engineer less active mutants of the enzyme to be fused to the DBD. 
In this respect, we constructed the M.SssI mutant C141S, with a remaining activity of 
~5% of the wildtype activity and conjugated this mutant to a gene-targeting TFO (50). 
No other CpGs than two targeted CpGs were efϐiciently methylated in a region of 700 
bp of the promoter or in an amplicon of 400 bp investigated within the reporter gene 
of the plasmid upon co-incubation in a cell-free system, conϐirming locus-speciϐic DNA 
methylation. Likewise, diverse mutants of M.HhaI and M.HpaII have been constructed 
(52). For the mutant M.HhaIQ237G, which has a remaining methylation activity of less 
than 5% in in vitro enzyme assays, target-speciϐic methylation was conϐirmed by 
absence of restriction of the coding plasmid, including the target site, by methylation 
sensitive restriction enzymes. For M.HpaII, an F35H mutant with reduced activity 
was created of which the mutated aa normally aids in positioning the adenine ring 
of S-adenosylmethionine (SAM) in the protein binding pocket (52). Also this mutant 
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shows target-speciϐic methylation in the same system. Evidently, the same approach 
of creating lower activity/afϐinity mutants could be used to restrict activity of histone 
modifying enzymes to the intended loci. 
As an alternative to constructing mutant enzymes, the so-called ‘split enzyme 
approach’ has been explored to improve the speciϐicity of targeted methylation. Only 
when the split parts of the protein localize at neighboring sites, the parts of the enzyme 
can combine and methylate the target sequence. For M.HhaI, a plasmid encoding two 
separate three-ϐinger ZFs fused to complementary halves of the enzyme and also 
containing the ZF target sites was transformed into E. coli (53). Site-speciϐic methylation 
of the cytosine ϐlanked by the two ZF binding sites was conϐirmed by bisulϐite sequencing. 
Very recently, another study on targeted split enzymes was reported. Here the M.SssI 
enzyme was split and recombined to successfully methylate CpGs at the in vivo target 
site in E. coli (121). Although selectivity was not fully supported in another M.HhaI 
split-enzyme study (122), the approach of splitting enzymes (as reviewed in reference 
(123)) might provide a promising tactic for increasing speciϐicity of Epigenetic Editing. 
Despite off-target effects, several examples exist where the effect of the targeted 
enzyme seems to be restricted, since it only takes place when indeed the recognition 
site of the DBD is present. For example, when targeting human Dnmt3a CD to 
mitochondrial DNA, no off-target methylation was shown for two distant mitochondrial 
regions, suggesting usefulness of human Dnmt3a in targeting purposes (59). Likewise, 
expression of Gal4-CBP had no effect without Gal4 targets being present in the reporter 
plasmid in a cotransfection study (118). 
The DNA binding domain
Off-target effects, on the same chromosome and on other chromosomes, might 
also be envisioned to occur due to ϐlexible linkers between the DBD and effector 
domain in combination with dynamic movement of chromatin. Despite the speciϐic 
binding of the DBD to its unique genomic target site, the effector domain might get in 
contact with distal sequences due to chromatin folding, but also due to cis and trans 
interchromosomal interactions. The basic reach-area of epigenetic enzymes has been 
investigated using oligonucleotides containing DBD recognition sites. In this respect, 
using oligonucleotides with varying distances (2-32 nucleotides) between the ZF binding 
site and the target CpG, methylation induced by Zif268-M.SssI was shown to occur 
preferentially at cytosines 16 or 22 bp upstream of the ZF binding site (49). Although 
this preference likely reϐlects the length of the linker between ZF and DNA MTase (19 
aa), linker dependence was not further investigated in this study. As for Zif268-M.SssI, 
the ϐlexibility of the ZF-M.HpaII fusion protein was tested in vitro and appeared to be 




bps between the ZF target site and the M.HpaII recognition site was most successful for 
binding and methylation activity of the fusion protein, with optimums at 13 and 34 bps. 
At 16 and 17 bps distance, a weaker point was detected, which might indicate a position 
unable to be reached by the effector part of the fusion protein.
Based on the above, the reach area of a ZF-DNA MTase fusion in cell-free systems 
is limited. Although cellular experiments suggest that recruitment of spreading 
mechanisms can easily enhance the initial effect, it is of importance to ensure the ϐirst 
hit is efϐicient. In that respect, it is necessary to know in which direction the effect will 
have to take place, upstream or downstream of the DBD recognition site, as the site of 
effect might be determined by the orientation of the effector domain relative to the DBD. 
For example, for ZF-M.SssI, the direction in which the methylation took place, upstream, 
was in line with the position of M.SssI in the ZF fusion protein (C-terminal) (49). In 
another study, for ZF-M.HpaII a preference for methylation of the 3’ end of the target 
site was observed, which is expected because of the orientation of the ZF-M.HpaII fusion 
protein on the target DNA (52). Also the observed DNA demethylation upon targeting 
VP64 was in the expected direction (98). Such orientation-dependency, however, might 
not be observed for all constructs as no clear orientation dependency was observed 
when targeting a ZF-Dnmt3a CD fusion to an endogenous gene (60). 
In addition, most likely it is necessary to modulate more different epigenetic marks 
to obtain a sustainable effect. As far as known, the effect of targeting two different 
epigenetic enzymes to the same repeat of DBD recognition sites has not been assessed. 
However, targeting of vErbA (recruiting the NCoR/SMRT co-repressor complex, 
executing HDAC activities) and the H3K9 MTase G9a to the same promoter showed an 
increase of the repressive effect observed compared with targeting either one of the 
proteins alone (29). Despite that it becomes clear from the above that induction of one 
epigenetic mark can be sufϐicient to cause a cascade of events leading to prolonged effects 
on gene expression, more research into combined targeting of epigenetic writers and/
or erasers would be beneϐicial, especially within the endogenous chromatin context.
Depending on the epigenetic enzyme, it is likely that the genomic site where the 
effector domain is targeted to (e.g. relative to the transcription start site) is of importance 
in determining the functional outcome. The target site position at least seems to be 
playing a role in the case of HATs, as this might explain the contradiction between the 
two studies targeting p300 aa 964-1922. In one of the studies, the Gal4 binding sites 
were situated upstream (117) whereas in the other the sites were situated downstream 
(116) of the transcription start site. Only in the study where the Gal4 binding sites were 
situated downstream of the transcription start site, an activating effect was seen, as 
also shown for full length p300 in a different study (124). Fusion of Gal4 to P/CAF again 
only resulted in upregulation of gene expression after cotransfections when the Gal4 
47
2
Review: Targeted epigenetic enzymes approaches
binding sites were situated downstream, not upstream, of the transcription start site 
of the reporter gene. When the Gal4 binding sites were located upstream, close to the 
TATA box, an SP1 binding site was needed for reporter gene activation by targeted P/
CAF (124). 
Evidently, not only the characteristics of the fusion protein, comprising the DBD, the 
linker and the epigenetic enzyme, inϐluence the speciϐicity and efϐicacy of the effect. 
Sensible selection of the target site itself might also be beneϐicial. In this respect, native 
chromatin context requirements might be identiϐied in the future which allow efϐicient 
Epigenetic Editing. From the studies described in this review, it becomes clear that one 
target site can be sufϐicient, underlining the feasibility of targeting epigenetic enzymes 
using a single gene-speciϐic DNA binding domain. Actually, a repeat of target sites is 
not per se required to improve the effect of histone modifying enzymes, as similar 
repression has been shown by LexA-RPD3 when the reporter plasmid contained just 
one LexA binding site when compared to a reporter plasmid with four LexA binding 
sites (112). For Gal4-Suv39H1, adding an additional Gal4 binding site to the reporter 
plasmid did not improve the repressive effect either (114).
CONCLUSION
Apart from the ultimate goals of inducing efϐicient and permanent gene expression 
modulation, Epigenetic Editing is likely to provide valuable insights in cause versus 
consequence of epigenetic marks with respect to gene expression modulation. It is still a 
matter of debate whether DNA methylation and posttranslational histone modiϐications 
inϐluence the gene expression levels directly or if they are merely byproducts of 
transcription (6, 7, 125). For example, DNA demethylation was reported to be 
associated with active histone marks in postmitotic cells, but not with transcriptional 
activity (126). Targeting minimal CDs of epigenetic writers (and their catalytically 
dead mutants) to deϐined chromatin environments allows comparisons determining 
the effect of the edited mark on higher order chromatin or on gene expression. In this 
respect, Epigenetic Editing might provide a unique tool to eventually settle this cause 
versus consequence debate.
Before Epigenetic Editing can become a straightforward approach, however, the 
inϐluence of the chromatin context on the dynamics of epigenetics has to be addressed 
in a systematic manner. It is expected that the positioning of the effector domain as well 
as the promoter type might affect the ultimate outcome. Similarly, dependent on the cell 
type, different regulatory protein complexes might be recruited to the same epigenetic 
mark (127), and different histone (variant) turnover rates and clipping of the histone 
tails will determine the transient vs. mitotically stable nature of the induced mark (128). 




coarse-grained stochastic model systematically adding epigenetic regulatory levels 
of increased complexity (i.e. epigenetic enzyme binding, its spreading, subsequent 
recruitment of regulatory proteins and chromatin folding) allowing to simulate and 
interpret the mechanistic and dynamic behavior of a nucleosomal stretch to attain a 
deϐined epigenetic composition.
Initial publications showed the promise of Epigenetic Editing for a handful of genes 
(MASPIN, Sox2, VEGF-A (29, 60, 80)) and from these studies some indications on 
heritability (DNA methylation) and spreading (H3K9me) can be distilled. Importantly, 
these proof-of-concept studies on targeted methylation clearly show the intended 
repressive effect on gene expression. Although it might be more challenging to 
effectively compete with spreading mechanisms to overwrite repressive histone marks, 
accessibility of inactive chromatin presents no limitations as Artiϐicial Transcription 
Factors have been successful in re-expressing silenced and even imprinted genes 
(98, 129). With recent developments in the targeted DNA demethylation ϐield (21), 
combinations of erasers together with certain writers might prove potent in this 
respect. In fact, Epigenetic Editing designed for upregulation of a gene of interest, is 
advantageous over cDNA approaches as with Epigenetic Editing all isoforms can be 
produced in their natural ratios and expression levels are controlled from the natural 
promoter and through natural signaling pathways. In addition, silencing via Epigenetic 
Editing through appropriate combinations of marks might prove to be advantageous 
over approaches like siRNA because the effect would be sustained after clearance of the 
drug (hit and run approach) (60), without saturating/affecting other cellular (RNAi) 
processes (39). 
With respect to such other gene-speciϐic gene expression modulating approaches 
(gene therapy or RNA interference), Epigenetic Editing promises several advantages, 
including the broad spectrum of delivery possibilities, ranging from chemical gene-
speciϐic epigenetic inhibitors (130) to direct mRNA (28) or protein delivery (27, 131) of 
the epigenetic editors. Eventually, it will be necessary to achieve efϐicient, cell- or tissue 
speciϐic delivery of the Epigenetic Editing-device if to be used as therapeutic agent. 
Although this requires further research, the use of complexes of antibodies recognizing 
speciϐic cells or tissue and a cationic lipid or liposomes might be powerful approaches 
to ensure tissue or cell type-speciϐicity (132). 
The need for novel epigenetic therapies is exempliϐied by the numerous ongoing 
clinical trials to test inhibitors of epigenetic enzymes (133, 134). Although promising, 
current (FDA approved) epigenetic drugs severely lack speciϐicity not only with respect 
to the intended target (also unintended non-chromatin proteins are affected), but 
more importantly with respect to the genome-wide effects (135). The identiϐication 
of epigenetic marks or combinations of marks which efϐiciently interfere with gene 
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expression proϐiles will open up new avenues in biomedical research. As virtually any 
(undruggable) gene can be targeted for up- and downregulation (22, 28), Epigenetic 
Editing adds a novel approach to the biomedical arena to investigate gene functions, to 
validate therapeutic targets and even to be further optimized to become a (synergistic) 
therapeutic approach (136). 
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Many diseases are associated with aberrant gene repression which can be caused 
by epigenetic mutations (including DNA hypermethylation and repressive histone 
modiϐications like H3K27me3). As epigenetic marks are potentially reversible, 
demethylation of DNA or modiϐication of histone tail residues could overcome aberrant 
repression of gene expression. 
In this study, Gadd45α and four other candidate DNA demethylases were investigated 
for their potency in inducing expression of epigenetically silenced genes. Also the effect 
of an H3K27 demethylase (UTX) was investigated. The enzymes (or domains thereof) 
were either overexpressed or targeted to predetermined sites by expressing fusions 
of the effectors to sequence- or gene-speciϐic DNA binding domains (LacRepressor; 
LacR or zinc ϐingers, respectively). Subsequently, gene expression and molecular 
epigenetic marks were analyzed genome-wide or at the targeted sites. Targeted effects 
were assessed either on reporter plasmids (LacR and zinc ϐinger) or on large repeats 
integrated in the genome of cells (LacR).
Out of the ϐive candidate DNA demethylases, Gadd45α was the only one showing 
slight genome-wide DNA demethylation. Furthermore, signiϐicant upregulation of 
reporter gene expression was observed upon cotransfections of a plasmid encoding 
untargeted Gadd45α and an in vitro methylated luciferase reporter plasmid. Fusion 
of Gadd45α to a sequence-speciϐic LacR DNA binding domain (targeting to a repeat of 
LacO sites) or to a gene-speciϐic zinc ϐinger did not result in any signiϐicant effect on 
gene expression or on DNA methylation at reporter plasmids. Nonetheless, an attempt 
to amplify possible effects by targeting the fusion proteins to a repeat of integrated LacO 
target sites showed decondensation and an increase of transcription by LacR-Gadd45α 
when looking at single cell level. Also for and LacR-UTX CD, this effect on transcription 
was detected.
These results indicate that Gadd45α and UTX likely are able to induce expression 
of epigenetically silenced genes. Furthermore, indications are obtained that Gadd45α 
might play a role in DNA demethylation. Epigenetic Editing (endogenous gene-speciϐic 
rewriting of epigenetic marks) could enlighten the exact role of Gadd45α in gene 
expression activation. Moreover, the results obtained in this study show that Gadd45α 
and UTX are interesting candidates to target to endogenous aberrantly epigenetically 
silenced genes to induce gene expression through Epigenetic Editing. 
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INTRODUCTION
In many types of diseases, genes have been shown to be aberrantly inactivated not 
only because of genetic mutations but even more frequently, as becomes more and 
more clear, because of epigenetic silencing (1, 2). Main features of such epigenetic 
silencing are DNA methylation (around the transcription start site and exon1 (3, 4)) 
and the presence of repressive or absence of activating histone modiϐications (like 
methylation of histone 3 lysine 27 (H3K27) (5) or hypoacetylated histone tail residues, 
respectively). Since epigenetic marks are reversible, it is interesting to remove marks 
associated with repressed genes or add marks associated with active genes to overcome 
aberrant silencing.
One approach to relieve the repressed state of the chromatin is active DNA 
demethylation. Although the existence of this phenomenon is accepted by now, the 
exact mechanism in mammals is still unknown. In plants, the mechanism of active DNA 
demethylation is well established and described to be performed by Ros1 and DME, 
bifunctional glycosylase/lyases, which cleave the phosphodiester backbone after they 
have removed the methylated cytosine, a gap which is subsequently repaired by DNA 
repair mechanisms (6). In mammals, several potential mechanisms (and proteins 
involved) have been suggested for active DNA demethylation (7, 8). For example, 
Gadd45α was implicated to actively demethylate DNA via nucleotide excision repair or 
base excision repair (9). In addition, Gadd45α was found to associate with deaminases 
AID and Apobec, as reviewed in (10). Also the DNA methyltransferases 3a and 3b 
(Dnmt3a, Dnmt3b), known for their capacity to methylate DNA, were described to be 
able to deaminate methylated cytosines to thymines, in order for the resulting T/G 
mismatch to be recognized by repair systems, eventually causing DNA demethylation 
(11, 12).
Another epigenetic mark also often associated with aberrantly repressed genes is 
H3K27 methylation (13). Therefore, removal of this mark might aid in inducing gene 
expression. In cells this is known to occur through the activity of histone demethylating 
enzymes such as UTX (ubiquitously transcribed tetratricopeptide repeat, X 
chromosome), which speciϐically recognizes H3K27 methylation (14, 15). 
A potent approach to optimally exploit such naturally occurring enzymes is to gene-
speciϐically reverse the repressive epigenetic marks by Epigenetic Editing (16). With 
Epigenetic Editing, epigenetic enzymes are fused to gene-speciϐic DNA binding domains 
to execute their effect only at the gene of interest, potentially leading to gene expression 
modulation. A beneϐit of this approach, as opposed to (FDA-approved) epigenetic drugs 
(17), is that it is gene-speciϐic, expected to cause less or no side-effects. Moreover, 
depending on the epigenetic enzyme fused, both up- and downregulation of genes can 




only affect epigenetic marks in order to upregulate gene expression. In comparison 
to other methods developed for activation of gene expression (such as cDNA), one 
advantage of Epigenetic Editing is that this approach ensures expression of the gene 
in all isoforms in natural ratios, which was proven to be of importance (18). Moreover, 
with Epigenetic Editing expression is controlled by the natural promoter. In addition, 
only two copies of DNA need to be targeted, likely increasing efϐiciency. For the same 
reason, also undruggable targets can be easily reached. In addition, epigenetic changes 
are inheritable (19, 20) and the effect thus can be sustained, whereas the effect of cDNA 
or siRNA might be cleared upon degradation of the drug.
Towards induction of gene expression by Epigenetic Editing, as aimed for in this 
study, a number of proteins (supposedly) involved in gene activating epigenetic 
pathways are screened for both their epigenetic as well as their gene expression 
modulation effects. In addition to mere overexpression of the proteins to investigate 
the function of the enzymes, sequence- or gene-speciϐic DBDs are fused to the proteins 
to tether the enzymes to predetermined DNA target sites in this study. Such targeting 
not only narrows down the region of investigation, facilitating detectability of the effect, 
it also enforces the presence of the enzymes at the predetermined target site, whereas 
overexpressed proteins ϐirst need to be recruited to the site of action.
Upon overexpression of the epigenetic enzymes, the effects are assessed at genome-
wide level or on reporter plasmids. The DNA binding domains used as targeting tools 
in this study are the Lac Repressor (LacR) from bacteria, which binds the Lac Operator 
(LacO) (21) and engineered gene-speciϐic zinc ϐinger proteins (22) (in this case 
targeting the EpCAM promoter (23)). The fusion proteins comprising these DBDs and 
the (putative) epigenetic enzymes are cotransfected with in vitro methylated reporter 
plasmids comprising a repeat of LacO sequences or the EpCAM promoter. Moreover, the 
plasmids encoding LacR fusion proteins are transfected in cells with a large repeat of 
LacO sequences integrated in their genome (24). It is expected that possible effects of the 
enzymes are ampliϐied by this system since it enables the targeting of multiple copies of 
the fusion protein (including the epigenetic enzyme to one target region. Subsequently, 
molecular epigenetic marks at the target site as well as reporter gene expression levels 
are analyzed. Furthermore, the effect of the LacR fused (putative) epigenetic enzymes is 
analyzed in single cells by immunohistochemistry.
MATERIALS AND METHODS
Plasmids
Ros1 catalytic domain (CD; aa 868-1105) and Demeter (DME) CD (aa 1189-1418) 
were ampliϐied from Arabidopsis cDNA (kindly provided by Dr. B.J. van der Zaal, 
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University of Leiden, the Netherlands) with forward and reverse primers including 
BamHI and BglII restriction sites at their 5’ end, respectively. pcDNA3.1mycnonHisKozak 
(pZ; (23)) was restricted with BamHI and the PCR-products were inserted. 
UTX CD (aa 401-1401), was ampliϐied from plasmid pGvh0064 (kindly provided by G. 
van Haaften, NKI, Amsterdam, the Netherlands (25)) with forward and reverse primers 
containing SalI and XhoI restriction sites at their 5’ end respectively. The ampliϐication 
product was inserted into pZ upon restricting the vector with XhoI. 
pcDNA3.1mycHisKozak-EGP2A-Dnmt3a CD (aa 608-908) and 
pcDNA3.1mycnonHisKozak-EGP2A-Dnmt3b CD (aa 558-859) (kindly provided by 
Dr. A. Jeltsch) were mutated in their S-Adenosyl Methionine (SAM) binding pocket 
by site directed mutagenesis to obtain F636A and F587A, respectively. Subsequently, 
murine Dnmt3a CD F636A and mDnmt3b CD F587A were ampliϐied from these plas-
mids, UTX and UTX CD from pGvH0064 and Gadd45α from human cDNA, using prim-
ers containing AscI restriction sites on the 5’ ends. The ampliϐication products were 
inserted in pU, which was created by insertion of a linker containing AscI restriction 
sites made by annealing two oligonucleotides: 5’AGCTTCCGCCATGGTTAGATCTC-
CAAAGAAGAAGAGAAAAGTTACCGGTGGATCCGGCCAGGCCGGCCAGGCGCGCCAGTTA-
ATTAATC 3’ and 5’TCGAGATTAATTAACTGGCGCGCCTGGCCGGCCTGGCCGGATCCACCG-
GTAACTTTTCTCTTCTTCTTTGGAGATCTAACCATGGCGGA 3’ into the HindIII and XhoI 
sites of pZ for untargeted overexpression approaches. 
The same ampliϐication products were also inserted into pV, which was (like pV-
VP16) created by cutting out LacR from peGFP-LacR (or peGFP-LacR-VP16, respectively 
(26)) with BamHI and StuI and insertion into pZ which was restricted with XhoI, ϐilled 
in with Klenow and subsequently restricted with BamHI. 
pZ-Up2-Gadd45α was created by restricting Gadd45α from pU-Gadd45α using BglII 
and XhoI and inserting it into pZ-Up2 (23) which was restricted with BamHI and XhoI. 
pCpGL, the luciferase reporter plasmid with a CpG-free backbone was kindly 
provided by Dr. Michael Rehli (27). To insert the EpCAM promoter, p39E (28) and 
pCpGL-Basic were restricted with BamHI and the promoter was ligated in the reporter 
backbone. The pGL3-8.LacO luciferase reporter plasmid (containing 8 Lac Operator) 
was reported previously (26). 
Cell culture
Cos7 cells were maintained in DMEM (BioWhittaker, Walkersville, MD, USA) 
supplemented with 50 μg/ml gentamicin sulphate, 2 mM L-glutamine and 10% FBS. 
A2780 cells were maintained in RPMI-1640 medium (BioWhittaker) supplemented 
with 50 μg/ml gentamicin sulphate, 2mM L-glutamine, 10% FBS, 1mM Na-pyruvaat and 




Belmont (24)) containing a condensed integration of LacO repeats were maintained in 
Ham’s F-12 medium without thymidine and hypoxanthine, supplemented with triple 
dialyzed FBS (Perbio) and 0.1 μM MTX, never allowing conϐluency to reach over 90% 
or less than 30%. U2os 2-6-3 cells, stably expressing ms2-yfp, were obtained from 
S.M. Janicki (29) and grown in glutamax DMEM (Gibco, Invitrogen, Life technologies, 
Bleiswijk, the Netherlands) supplied with 10% tet-approved FCS (Clontech, via 
Westburg, Leusden, the Netherlands) and 40 μg/ml G418 (Gibco). All cells were cultured 
at 37°C under 5% CO
2
. 
As a positive control in DNA demethylation assays, CHO DG44 AO3_1 cells were 
incubated with different concentrations of zebularine for 48 hrs (as indicated at the 
ϐigures).
Transfection/profection
Transfection of cells was performed at 60-80% conϐluency using SAINT-2:DOPE (SD; 
0.75mM, Synvolux Therapeutics, Groningen, The Netherlands). 250 ng total plasmid 
DNA was dissolved in 25 μl HBS and added to 25 μl SD/HBS mixture, consisting of 20 μl 
HBS and 5 μl SD. This was added to 200 μl serum-free medium and added to one well 
of a 24 wells plate. 48 hrs after transfection cells were harvested for further analysis. 
Profection with M.SssI (New England Biolabs, via Bioké, Leiden, the Netherlands) was 
performed as described before (30). Transfection of the LacR fusion constructs in 
U2os 2-6-3 cells was performed with Lipofectamin 2000 (Invitrogen), according to the 
recommendations of the manufacturer.
Genome-wide methylation levels
gDNA was isolated from cells using chloroform/isopropanol precipitation. For 
methylation sensitive restriction analysis, DNA was either restricted with MspI or with 
its methylation sensitive isoschizomer, HpaII. Analysis of restriction products was 
performed on agarose gels.
For LUMA, assays were performed as extensively described in (31, 32). Brieϐly, 
gDNA was restricted with EcoRI and HpaII or MspI. Using pyrosequencing, the sticky 
ends were ϐilled in and quantiϐied using the Pyromark Q24 MD pyrosequencer (Qiagen, 
Hilden, Germany). Percentage of methylation was calculated by dividing the ratio of 
ϐilled in cytosines and guanines per adenine upon HpaII digestion by the same ratio 
upon MspI digestion.
Acid extraction and western blot
Histones were extracted from transfected cells using acid extraction. Cell pellets were 
dissolved in cold TEB (0.5% Triton-X, 2mM PMSF and 0.2% NaN
3
 in PBS) to a density 
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of 107 cells/ml and lysed on ice for 10 min. The lysates were centrifuged for 10 min at 
2000 RPM at 4˚C and the pellet was washed with half the volume of cold TEB. After 
centrifuging again the histones were acid extracted overnight at 4˚C by dissolving the 
pellets in HCl (0.2 M) at a density of 4.107/ml. The next day supernatant (predominantly 
histones) was collected. To neutralize the samples, 10 μg of histone extract was mixed 
with 9.5% v/v NaOH (2 M). The samples were separated by SDS-PAGE and blotted 
on a nitrocellulose membrane. As a loading control, membranes were stained with 
Ponceau S. Subsequently, membranes were incubated with primary antibody against 
H3K27me3 (Millipore, Amsterdam, the Netherlands) overnight at 4˚C The next day, the 
membrane was incubated with goat-anti-rabbit conjugated to alkaline phosphatase 
(Jackson Immunoresearch, via Sanbio, Uden, the Netherlands) for at least 1.5 hours at 
RT. To visualize the bands, the membrane was incubated with NBT and BCIP (nitro-blue 
tetrazolium and 5-bromo-4-chloro-3’-indolyphosphate) substrates.
Western blotting to detect the LacR fusion proteins was performed following the 
above protocol with regular cell lysates, using a primary antibody (Millipore) against 
LacR and goat-anti-mouse conjugated to alkaline phosphatase (DAKO, Glostrup, 
Denmark).
Dual luciferase assay
Dual luciferase assays were performed using the Dual Luciferase assay kit from 
Promega according to the protocol of the manufacturer. In brief, cells were lysed, and 
added to LARII reagent. After measurement of Fireϐly luciferase activity, Stop&Glo 
reagent was added and Renilla luciferase activity was measured using a Luminoskan 
Ascent luminometer (Thermo Scientiϐic, Breda, the Netherlands). For calculation of 
relative luciferase expression, relative light units measured for Fireϐly luciferase were 
divided by the relative light units for Renilla luciferase. Subsequently fold induction 
compared to cotransfections with empty vector were calculated and T-tests were 
performed to calculate statistical signiϐicance.
Plasmid recovery and bisulϐite sequencing
For plasmid recovery, cells were ϐirst incubated with DNAse (Fermentas, Leon-Rot, 
Germany) to degrade any plasmid DNA that was not taken up by the cell. Subsequently, 
plasmid DNA was isolated using the Tip20 kit (Qiagen).
Recovered plasmids were bisulϐite converted using the EZ DNA Methylation-Gold 
Kit (Zymo Research via Baseclear, Leiden, the Netherlands) following manufacturers’ 
recommendations. PCR was performed using primers binding the EpCAM promoter, as 
described before (33). PCR products were extracted from gel using the Qiaquick gel 




clones were send for sequencing (Baseclear).
qRT-PCR
Total RNA was isolated using an RNeasy RNA isolation kit (Qiagen). cDNA was 
synthesized by reverse-transcription using the revertaid cDNA kit (Fermentas). 10 ng 
of cDNA was used for qRT-PCR on an AB ViiA7 Sequence Detection System (Applied 
Biosystems, Carlsbad, CA, USA) using Taqman assays for mGapdH (Mm99999915_g1) 
and for mDHFR (Mm00515662_m1; both Applied Biosystems). Analysis was performed 
using the comparative Ct-value method.
Methylated DNA Immuno Precipitation (MeDIP)
gDNA was isolated using chloroform/isopropanol precipitation and subsequently 
sonicated. The DNA was denatured and dynabeads (Invitrogen) loaded with 5mC 
antibody (Eurogentec, Seraing, Belgium) or mIgG antibody (Millipore) were added. 
After overnight incubation, beads were washed and DNA was eluted from the beads. The 
eluted DNA was puriϐied using a Qiaquick PCR puriϐication kit according to the protocol 
of the manufacturer. 2 μl of DNA was used in PCR reaction with primers binding to the 
region right in front of or right behind the extensive LacO repeat.
Chromatin Immuno Precipitation (ChIP)
 Transfected cells were ϐixated using formaldehyde. Subsequently, cells were 
sonicated to shear the DNA (Bioruptor, Diagenode, Liège, Belgium). Dynabeads loaded 
with antibodies (mIgG, rIgG, LacR, H3K4me3 and H3K27me3 from Millipore, H3core 
from Abcam, Cambridge, United Kingdom) were added and incubated overnight. Beads 
were washed and the DNA/protein complexes were eluted from the beads. Protein and 
RNA was removed and the DNA was puriϐied and used for PCR like for MeDIP.
Immunohistochemical staining and confocal miscroscopy
Transfected U2os 2-6-3 cells were ϐixated for 10 min. using 2% formaldehyde. 
Subsequently the cells were permeabilized by 0.5% Triton-x100, and quenched with 
100 mM Glycin. 2.5% BSA was used for blocking and cells were incubated with rabbit 
and mouse LacR antibodies (obtained from A.S. Belmont) diluted 1:2000 and 1:200, 
respectively. As secondary antibody, cy3-labeled donkey anti rabbit or mouse (Jackson 
Immunoresearch) was used, diluted 1:200.
Imaging was performed using a confocal microscope (LSM510, Zeiss, Sliedrecht, the 
Netherlands). Stacks were taken from 0.2 μm. Optical slices are shown, the bar in the 
ϐigures represents 5 μm.
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RESULTS
Effects of overexpressing untargeted enzymes.
To quantify the genome-wide effect of Gadd45α and mutants of CDs of Dnmt3a 
and Dnmt3b on methylation levels, LUMA assays were performed upon expression of 
the constructs in Cos-7 cells (Fig. 1a). The positive control, treatment of the cells with 
DNA methylation inhibitor zebularine (100 μM), resulted in approximately 5%, but not 
signiϐicant, reduction of genome-wide DNA methylation levels compared to untreated 
cells. However, a very slight but signiϐicant decrease in genome wide methylation levels 
was observed upon overexpression of Gadd45α (11.6 + 3.1 %, p<0.05) compared to 
treatment of cells with the transfection agent only. mDnmt3a CD F636A and mDnmt3b 
CD F587A did not decrease genome wide methylation levels signiϐicantly, nor did 
transfection of the empty vector. Using methylation sensitive restriction analysis, no 
clear effect of domains of plant DNA demethylases Ros1 and DME was observed either 
(data not shown). 
To investigate the effect of Gadd45α more closely, the plasmid causing overexpression 
of Gadd45α was cotransfected with a reporter plasmid containing the promoter 
originating from the EpCAM gene and a CpG-free backbone. The effect of Gadd45α was 
tested in two conditions; upon cotransfection with the unmethylated reporter plasmid 
and with the same reporter plasmid which was in vitro methylated before transfection. 
Indeed, reporter expression is decreased to 4 + 2% upon methylation of the reporter 
plasmid. Interestingly, overexpression of Gadd45α, compared to transfection with the 
empty vector, only showed signiϐicant upregulation of luciferase expression (4.7 + 0.9-
fold, p<0.001) from the methylated reporter, not from the unmethylated one (Fig. 1b). 
Moreover, after recovery of the reporter plasmid from the cell, bisulϐite sequencing 
showed one out of eleven clones had a stretch of demethylated CpGs in the most 
upstream region of the two regions investigated. None of the six sequenced clones 
from the reporter plasmid cotransfected with the empty vector showed signiϐicant 
DNA demethylation (Fig. 1c). The effect was also tested on another in vitro methylated 
reporter plasmid (27 + 13% luciferase expression compared to the unmethylated 
reporter plasmid), which does not contain a CpG free backbone, has a different promoter 
and comprises 8 Lac Operator sequences. Cotransfection of this in vitro methylated 
plasmid with the plasmid encoding Gadd45α also resulted in upregulation of reporter 
gene expression (1.9 + 0.4-fold, p<0.01) compared to cotransfection with the empty 
vector (Fig. 1b).
In addition to candidate DNA demethylases, certain histone modifying enzymes 
might aid in activation of gene expression. To investigate genome-wide histone 




or aa 401-1401) in Cos-7 cells, a western blot was performed. Although slight decreases 
in H3K27me3 seem to be detected upon overexpression of UTX CD, no clear differences 




Figure 1. Overexpression of potentially gene 
expression activating epigenetic enzymes
(A) Genome-wide DNA methylation levels of gDNA 
from Cos7 cells determined by LUMA after transfection 
with the indicated constructs.  Error bars show the 
standard error of the mean. * p< 0.05, paired t-test. 
(B) Luciferase assay showing the fold induction of 
luciferase gene expression after cotransfections of an 
unmethylated (open bars) or in vitro methylated (ϐilled/
striped bars) reporter plasmids and a plasmid encoding 
Gadd45α. Error bars show the standard error of the 
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of recovered reporter plasmids; each box represents a CpG, grey is unmethylated, black is methylated. (D) 
Western blot to determine genome-wide H3K27me3 levels upon overexpression of UTX or UTX CD.
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Speciϐic targeting of candidate DNA demethylases to reporter plasmids
Speciϐic targeting of an enzyme might increase the detectability of the effect. 
Previously, cotransfections of plasmids encoding Up2-VP64 fusions (targeting the 
EpCAM promoter) and reporter plasmids containing the EpCAM promoter showed 
signiϐicant upregulation of gene expression (23). Therefore, Gadd45α was fused 
to Up2 and overexpressed upon cotransfection of its encoding plasmid with the in 
vitro methylated reporter plasmid comprising the EpCAM promoter. Upregulation of 
reporter gene expression by Up2-VP64 was conϐirmed for this reporter plasmid with a 
CpG-free backbone (8.4 + 0.8-fold, p<0.05) compared to cotransfections of the reporter 
plasmid with the empty vector. Upon in vitro methylation of the reporter plasmid before 
transfection, Up2-VP64 seems to still be able to induce reporter gene expression (5.9 
+ 2.1-fold, p=0.0643). This indicates that the ZF can bind despite hypermethylation of 
its recognition site. Data obtained for ZF-targeted Gadd45α, however, are inconsistent 
(Fig. 2a). 
To investigate whether the effect of untargeted Gadd45α (Fig. 1 and Fig. 2a) could 
be increased by combination with the Dnmt3 mutant enzymes, which are supposed to 
deaminate methylated cytosine, combined cotransfections were performed. In addition 
to overexpression of Gadd45α, plasmids encoding fusions of the Dnmt3 mutants to 
a ZF targeting the EpCAM promotor (EGP2A) were cotransfected with the reporter 
plasmid containing the EpCAM promoter. No additional effects were observed upon 
these cotransfections compared to Gadd45α alone (Fig. 2b). Also cotransfections of the 
reporter plasmid with only the plasmids encoding ZF-fused Dnmt3 mutants did not 
result in any signiϐicant change in gene expression (data not shown).
Targeting of candidate DNA demethylases to a repeat of target sites in a reporter 
plasmid
To exclude that one binding site for targeting is insufϐicient, the enzymes were fused 
to LacR and targeted to a reporter plasmid containing eight LacO sites. First, to be sure 
that the LacR fusion proteins were indeed expressed, western blots were performed 
(Fig. 3a). From the western blot of AO3_1 cell lysates it becomes clear that all LacR 
fusion proteins containing (putative) DNA demethylases are expressed and bands are 
detected at the expected heights. The LacR-UTX and LacR-UTX CD fusion proteins were 
not detectable. For LacR-UTX CD a band was detected upon expression of the constructs 
in Cos7 cells, although the height of the band seems to be higher (~150 kDa) than the 
predicted band height (74 kDa) (data not shown).
As for the reporter plasmid with the EpCAM promoter, in vitro methylation of the 
reporter plasmid containing eight LacO sites also resulted in efϐicient repression of gene 
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Figure 2. Targeted DNA demethylation to an EpCAM-luciferase reporter plasmid 
(A) Luciferase assay upon cotransfections of the indicated constructs with an unmethylated (open bars) or an 
in vitro methylated (black dots) EpCAM-reporter plasmid. For the methylated reporter plasmid, each of the 
three individual experiments is represented separately with black dots.  Error bars represent the standard 
error of the mean. * p<0.05, paired t-test. (B) Luciferase assay upon cotransfections of in vitro methylated 
(ϐilled bars) EpCAM-reporter plasmid with a combination of plasmid encoding untargeted Gadd45α and a 
plasmid encoding ZF-targeted mDnmt3a/b mutants. Error bars represent the standard error of the mean. * 
p<0.05, paired t-test. 
expression (2.3 + 1.1-fold, p<0.05) upon cotransfections with the unmethylated 
reporter plasmid (Fig. 3b). Moreover, expression of this construct also caused induction 
of luciferase expression when the reporter plasmid was in vitro methylated before 
cotransfections (2.8 + 0.9-fold, p<0.05), indicating that LacR binding, like ZF binding, is 
not completely prevented by methylation. However, whereas Up2-Gadd45α gave some 
indications of being able to induce luciferase expression when targeted to a methylated 
reporter plasmid, LacR-Gadd45α was not able to do so (Fig. 3b). 
Also in this system with more DNA binding domain target sites, targeted (LacR-
fused) mDnmt3 mutant enzymes could not further increase luciferase expression 
compared to untargeted Gadd45α (Fig. 3c). Cotransfection of the reporter plasmid with 
plasmids encoding the LacR-fused mDnmt3 mutant enzymes alone did not result in 
a difference in reporter gene expression compared to cotransfection with the empty 
vector (data not shown).
Targeting enzymes to large endogenous LacO repeats (total cell population 
analysis)
To investigate effects of the epigenetic enzymes in a situation closer to the natural 
situation, the enzymes were targeted to an extensive repeat of LacO sequences which 
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was integrated in a condensed chromatin region of mammalian AO3_1 cells (24). First, 
transfectability of AO3_1 cells was established by transfection of a plasmid with the 
same backbone and promoter (CMV) as the plasmids encoding for the LacR fusion 
constructs. ~60% of the cells were GFP positive, compared to ~5% for cells transfected 
with peGFP-LacR-VP16, containing a much weaker promoter (data not shown).
Upon targeting Gadd45α and the mDnmt3 mutants, MeDIP was performed to assess 
locus-speciϐic DNA methylation levels. Treatment of the cells with zebularine and 
M.SssI was used as a positive and negative control for DNA demethylation, respectively. 
It is difϐicult to perform PCR within the small repeats, as primers will bind in every 
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Figure 3. Targeted DNA demethylation at a LacO-luciferase reporter plasmid
(A) Western blot showing expression of LacR fusion proteins, using a LacR antibody. (B) Luciferase assay 
upon cotransfections of an in vitro methylated (ϐilled bars) LacO containing reporter plasmid and a plasmid 
encoding LacR-fused Gadd45α. Error bars show the standard error of the mean. * p<0.05, paired t-test. (C) 
Luciferase assay upon cotransfections of an in vitro methylated (ϐilled bars) LacO-reporter plasmid with 
a combination of a plasmid encoding untargeted Gadd45 and a plasmid encoding targeted mDnmt3a/b 






close proximity of the start of the LacO repeat or binding just behind the LacO repeat. 
However, differential DNA methylation was difϐicult to detect as also with the positive 
and negative control no visible effect on DNA methylation was obtained (Fig. 4a). 
Towards obtaining induction of expression of epigenetically silenced genes, also the 
histone modifying enzyme UTX CD was targeted to the extensive LacO repeat. The effect 
of this H3K27 demethylase was analyzed by ChIP, using the same primer sets as for 
MeDIP (Fig. 4b). However, no clear reproducible effects on histone modiϐication levels 
could be detected.
To investigate whether targeting of the epigenetic enzymes to the LacO repeat 
had any effect on expression of the mDHFR reporter gene present in the integrated 
construct, qRT-PCR was performed (Fig. 4c). 100 μM of DNA methylation inhibitor 
zebularine was able to induce a slight but signiϐicant increase in gene expression (1.4 
+ 0.2-fold, p<0.05), and 1 mM caused a 1.6 + 0.3-fold (p 0.0604) increase of mDHFR 
expression compared to untreated cells. No signiϐicant differences were detected upon 
profection of M.SssI. Also LacR-VP16, without or with eGFP fused to the construct, 
showed signiϐicant increases in expression of mDHFR (2.1 + 0.3-fold; p 0.0503 and 2.1 
+ 0.1-fold; p<0.05, respectively). However, in agreement with the assays to determine 
the change in molecular epigenetic marks, no signiϐicant changes in mDHFR mRNA 
expression were observed upon transfection of the (putative) epigenetic enzymes fused 
to LacR.
Targeting enzymes to endogenous LacO repeats (single cell analysis)
To by-pass the possibility that low transfection efϐiciencies cause the lack of effect 
seen in the AO3_1 cells, we also transfected the LacR fusion constructs in a different 
model cell line (U2os 2-6-3) where effects can be analyzed at single cell level through 
confocal imaging (Fig. 5). In this model system, transcripts of a gene in proximity of a 
repeat of LacO sites are visualized by marking them with a YFP-tag. Furthermore, the 
LacR fusion proteins are visualized using a secondary antibody with cy3 label which 
recognizes the LacR antibody. Decondensation of the LacO array as well as an increase 
in transcription of ms2 is clearly seen for LacR-VP16, as expected. Interestingly, also 
fusions of LacR to Gadd45α or the catalytic domain of UTX seem to increase expression 
of ms2 transcripts. The Dnmt3 mutant proteins and full length UTX did not show an 
increase in ms2 transcripts.
DISCUSSION
In this study, we set out to identify domains which, upon targeting to epigenetically 
silenced genes, would result in re-expression of that particular gene and methods to 
identify such domains. We show that out of ϐive different candidate DNA demethylases, 
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Figure 4. Targeting epigenetic effects to an extensive repeat of LacO sites integrated in a mammalian 
cell line
(A) MeDIP of two regions in close proximity of the LacO repeat upon treatment with zebularine, profection 
with M.SssI (left) or transfection with plasmids encoding LacR-fused putative DNA demethylases (right). (B) 
ChIP of two regions in close proximity of the LacO repeat upon transfection with LacR-UTX CD. (C) qRT-PCR 
of mDHFR expression upon treatment with zebularine, profection with M.SssI or transfection with LacR-
fusion proteins. Experiment with LacR-UTX fusion proteins (ϐigure on the right) is showing the average of 

















































































































































































































































































































overexpression of Gadd45α is able to show slight (but signiϐicant) genome-wide 
DNA demethylation. The enzyme is also able to induce gene expression from in vitro 
methylated reporter plasmids upon cotransfections, which is associated with some 
DNA demethylation. Importantly, when analyzing the effect of LacR fused to Gadd45α 
at single cell level in cells with an integrated LacO repeat (29), decondensation and an 
increase in transcription of the targeted reported gene was observed. Also LacR-UTX CD 
seems to have a positive effect on chromatin decondensation and transcription when 
analyzed at single cell level. 
Gadd45α overexpression caused signiϐicant increases in reporter gene expression 
of 5- or 2-fold, depending on the reporter plasmid used for cotransfections. The 
highest induction is achieved with a reporter plasmid that does not contain CpGs in its 
backbone (EpCAM reporter plasmid), whereas the other does (LacO reporter plasmid). 
It was described before that methylation of CpGs in the backbone and reporter gene of 












Figure 5. Single cell analysis of the 
effect of LacR-fused epigenetic 
enzymes
In this ϐigure, confocal imaging 
pictures are shown of U2os 2-6-3 
cells transfected with the constructs 
as indicated. The pictures in the left 
row show yfp-tagged ms2 transcripts. 
The middle row shows detection of 
the LacR-fused proteins using a LacR 
antibody. The row on the right is the 
overlay of the pictures. Arrows point 
towards the integrated LacO array. Bars 
at the bottom of the pictures represent 
a size of 5 μm.
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luciferase expression upon in vitro methylation was less in the LacO reporter plasmid 
compared to the EpCAM reporter plasmid, which also might (partially) explain the 
weaker increase in relative expression upon overexpression of Gadd45α. Nonetheless, 
the extent of induction of reporter gene expression by Gadd45α seems to be in a similar 
range as described by Barreto et al. where induction was approximately 3-fold (9). 
Although Barreto et al. could demonstrate that Gadd45α might play a role in active 
DNA demethylation, the extent of DNA demethylation is difϐicult to compare with our 
data since different methods were used. However, in both studies no massive DNA 
demethylation seems to occur. As bisulϐite sequencing only analyzes selected clones, the 
effect might be underestimated. In this respect, pyrosequencing can be performed to give 
quantitative results and might be able to detect more signiϐicant DNA demethylation.
Intuitively, the effect of an enzyme on a speciϐic locus would be increased upon 
fusing a locus-speciϐic DNA binding domain to the enzyme. Activation and repression 
of reporter gene expression by cotransfections was described previously upon fusion 
of the EpCAM ZFs used in this study to the transcription activator VP64 (four copies of 
the viral protein VP16) or the repressor KRAB, respectively (23). However, the effect 
on gene expression upon targeting Gadd45α to the EpCAM promoter of the reporter 
plasmid by fusing it to the speciϐic ZF was not signiϐicant, whereas a signiϐicant >4-fold 
induction was observed upon overexpression of the untargeted enzyme. Interestingly, 
the effects of untargeted Gadd45α and Up2-VP64 did not reach statistical signiϐicance in 
this experiment (Fig. 2a), in contrast to another experiment (Fig. 1b). So, it might be that, 
for example, the transfection efϐiciencies were low in this particular set of experiments. 
The lack of improved effects upon targeting Gadd45α speciϐically to the reporter 
plasmids could be explained by Gadd45α not being the ϐirst step in the DNA demethylation 
machinery. As such, the effects observed upon untargeted overexpression could be 
caused by recruitment of Gadd45α by other proteins and/or its recruitment of again other 
proteins as also indicated in (10). It could be of interest to investigate the other proteins 
in the complex and it might be beneϐicial to co-target one of those proteins. As Gadd45α 
activity was suggested to possibly be associated with deamination of the methylated 
cytosine (10), we decided to target DNA methyltransferases in combination with the 
overexpression of Gadd45α. The catalytic domains of the DNA methyltransferases used 
in this study were previously reported to be active in DNA methylation (34). As the 
observed role of these DNA methyltransferases in DNA demethylation (11, 12) was 
suggested to be most effective without the methyl donor (12), we made mutations in 
the S-Adenosyl Methionine (SAM) binding pocket. The lack of observation of signiϐicant 
genome-wide DNA demethylation effects of the DNA methyltransferases cannot be 
explained by the fact that in the present study only the catalytic domains of the proteins 




mutant enzyme created in this study was not tested before and might be ineffective 
in deamination. This could also explain the lack of additional effect upon targeting 
the protein domains to the reporter plasmids in fusions to ZFs in combination with 
overexpression of Gadd45α. Further investigation into the deamination mechanism 
of the DNA methyltransferases might give more indications on creating an effective 
domain for targeted approaches. 
As it might be that the ZF binding site is not located at a position that is interesting for 
DNA demethylation with regard to reporter gene expression (35) and, moreover, there 
is only one ZF binding site in the reporter plasmid (good for speciϐicity but perhaps 
not for efϐicacy), fusion to LacR and targeting to a repeat of 8 LacO sites in the reporter 
plasmid was exploited. However, no differences were detected compared to the EpCAM-
luciferase plasmid.
An even more extensive repeat of LacO sites has been integrated in mammalian cells 
(24). Whereas the intention of using the cells with the integrated extensive repeat of 
LacO sites was to amplify the effect of targeted epigenetic enzymes, some difϐiculties 
appeared for detection of the molecular epigenetic effects. Since there is such an amount 
of repeats of the LacO sites, PCR-based read-outs are difϐicult because primers will bind 
in every of the small LacO repeats. This might also explain the lack of detectable effects 
of LacR-fused UTX CD. A way to circumvent these problems might be through probe-
based detection of immunoprecipitated DNA (36).
This LacO/LacR system has proven its utility in visualization of effects on chromatin 
condensation (24, 26). In this way, fusion of LacR to the activation domain VP16 was 
shown to lead to decondensation of the chromatin and movement of the chromatin 
to the interior of the nucleus (37, 38). Expression of the mDHFR gene, which is also 
present in multiple copies in this system, has never been analyzed before upon targeting 
a LacR fusion protein to the repeat. Despite the fact that in the AO3_1 cells the repeat is 
integrated in a condensed chromatin region, DHFR seems to be considerably expressed 
in the control situation, because of the many copies of the DHFR gene present in the 
cell line (37). Nonetheless, in this study a slight increase of DHFR expression was still 
achieved by targeting LacR-VP16 to the repeat of LacO sequences and by treating the 
cells with zebularine. No difference in DHFR induction seems to occur when using a 
plasmid with a strong (CMV) promoter and no GFP compared to a plasmid with a weak 
promoter and encoding GFP-tagged LacR-VP16. Low induction of DHFR expression 
might be due to transfection efϐiciency, as is also indicated upon FACS sorting of GFP-
positive cells upon expression of the GFP fused LacR-VP16, showing an increased 
induction of gene expression of about 2.5 times (data not shown). 
However, transfectability of AO3_1 cells was established by transfection of a plasmid 
encoding GFP under the control of the highly active CMV promoter and appeared to 
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be ~60%, compared to ~5% for peGFP-LacR-VP16. This could also be due to very low 
levels of expression of GFP in the peGFP-LacR-VP16 construct, which might be below 
the detection limit. Interestingly, upon visually analyzing the effect of LacR-Gadd45α 
and LacR-UTX at a single-cell level in U2os 2-6-3 cells, decondensation and an increase 
of transcription were clearly visible. As these targeted effects could not be detected in 
total cell populations, this could indicate that transfection efϐiciency indeed caused an 
underestimation of the effect in the AO3_1 cells.
In conclusion, we conϐirm that Gadd45α seems to play a role in gene expression 
activation, which might be occurring through DNA demethylation. From the results 
obtained here, however, the other tested enzymes can not be excluded from the list of 
putative DNA demethylases. In addition, the catalytic domain of UTX is an interesting 
candidate for re-expressing epigenetically silenced genes. Further research is needed 
to identify the most potent enzyme or enzymes for activation of epigenetically silenced 
genes. Epigenetic Editing, the gene-speciϐic rewriting of epigenetic marks at endogenous 
genes is an interesting and promising tool to study the (sequence of) effects of the 
enzymes in more detail (16).
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The Epithelial Cell Adhesion Molecule (EpCAM) is overexpressed on carcinomas and 
its downregulation inhibits the oncogenic potential of multiple tumour types. Here, we 
investigated underlying mechanisms of EpCAM overexpression in ovarian carcinoma. 
EpCAM expression and DNA methylation (bisulphite sequencing) was determined 
for ovarian cancer cell lines. The association of histone modiϐications and sixteen 
transcription factors with the EpCAM promoter was analyzed by chromatin 
immunoprecipitation. Treatment with 5-Aza-2’-deoxycytidine (5-AZAC) was used to 
induce EpCAM expression. 
EpCAM expression was correlated with DNA methylation and histone modiϐications. 
Treatment with 5-AZAC induced EpCAM expression in negative cells. Ten transcription 
factors were associated with the EpCAM gene in EpCAM expressing cells, but not in 
EpCAM-negative cells. Methylation of an Sp1 probe inhibited the binding of nuclear 
extract proteins in electromobility shift assays; such DNA methylation sensitivity was 
not observed for an NF-κB probe. 
This study provides insights in transcriptional regulation of EpCAM in ovarian 
cancer. Epigenetic parameters associated with EpCAM overexpression are potentially 
reversible, allowing novel strategies for sustained silencing of EpCAM expression.
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INTRODUCTION
The Epithelial Cell Adhesion Molecule (EpCAM; CD326) is a transmembrane 
glycoprotein, highly overexpressed on most carcinomas. Recently, EpCAM also gained 
interest as a signal transducer (1) and as a marker of cancer-initiating cells (2). The role 
of EpCAM in the development of cancer and in tumour progression is dependent on the 
tumour type as recently reviewed by us (3). For example, in breast cancer high EpCAM 
expression correlates with poor prognosis (4), and downregulation of EpCAM has been 
shown to decrease the oncogenic potential (5). In contrast, high EpCAM expression in 
for example primary renal cell carcinomas is associated with improved patient survival 
(6, 7). In other types of carcinoma like ovarian cancer, the role of EpCAM is not clear and 
contradictory results have been reported. 
 In normal ovary and benign ovarian tumours, EpCAM expression is lower 
compared to malignant ovarian tumours (8). Numerous studies conϐirmed the EpCAM 
overexpression in ovarian carcinomas (9, 10, 11), turning EpCAM into a well established 
ovarian tumour marker (12). The role of EpCAM in ovarian tumour progression, 
however, is unclear: one study reported that FIGO stage III/IV showed lower EpCAM 
expression than stage I (8), while in another study, FIGO stage III/IV showed higher 
EpCAM expression than stage I/II disease (9). Importantly, metastatic and recurrent 
tumours were found to express signiϐicantly higher levels of EpCAM protein when 
compared with primary ovarian carcinomas (13). Despite some contradictory results, 
the observations suggest a promoting rather than a protecting role for EpCAM in ovarian 
cancer. This promoting role is further conϐirmed for patients with stage III/IV disease, 
for whom EpCAM overexpression was shown to correlate signiϐicantly with decreased 
overall survival (11). 
 Besides its possible prognostic role in ovarian cancer, EpCAM is used as 
a therapeutic immunotarget for the treatment of malignant ascites. For example, 
catumaxomab is a trifunctional monoclonal antibody (anti-EpCAM X anti-CD3) 
approved to treat ovarian cancer patients with malignant ascites (14). Recently, it has 
been reported that catumaxomab treatment might also have an effect on tumour cells 
in blood of ovarian cancer patients (15). Similarly, the human monoclonal antibody 
MT201 could effectively eliminate malignant cells in metastic tumour specimens from 
patients with ovarian cancer (16).
For various tumour types, EpCAM overexpression has been associated with DNA 
hypomethylation of the promoter and treatment of EpCAM-negative cells with a DNA 
methylation inhibitor induced EpCAM expression (17, 18, 19). Alternatively, we also 
demonstrated that endogenous EpCAM expression can be actively downregulated 
by nuclear delivery of a DNA methyltransferase (19). Here, we investigate epigenetic 




ovarian cancer. Unlike genetic mutations, epigenetic mutations are reversible: a better 
understanding of the regulation of EpCAM gene expression may thus provide new 
opportunities for cancer therapy based on reversing epigenetic marks.
MATERIALS AND METHODS
Cell culture and 5-AZAC treatment 
Ovarian cancer cell lines (H134S, SKOV3, CaOV3, OVCAR3) were cultured in DMEM 
(BioWhittaker, Walkersville, MD) and A2780 in RPMI-1640 (BioWhittaker) with 
50 μg/ml gentamicin sulphate, 2 mM L-glutamine and 10% FBS. Culture medium of 
A2780 contained also 1 mM Na-pyruvaat and 0.05 mM β-mercapto-ethanol. For DNA 
methylation inhibition studies, H134S and A2780 were cultured in their appropriate 
media with a ϐinal concentration of 5 μM 5-Aza-2’-deoxycytidine (5-AZAC; Sigma, St 
Louis, MO). Every day freshly prepared 5-AZAC was added, and after 3 days cells were 
harvested for extraction of protein and mRNA.
EpCAM protein expression 
EpCAM protein was detected by mouse Mab MOC31 hybridoma supernatant, 
followed by RM-F(ab)
2
-FITC (DAKO, Glostrup, Denmark) or mouse CD326-APC 
(Biolegend, Uithoorn, Netherlands). The Mean Fluorescence Intensity (MFI) was 
measured on a Calibur ϐlow cytometer (Beckton Dickenson Biosciences, San Jose, CA). 
Quantitative gene expression analysis by Real-Time RT-PCR 
RNA was isolated using Rneasy Mini Kit (Qiagen, Venlo, Netherlands), 1 
μg was reverse-transcribed (RevertAid cDNA Synthesis Kit, Fermentas, Leon-
Rot Germany). Q-PCR was performed (ABIPrism 7900HT, Applied Biosystems, 
Nieuwekerk, Netherlands) for EpCAM (Hs00158980_m1, Applied Biosystems) and 
GAPDH (F5’-CCACATCGCTCAGACACCAT-3’, R5’-GCGCCCAATACGACCAAAT-3’, probe: 
CGTTGACTCCGACCTTCACCTTCCC (Eurogentec, Maastricht, Netherlands)) in triplicate. 
Relative gene expression levels were calculated based on the comparative cycle 
threshold (Ct) method (ΔCt = Ct EpCAM - Ct GAPDH). To compare EpCAM expression of 
different samples, the differences in ΔCt of individual samples (ΔΔCt) was used (A2780 
was set at 1).
DNA methylation analysis 
EZ DNA Methylation-Gold Kit (Baseclear Lab Products, Leiden, Netherlands) was 
used to modify 1 μg of DNA. DNA methylation analysis was performed as described 
(20). Bisulphite primer sequences for regions A and B are depicted in Fig. 1a. The 
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correlation between EpCAM expression and DNA methylation was assessed by 
Spearman correlation test.
Chromatin ImmunoPrecipitation (ChIP) 
Histone modiϐications were determined using antibodies from Upstate 
Biotechnology (Lake Placid, NY, USA): rabbit IgG, acH4, acH3, H3K4me1, H3K4me3, 
H3K9me3, H3K27me3, H3K36me2 according to the Upstate protocol with the following 
modiϐications. Fixated cells were sonicated using a Bioruptor (High, 15 cycles: 30’’on 
30’’off) (Diagnode, Liège, Belgium). Chromatin fragments were diluted 2.5-fold and 
precleared for 2h at 4°C. Incubation with antibody was followed by 2h incubation with 
60 μl protein A/G-agarose beads. DNA was puriϐied using QiaQuick DNA spin columns 
(Qiagen, Venlo, Netherlands). To detect association of transcription factors, ChIP 
was performed as described (21), using the antibodies: mouse IgG, LEF-1(REMB6)
TCF (Millipore, Amsterdam, Netherlands), Sp1 (Upstate), STAT3 (Upstate), and from 
Santa Cruz Biotechnology (Heidelberg, Germany): NF-κBp50(NLS), NF-κBp65(A), 
ESE-1(H-270), SNAI1(E-130), SLUG(H-140), Ets-1(C-20), Ets-2(C-20), AP2-α(C-18), 
PEA3(H-120), PDEF(H-250), E2F-2(C-20), E2F-4(C-20) and p53. For the Real Time PCR 
a freshly made calibration line was included for every primer set used and PCR was 
ϐinished with a dissociation curve. Conventional PCR was performed according to the 
protocol of  Fermentas (St. Leon-Rot, Germany). 
Real Time PCR was performed using AbsoluteTMQPCR SYBRGreenROXMix (Abgene, 
Surrey, UK), ABI7900HT. The % input was expressed as AE(Ctinput-CtChIP)* Fd *100%, where 
Fd is a dilution compensatory factor and AE represents the primer efϐiciency. Primers 
for region A1, B1, B2 and C are depicted in Fig. 1a and underlined in Fig. 1b. 
ElectroMobility Shift Assay 
OVCAR3 nuclear extract was prepared using an NE-PER kit (Pierce Biotechnology, 
Etten-Leur, Netherlands). RDY681-labelled probes (Isogen, De Meern, Netherlands) are 
depicted in Fig. 1b. Probes were incubated with 4 μg nuclear extract in 20 μl binding 
buffer (Pierce Biotechnology) for 20’ at R.T. For competition assays, a 100-fold excess 
of unlabelled competitor was premixed with RDY681-labelled probe and added to the 
binding mixture. Probes were in vitro methylated by M.SssI (New England Biolabs, 
Ipswich, MA). Unmethylated probes were treated similarly but in the absence of methyl 
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Region B -130-443 







                               Region C 
-617.TAGAAATGCT TATGAAAACG AAAAAAGAAT TATTAAGAGT AATTATAAAG AAACACTCAT TTTCTTCCCA AGAGAGCCAA  
    PU1.01/Ets         LEF1              LEF1 
-537.GATTTCTTCT TTCCTCTTCT TTCTTTTTTT TTTCTTTCTA ATTTCAAAGG AGTATAATTA AATTGCCAGG TAAAAGCTCA 
   Start region B  B2                   PU1.01/Ets  C   STAT1    
-457.AAGGTCTTTT TTATAGTGTT CTGGAAGGTT CTCTGCCTGT GTTTGTATTT CCTTTAGCCT CCACGTTCCT CTATCCAGTT  
      E2F4             AP-2     B1    PEA3  
-377.CCCGCACCCT TCCCCCCAGG CCCCATTCTT CAAGGCTTCA GAGCAGCGCT CCTCCGGTTA AAAGGAAGTC TCAGCACAGA  
                  LEF1    B2                     Sp1/Sp1a 
-297.ATCTTCAAAC CTCCTCGGAG GCCACCAAAG ATCCCTAACG CCGCCATGGA GACGAAGCAC CTGGGGCGGG GCGGAGCGGG 
      B1     RNApolIIB             Sp1   Start region A 
-217.GCGCGCGGGC CCACACCTGT GGAGAGGGCC GCGCCCCAAC TGCAGCGCCG GGGCTGGGGG AGGGGAGCCT ACTCACTCCC 
     A1     Sp1     AP-1             STAT1/3/Ets   
-137.CCAACTCCCG GGCGGTGACT CATCAACGAG CACCAGCGGC CAGAGGTGAG CAGTCCCGGG AAGGGGCCGA GAGGCGGGGC 
                         Sp1b                      TSS 
 -57.CGCCAGGTCG GGCAGGTGTG CGCTCCGCCC CGCCGCGCGC ACAGAGCGCT AGTCCTTCGG CGAGCGAGCA CCTTCGACGC  
       NFțB-p50      A1      HIF1 
 +23.GGTCCGGGGA CCCCCTCGTC GCTGTCCTCC CGACGCGGAC CCGCGTGCCC CAGGCCTCGC GCTGCCCGGC CGGCTCCTCG 
 
+103.TGTCCCACTC CCGGCGCACG CCCTCCCGCG AGTCCCGGGC CCCTCCCGCG CCCCTCTTCT CGGCGCGCGC GCAGCATGGC 
 







   
Figure 1. Part of the EpCAM gene under investigation 
(A) Schematic overview: nucleotide position -610 to +282 relative to the transcription starting site (TSS); 
the ATG start codon is shown; CpGs are depicted by vertical bars. Region A and B were analyzed for DNA 
methylation, region C, B2, A1 for histone modiϐications and region B1 and A1 for transcription factors. Open 
circles represent putative Sp1 and NF-κB  binding sites. (B) Nucleotide positions -617 to +282 relative to 
the TSS are shown; the ATG start codon is depicted in bold. The start of region A and B are indicated in blue 
and PCR primers are underlined. Putative transcription factor binding sites analyzed by in silico analysis 
(Genomatix, MatInspector version 7.7.3.1) are indicated in red. Probes for EMSA to investigate interference of 
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levels: two EpCAM-negative lines (H134S, A2780; MFI: 4.6±0.05, 2.6±0.14 respectively), 
SKOV3 with an intermediate EpCAM expression level (MFI: 104±3) and two cell 
lines (CaOV3, OVCAR3) with a high EpCAM expression level (MFI: 461±30; 496±24, 
respectively) (Fig. 2a). The protein data are in line with the EpCAM mRNA levels (Fig. 2b). 
To determine the role of DNA methylation in silencing EpCAM expression, the EpCAM 
negative cell lines were treated with a DNA methylation inhibitor. Indeed, treatment 
with 5-Aza-2’-deoxycytidine resulted in induction of EpCAM expression in the EpCAM 
negative cell lines H134S and A2780, both on protein and mRNA level (Fig. 2a and 2b). 
To further investigate the correlation between EpCAM expression and DNA methylation, 
the methylation status of the EpCAM promoter and part of exon 1 was analyzed. In the 
EpCAM-negative cell lines, the 61 CpGs present in region A were hypermethylated 
(A2780: 100±0%; H134S: 89±23%), whereas region A in EpCAM-positive cell lines 
was hypomethylated (SKOV3: 1±3%; CaOV3: 0.5±3%; OVCAR3: 0±2%) (Fig. 2c, Table 
1). Interestingly, low to undetectable EpCAM expressing normal epithelial ovarian 
cancer cells (HOSE) (8, 13) displayed a variable DNA methylation level of 15±21% (n = 
10 clones). For region B (18 CpGs), the DNA methylation levels were 99±2%, 56±17%, 
9±13%, 3±6%, 1±5% for A2780, H134S, SKOV3, CaOV3, OVCAR3, respectively (Fig. 2c, 
Table I). In the cell lines, an inverse correlation between EpCAM expression and DNA 



















































































DNA methylation A2780 H134S SKOV3 CaOV3 OVCAR3
Region A 100% (4) 89% (6) 1% (9) 0.5% (6) 0% (6)
Region B 99% (11) 56% (10) 9% (10) 3% (10) 1% (10)
A B
C
Figure 2. EpCAM expression in correlation with DNA methylation in ovarian cancer 
To compare EpCAM expression between the different cell lines, untreated A2780 was set at 1. A) The average 
(±SD) of the relative Mean Fluorescence Intensity of one representative staining performed in triplicate is 
shown. B) Quantitative RT-PCR analysis showing relative EpCAM mRNA levels C) The % of DNA methylation 
represents the number of methylated CpGs divided by the total number of CpGs present in the region. For 




Histone modiϐications associated with EpCAM expression
In EpCAM-positive cells, region C and B2 were associated with acetylated histone 
4 (acH4), acetylated histone 3 (acH3) and with trimethylation of lysine 4 of histone 
3 (H3K4me3) (Fig. 3a and 3b, Table 1). For region A1 covering the TSS, the presence 
of these active marks was even more pronounced (Fig. 3c). In EpCAM-negative cells, 
association of these histone modiϐications was not detected, except for low levels of 
acH3 up to 1% of input DNA at region A1 (Fig. 3d).
The repressive histone modiϐications H3K9me3 as well as H3K27me3 were not 
detected in EpCAM-positive cells. Interestingly, in the EpCAM-negative cells region 
A1 was associated with repressive marks: in A2780, region A1 was associated with 
H3K9me3; whereas in H134S the promoter was associated with H3K27me3 (Fig. 3d, 
Table 1).
In vivo EpCAM gene occupancy by transcription factors 
Locations of transcription factor binding sites in the EpCAM promoter as described 
in literature (22, 23, 24, 25), as well as additional putative sites obtained by Genomatix 
MatInspector are shown in Figure 1b. The transcription factors screened for in vivo 
association with the EpCAM promoter were selected based on evidence for a biological 
role in EpCAM regulation (18, 24, 25, 26) and their potential role in ovarian cancer (27, 
28, 29, 30).
In the EpCAM-positive OVCAR3 cells, the promoter was associated with Sp1, NF-κB, 
 ʹ͹ͺͲ ͳ͵Ͷ ͵ ͵ ͵
 Ǧ Ǧ Ϊ ΪΪ ΪΪ
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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activehistonemarksRegionA1
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Ͷ Ǧ Ǧ ΪΪ ΪΪ ΪΪ
͵ Ǧ Ǧ ΪΪ ΪΪ ΪΪ
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͵ͻ͵ Ϊ Ǧ Ǧ Ǧ Ǧ
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Ȁ ΪΪΪ ΪΪ ΪȀǦ Ǧ Ǧ
Table 1. Epigenetic marks associated with EpCAM expression
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Figure 3. Histone modiϐications associated with EpCAM expression. 
Histone modiϐications associated with region C (A), region B2 (B) and A1 (C,D) 
within the EpCAM gene in EpCAM-negative (-) and -positive (+) cells. The absence 
of antibody (no Ab) and rIgG were used as negative controls. The bars represent the 










































































































































































Region A1 EpCAM pos. cells
Region B2
Region A1 EpCAM neg. cells
Region C
LEF-1, E2F2, Ets-1 and Ets2 for both regions tested (Table 2 and Fig. 4), whereas E2F4, 
p53, AP-2α and STAT3 were only associated with region B1. In the EpCAM-positive 
CaOV3 cells, the promoter was associated with the same transcription factors as for 
OVCAR3, except that for p53 and STAT3 no association was detected. The transcription 
factors LEF-1 and Ets1 were associated with region A1, whereas association of Sp1, 
E2F2, Ets2 and again AP-2α were only found in region B1. In the EpCAM-negative cells 
A2780 and H134S, no association of any of the transcription factors with region A1 
nor with region B1 was detected (Table 2). In addition, no association of ESE-1, SNAI1, 
SLUG, PEA3, and PDEF was detected in EpCAM-positive nor in EpCAM-negative cells 
(data not shown). 
Interference on binding of transcription factors by DNA methylation 
The ChIP data suggest a role for NF-κB and Sp1 in regulating EpCAM gene e xpression. 
Our bisulphite sequencing revealed that the CpG next to the putative binding site of NF-
κB (located at +27, NF-κB in Fig. 1b) was methylated in all clones of the EpCAM-negative 
cells and not methylated in the EpCAM-positive cells. Similarly, for the CpG present in 
a putative binding site for Sp1 (located at -32 , Sp1b in Fig. 1b), complete methylation 
in all clones was observed in the EpCAM-negative cells, whereas in the EpCAM-positive 
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Figure 4. Transcription factors associated with the EpCAM gene. 
ChIP analysis on EpCAM-positive (OVCAR3, CaOV3) cells performed with the indicated antibodies, IgG was 
used as a negative control, PCR was performed with primers for region A1 and B1.
putative binding sites for Sp1 (located at -231 and -226, Sp1a in Fig. 1b), were both 
methylated in the EpCAM-negative cells (A2780: 22/22 clones, H134S: 14/20 clones), 
whereas in the EpCAM-positive cells, these two CpGs were not methylated (SKOV3 and 
CaOV3: 1/20 clones, OVCAR3: 0/20 clones). 
To investigate whether the observed DNA methylation actually interferes with 
binding of the transcription factors to the EpCAM promoter, EMSA competition studies 
were performed. Shift assay with unmethylated probe Sp1a (Fig. 1b) and nuclear 
protein extract of OVCAR3 cells revealed two bands (a+b) (Fig. 5a). Both bands were 
also observed for the methylated Sp1a probe, but the binding of nuclear protein to the 
methylated probe was less efϐicient than to the unmethylated probe (lane 2 compared 
with 6). Also competition with an excess of cold unmethylated Sp1a probe was more 
efϐicient than with a methylated probe, indicating that Sp1 binds preferentially to the 
unmethylated Sp1a binding site within the EpCAM promoter. Shift assay with the Sp1b 
probe and nuclear extract of OVCAR3 cells revealed two bands with the unmethylated 
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DISCUSSION
Epigenetic aberrations, including DNA methylation and histone modiϐications, 
are well established in the development and progression of ovarian cancer (31, 32). 
A number of protein coding genes are overexpressed in ovarian cancer due to loss of 
DNA methylation, including maspin, claudin-3 (33) and claudin-4 (32). In addition, 
overall loss of the repressive histone mark H3K27me3 has been associated with poor 
prognosis in ovarian cancer (34). In this study, we set out to unravel the epigenetic 
marks underlying EpCAM overexpression in ovarian cancer. 
In our ovarian cancer cell line panel, EpCAM expression was inversely correlated 
with the DNA methylation status of the promoter and part of exon 1, as reported for 
several other tumour types (17, 18, 19, 35). Interestingly, treatment of our EpCAM 
negative ovarian cancer cells with a DNA methylation inhibitor induced EpCAM 
expression, both on mRNA and protein level. The role of DNA methylation in silencing 
EpCAM has been previously published by us for the intermediate EpCAM expressing 
SKOV3 ovarian cancer cells, and is in line with observations in other tumour types (17, 




































Hot-unmethylated Hot-methylated Hot-unmethylated Hot-methylated
Figure 5. Interference of DNA methylation on binding of Sp1. 
Competition EMSA’s were performed with hot (un)methylated Sp1a and Sp1b probes and nuclear extracts 
(NE) of OVCAR3 cells. The speciϐicity and methylation sensitivity of the band of interest were shown by using 
the cold competitors (lane 1,5: probe; 2,6: probe with NE; 3,4: probe with NE in the presence of 100-fold 
excess of indicated competitor).
probe as well as with the methylated probe (Fig. 5b). One of the bands is not speciϐic 
(N.S.) since the band intensity was not reduced with an excess of competitor. The other 
band indicated with an S, showed competition with both an excess of unmethylated as 
well as an excess of methylated probe, indicating that for this particular sequence the 
transcription factor binds to the Sp1b probe regardless of DNA methylation status of the 
CpGs within this probe. Also for the NF-κB probe, no difference in binding patterns to 




several ovarian cancer cell lines, including SKOV3, CaOV3 and OVCAR3, EpCAM mRNA 
was reported to be 3 log higher compared to HOSE cells (8). Also on protein level, HOSE 
cultures showed negative to negligible levels of EpCAM expression (13). This unexpected 
low DNA methylation level for EpCAM HOSE cells is in line with data of differentiating 
human embryonic stem cells, where EpCAM silencing was not associated with increased 
DNA methylation (36). In these cells, EpCAM silencing was associated with a reduction 
of active histone marks and an enhancement of repressive histone marks (36). Also 
in our panel of EpCAM-negative cell lines, we found the silenced EpCAM promoter to 
be associated with repressive marks (H3K9 or H3K27 trimethylation); while relative 
low levels of active histone marks (H3/H4 acetylation, H3K4 trimethylation) were 
observeThe epigenetic marks found in the EpCAM-negative cells indicate a closed 
chromatin conformation, which might explain the absence of association of any of the 
tested transcription factors with the EpCAM gene in H134S and A2780 cells. Out of 
the sixteen tested transcription factors, ten were associated with the promoter in the 
EpCAM expressing cells. We are the ϐirst to show association of AP2α, Ets1, Ets2, E2F2, 
E2F4 and STAT3 with the EpCAM gene. Of special interest are the associations found for 
nuclear AP2α and Ets-1, as high levels of these transcription factors have been related 
to poor prognosis in ovarian cancer (27, 28). Similarly, a high E2F2 to E2F4 ratio was 
reported to be of prognostic value for ovarian cancer-free survival (29). Also STAT3 is 
overexpressed in ovarian cancer compared to normal or benign ovarian tumour tissue, 
and its expression was signiϐicantly higher in FIGO stage III/IV compared to stages I/
II (30). Although our data indicate that the relation between transcription factors and 
clinical parameters might partially take place via EpCAM expression regulation, the 
direct biological signiϐicance needs to be further established. 
For the transcription factors, p53, NF-κB, Sp1 and LEF-1 (25) evidence for regulating 
EpCAM expression was previously demonstrated in other tumour types. Although wild-
type p53 and not mutant p53 has been reported to repress EpCAM expression (24), we did 
not observe p53 association in EpCAM negative cells. The observed association of p53 in 
the EpCAM-positive, p53-mutant OVCAR3 cells (37) is in agreement with the acetylated 
histones associated with the promoter in these cells, as mutant p53 recruits the histone 
acetyl transferase p300 (38). In the presence of p300, the repressive action of NF-κB 
on EpCAM promoter activity was abolished (26), which might explain the association 
of NF-κB and acetylated histones with the EpCAM promoter in EpCAM-positive cells. 
Also Sp1 has previously been reported to be involved in EpCAM transcription (18). 
Interestingly, our observation that the CpG located at -231 within the Sp1 binding site 
was methylated in EpCAM-negative ovarian cell lines and unmethylated in the EpCAM-
positive lines was also reported for several other types of tumours (35). Together with 
our in vitro ϐinding that methylation of this particular CpG affects Sp1 binding, this 
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region is currently explored by us for targeted DNA methylation approaches (20).
Apart from DNA methylation and histone modiϐications, other epigenetic 
mechanisms, including non-coding RNAs, may be (directly and indirectly) involved in 
EpCAM gene regulation. In this respect, microRNA-181 has been shown to upregulate 
EpCAM gene expression, possibly via a positive feedback loop between miR-181 and 
Wnt/β-catenin signalling (39). These observations are in line with our data showing 
association of the Wnt-pathway transcription factor LEF1 with the active EpCAM 
promoter. Alternatively, several endogenous non-coding RNAs have been reported to 
be capable of modulating gene expression directly on the transcriptional level e.g. by 
inducing DNA methylation (40).
At present, EpCAM is exploited as therapeutic target in several antibody-based clinical 
trials. Recently, the European Medicines Agency approved the use of catumaxomab for 
the intraperitoneal treatment of malignant ascites (14). The oncogenic role of EpCAM 
broadens the interest to use EpCAM not only as an immunotarget, but also as a target 
for epigenetic silencing. In this respect, transient siRNA-mediated silencing of EpCAM 
expression has been shown to reduce the oncogenic potential of breast (5), gastric (41), 
hepatocellular (25) and oral squamous cell (42) carcinomas. 
To silence gene expression in a more sustained way, targeted DNA methylation has 
been achieved by fusing a DNA methyltransferase to a DNA binding domain like zinc 
ϐingers (43). Similarly, transcription effector domains fused to zinc ϐingers targeting the 
EpCAM promoter modulated EpCAM promoter activity (44). Recently, we showed that 
an EpCAM speciϐic Triple helix Forming Oligonucleotide coupled to a methyltransferase 
variant is able to target methylation predominantly to a speciϐic CpG in the EpCAM 
promoter (20). Interestingly, targeted methylation in living cells induced dense 
methylation up to 380bp on both sides of the target site (45), suggesting that initial 
DNA methylation might serve as a trigger for DNA methylation spreading. Elucidating 
the regulation mechanisms of EpCAM in ovarian cancer as presented here thus opens 
up new possibilities to exploit EpCAM as a therapeutic target.
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Ovarian cancer is a difϐicult-to-treat cancer with a 5-year survival rate of only ~45 
%, partially due to late diagnosis and therapy resistance. In need of new therapeutic 
approaches, induction of InterCellular Adhesion Molecule-1 (ICAM-1) expression might 
be of interest, since the expression of ICAM-1 is lower in ovarian cancer cells compared to 
healthy ovarian cells and positively correlated with decreased tumorigenicity. Whereas 
ICAM-1 expression on tumor cells is described to be of importance for adherence to 
immune cells, the cellular role of ICAM-1 in tumorigenicity and therapy resistance of 
ovarian cancer is unclear.
Here, we conϐirmed epigenetic silencing of the ICAM-1 gene in ovarian cancer cells, 
enabling re-expression from the endogenous locus. To investigate its cell-biological role, 
ICAM-1 expression was gene-speciϐically induced in vitro in a panel of ovarian cancer 
cells via retroviral transduction of Artiϐicial Transcription Factors (ATFs). Subsequently, 
tumor growth and cisplatin sensitivity were evaluated with MTT assays and activation 
of monocytes by transduced ovarian cancer cells (with induced ICAM-1 expression) 
was determined by ICAM-1 protein staining of the monocytes upon co-culture. 
Induction of ICAM-1 expression ranged from 2- to 228-fold on mRNA level and 1.7- 
to 108-fold on protein level. This resulted in a slight activation of monocytes, a decrease 
of ovarian cancer cell growth (up to 2-fold) and (consequently) reduced cisplatin 
sensitivity.
This study shows that, apart from its established role in the immune system, ICAM-
1 plays a role in cell biological behavior of ovarian cancer cells. Moreover, this study 
shows that re-expression by ATFs represents a powerful approach for target validation 
of genes epigenetically silenced in cancer, like ICAM-1.
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INTRODUCTION
Ovarian cancer is one of the most difϐicult to treat cancers with a ϐive-year survival 
rate of only ~45% (in the UK (1)), which is partially due to subtle early symptoms, 
resulting in late diagnosis. The use of platinum based agents such as cisplatin is one 
of the major therapies for ovarian cancer. However, the therapeutic effects of cisplatin 
are insufϐicient because many patients either develop resistance against cisplatin or 
intrinsically resistant (cancer stem) cells eventually grow out (2). Thus, there is a need 
for new approaches and novel therapeutic targets. Immunotherapy to attract immune 
cells is an example of such an alternative approach that is currently explored to increase 
therapeutic efϐicacy for ovarian cancer patients (3).
In this respect, overexpression of proteins (in tumor cells) that provoke an 
immune response, such as InterCellular Adhesion Molecule-1 (ICAM-1) (4), might 
be an effective approach. Indeed, the percentage of ICAM-1 positive tumor cells was 
positively correlated with the amount of mononuclear inϐiltration in renal-cell cancer 
(5). In addition, for the majority of ovarian cancer cell lines and primary ovary tumors, 
the expression of ICAM-1 was shown to be reduced compared to healthy ovary cells, 
as described by Arnold et al. and references therein (6). In fact, a signiϐicant positive 
association was observed between ICAM-1 expression and survival of ovarian cancer 
patients (6). In line with these ϐindings in ovarian cancer, also for other cancer types 
(including lymphoma, colorectal cancer and head and neck cancer) tumor growth and 
metastasis were lower and a better prognosis was reported for patients with ICAM-1 
positive tumors compared to ICAM-1 negative tumors (7, 8, 9). 
Despite these reports, suggesting a tumor suppressive role for ICAM-1, ICAM-1 
expression can also negatively affect prognosis of a patient, as studies in e.g. melanoma 
and gastric cancer associated higher ICAM-1 expression with an increase in metastasis 
(10, 11). Adhesion of ICAM-1 expressing tumor cells to activated leukocytes and thereby 
induction of migration of tumor cells away from the primary tumor was suggested to 
explain the observed metastasis.
Dependent on cellular context, ICAM-1 seems to have different roles in tumorigenicity 
and even within the same cell type inconsistent data was reported: in one breast cancer 
study ICAM-1 expression on the tumor cells was correlated with reduced tumorigenicity 
(12), whereas in another study (13) increased tumorigenicity was shown when ICAM-1 
was expressed on the breast cancer cells. This discrepancy might be explained by the 
differential expression of other genes that were not taken into account in these studies, 
showing the need of further speciϐic investigation of single genes.
To address the biological role of one particular gene, Artiϐicial Transcription Factors 
(ATFs) are a suitable tool, since they speciϐically modulate the expression of the target 




sequence of interest, such as Zinc Fingers (ZFs)(14), fused to transcriptional activation 
or repression domains, like VP64 (four copies of the viral protein VP16) or SKD (Super 
KRAB Domain), respectively (15). Such ATFs have previously been shown by us(16) 
and others(17, 18) to effectively up- or downregulate genes both in vitro and in vivo, 
including epigenetically silenced genes and including ICAM-1 (18). 
In this study, ATFs were exploited to determine the cell-biological role of ICAM-1 in 
ovarian cancer. Gene-speciϐic induction of ICAM-1 expression resulted in inhibition of 
ovarian cancer cell growth and (thereby) in decreased sensitivity of the ovarian cancer 
cells to cisplatin. This study is the ϐirst to describe an immune-response-independent 
cellular role of ICAM-1 in ovarian cancer.
MATERIALS AND METHODS
Cell culture
Ovarian cancer cell lines A2780, SKOV3, H134S, OVCAR3 and CaOV3 and virus 
producing HEK293T cells were cultured in DMEM (BioWhittaker, Walkersville, MD, 
USA), supplemented with 50 μg ml-1 gentamicin sulphate, 2 mM L-glutamine and 10% 
FBS. Monomac-6 cells (19) were cultured in RPMI-1640 medium (BioWhittaker), 
supplemented with 50 μg ml-1 gentamicin sulphate, 2mM L-glutamine, 10% FBS, 1mM 
Na-pyruvaat and 0.05 mM ß-mercapto-ethanol. All cells were cultured at 37°C under 
5% CO
2
. Cells were treated for 24 hrs with 20 ng ml-1 TNF-α or every 24 hrs with 5 μM 
5-Aza-2’deoxycytidine (5-aza) and then harvested for subsequent analysis.
Retroviral transductions
Retroviral transductions were performed using a standard protocol (20). HEK293T 
cells were transfected using calcium phosphate with virus particle producing plasmids 
and 7.5 μg of pMX-IRES-GFP (empty vector), pMX-CD54-opt31 (ZF only), pMX-CD54-
opt31-VP64 (ZF-VP64) or pMX-CD54-opt31-SKD (ZF-SKD), kindly provided by C.F. 
Barbas III (The Scripps Research institute, La Jolla, CA, USA)(18). 48 hrs after transfection, 
medium of the HEK293T cells was harvested and replenished. The harvested medium 
was supplemented with FBS and 5 μg ml-1 polybrene (Sigma, St Louis, MO, USA) and 
added to the ovarian cancer host cells. This procedure was repeated the next day. 72 
hrs after the ϐinal transduction, host cells were harvested and divided for RNA isolation, 
protein staining, or cellular read out assays.
Co-culture monomac-6
For co-culture experiments, transduced A2780 and SKOV3 cells were replated 72 
hrs after the ϐinal transduction. 24 hrs later, medium was removed and monomac-6 
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cells were added to obtain a 1:1 ratio. After 24 hrs of coculture, cells were harvested, 
stained for CD45 and ICAM-1 and analyzed by ϐlow cytometry. In parallel, monomac-6 
cells were stimulated with 2 μg ml-1 LPS for 4 hrs as a positive control.
qRT-PCR
RNA was isolated using a Qiagen RNeasy plus mini kit (Qiagen, Hilden, Germany). 
Subsequently, cDNA was synthesized with random hexamer primers using the 
Fermentas Revertaid cDNA synthesis kit (Fermentas, Leon-Rot, Germany). qRT-PCR 
was executed with 10 ng cDNA for ICAM-1 expression (Taqman gene expression assay 
Hs00164932_m1; Applied Biosystems, Carlsbad, CA, USA) and for GAPDH expression 
(primers: Fw 5’-CCACATCGCTCAGACACCAT-3’, Rev 5’-GCGCCCAATACGACCAAAT-3’ 
and probe: CGTTGACTCCGACCTTCACCTTCCC (Eurogentec, Maastricht, Netherlands)) 
using an ABI ViiA7™ real-time PCR system (Applied Biosystems). Results are shown as 
relative expression compared to GAPDH levels, using the ΔCt values method.
Flow cytometry
Cells were incubated with 100 μl of mouse-anti-ICAM-1 mAB (hu5/3-2.1 hybridoma 
supernatant, kindly provided by Dr. M. A. Gimbrone, Harvard Medical School, Boston, 
MA, USA) at 4°C for 1 hr. After washing with PBS, the cells were incubated with 100 
μl of PE- or FITC-labeled rabbit-anti-mouse secondary antibody (R0439 or F0313 
respectively; DAKO, Glostrup, Denmark), diluted 1:40 in 5% pooled serum in PBS at 4°C 
for 30 minutes. To distinguish monocytes, cells harvested after co-culture experiments 
were additionally incubated with 100 μl PE-labeled mouse-anti-human CD45 antibody 
(cat. No. 304008; Biolegend, Uithoorn, Netherlands), diluted 1:60 in 5% mouse serum 
in PBS. After the ϐinal wash, cells were resuspended in PBS and analyzed using a BD 
FACS Calibur ϐlow cytometer (Beckton Dickenson Biosciences, San Jose, CA, USA).
Bisulϐite sequencing
DNA was isolated using the Quick-gDNA™ MiniPrep kit (D3007, Zymo research via 
Baseclear, Leiden, Netherlands). Bisulϐite conversion was performed using the EZ DNA 
methylation gold kit (D5006, Zymo research). ICAM-1 DNA was ampliϐied with primers 
5’-GATTTAAGTTTAGTTTGG-3’ (Fw) and 5’-TCACCTAAAAACAAAACCCC-3’ (Rev) (see 
Fig. 1a). Subsequently, the PCR product was extracted from gel (QIAquick Gel extraction 
kit, Qiagen) and ligated in the pCR2.1 vector (Invitrogen TA cloning kit, Invitrogen, Life 
technologies, Bleiswijk, the Netherlands). Clones were sequenced and subsequently 






To quantify methylation, ϐive CpGs (#10-14, see Fig. 1a) were subjected 
to pyrosequencing. Bisulϐite converted DNA was ampliϐied using primers 
5’-GGGGAAGTTGGTAGTATTTAAAAGT-3’ (Fw; 5’ side biotinylated) and 
5’-CCTTCCCCTCCCAAACAAATACTACAATTA-3’ (Rev) (Biolegio, Nijmegen, the 
Netherlands) using the Pyromark PCR kit (Qiagen). Subsequently, the ampliϐication 
product was sequenced, using primer 5’-ATTTCCCAACTAACAAAATACCC-3’ on a 
Pyromark Q24 machine (Qiagen).
Matinspector
Prediction of binding of transcription factors to the ICAM-1 promoter was performed 
using Matinspector software (Genomatix, Munich, Germany) analyzing matrices for 
vertebrates and general core promoter elements with default settings (Fig. 1b).
TSS
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ChIP primer FW (-3/+21)
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Figure 1. Schematic representation of ICAM-1 promoter around TSS.
(A) Vertical bars are CpG sites. The arrow designated with TSS indicates the position of a described 
transcription start site. The translation start site (ATG) is indicated with a star. All positions are in base pairs 
relative to the TSS. Arrows below the ϐigure show the binding positions of the primers used for bisulϐite 
sequencing (BSS) and ChIP. CpGs surrounded by dashed box (#10-14) were analyzed by pyrosequencing. 
With a horizontal line, the ZF binding site is depicted. (B) Putative binding sites of a set of transcription factors 
as predicted by Matinspector.
Chromatin ImmunoPrecipitation (ChIP)
Chromatin ImmunoPrecipitation (ChIP) was performed essentially as described 
before (21). ChIP for histone modiϐications was performed according to the Upstate 
Biotechnology (Lake Placid, NY, USA) protocol and for transcription factors, the 
protocol described by Weinmann and Farnham was used (22). Antibodies used 
were from Upstate Biotechnology (Lake Placid, NY, USA), except for mouse IgG, 
LEF-1(REMB6)TCF (Millipore, Amsterdam, Netherlands), NF-κBp50(NLS), E2F-
4(C-20) and p53 (Santa Cruz Biotechnology, Heidelberg, Germany). qRT-PCR 





Re-expression of epigenetically silenced ICAM-1
and ICAM-1 ChIP primers: 5’-ATTCAAGCTTAGCCTGGCCGGGAAA-3’ (Fw) and 
5’-CCCTCCGGAACAAATGCTGCAGTTA-3’ (Rev) (See Fig.1a) using an ABI ViiA7™ real-
time PCR system (Applied Biosystems).
MTT assay
Per cell line, equal amounts of transduced cells were replated 72 hrs after the 
ϐinal transduction. Twenty-four, 48, 72 and 96 hrs after plating, MTT (M2128; Sigma) 
was added to the cell medium and incubated for 3.5 hrs at 37°C. Subsequently, 
cell medium was aspirated and 200 μl DMSO was added to the wells to dissolve the 
crystals. Absorption was measured at 560 nm and 670 nm (Varioskan microplate 
spectrophotometer, Thermo Scientiϐic, Breda, the Netherlands). 670 nm values were 
subtracted from 560 nm values and the values for empty vector at 24 hrs after plating 
were set at 1 in the graphs. To determine chemo-resistance, cisplatin was added 24 hrs 
after plating (concentrations indicated) and MTT assays were performed 72 hrs after 
cisplatin addition. For each cell type, 0 μM cisplatin was set at 100% in the graphs.
RESULTS
ICAM-1 re-expression in an ovarian cancer cell line panel
In this study, a panel of ovarian cancer cell lines differentially expressing ICAM-1 
was used (Fig. 2a): A2780 and SKOV3 as ICAM-1 negative or weakly expressing ICAM-1 
(mRNA, relative to GAPDH: 1.1x10-5 + 2.4x10-6, Mean Fluorescence Intensity; MFI: 1.8 
+ 0.5, mRNA: 1.3x10-4 + 1.8x10-5, MFI: 7.9 + 0.8, respectively), H134S as intermediately 
expressing ICAM-1 (mRNA: 1.3x10-3 + 1.8x10-4, MFI: 99.5 + 7.2) and OVCAR3 and CaOV3 
as highly positive for ICAM-1 expression on mRNA level (3.9x10-3 + 2.7x10-5 and 7.9x10-
3 + 4.3x10-4, respectively), with corresponding levels of protein expression (MFI: 481 + 
109 and MFI: 1822 + 102, respectively).
To investigate whether ICAM-1 induction from the endogenous locus is possible 
in ovarian cancer cells, cells were treated with a subtoxic concentration of the DNA 
methylation inhibitor 5-aza. This resulted in re-expression of ICAM-1 in the ICAM-1 
negative cell lines (Fig. 2b). The most pronounced effect is seen in A2780 cells (over 400-
fold on mRNA level; p<0.05), but also in SKOV3 cells induction was observed (11 + 3-fold; 
p<0.01). Treatment of SKOV3 cells with TNF-α, known to induce ICAM-1 expression in 
endothelial cells(23), resulted in 145-fold upregulation of ICAM-1 expression on mRNA 
level (data not shown). Although TNF-α could further induce expression of ICAM-1 in 
ICAM-1 highly positive OVCAR3 cells (~3-fold on protein level, data not shown), no 
signiϐicant upregulation was observed after treating the intermediately ICAM-1 positive 





















































































Figure 2. Pharmacologically induced re-expression of ICAM-1 in a panel of ovarian cancer cell lines.
(A) Left: ICAM-1 mRNA expression relative to GAPDH of the ovarian cancer cell line panel. Error bars depict 
the standard deviation of the experiment performed in triplo. Right: ICAM-1 protein expression (Mean 
ϐluorescence intensity; MFI) of the ovarian cancer cell lines. The analysis was performed three times in 
triplicates. Error bars are the SEM of the three means of the experiments. (B) mRNA expression of ICAM-1 
after daily treatment with 5μM 5-aza for 96 hrs. Experiment was performed three times in triplicate. The 
error bars represent the SEM of the three means of the experiments. * p<0.05; T-test.
Epigenetic regulation of ICAM-1 expression in ovarian cancer cells in vitro
To further investigate the role of DNA methylation in the regulation of ICAM-1 
expression in ovarian cancer cell lines in more detail, bisulϐite sequencing of a part of the 
promoter region (see Figure 1 for primer positions) was performed. Hypermethylation 
of the investigated promoter part was observed in the ICAM-1 negative A2780 cell line 
(90 + 5% of the 30 CpGs). In SKOV3 cells, weakly positive for ICAM-1 expression, and in 
the intermediately ICAM-1 positive cell line, H134S, the DNA of the investigated region 
was moderately methylated (Fig. 3a). The induction of ICAM-1 expression observed upon 
treatment of A2780 cells with 5-aza was not associated with hypomethylation of the 
ICAM-1 part surrounding the TSS, as observed by bisulϐite sequencing of 5-aza treated 
cells (87 + 7%) compared to untreated cells (87 + 6%) (Fig. 3b). By pyrosequencing of 
5 CpGs (#10-14), some DNA demethylation could only be detected in A2780 cells after 
5-aza treatment, not in SKOV3 cells and H134S cells (Fig. 3c). 
Besides DNA methylation, repressive histone modiϐications could underlie 
repression of ICAM-1 expression. Although the H3K9me3 mark is not strongly present 
on the ICAM-1 promoter in any of the three cell lines not, weakly or intermediately 
expressing ICAM-1 (A2780, SKOV3 and H134S), the repressive mark H3K27me3 was 
detected on the ICAM-1 promoter in all three cell lines with an average fold enrichment 
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ICAM-1 negative or weakly positive cell lines, in the moderately ICAM-1 expressing cell 
line H134S, the promoter was co-occupied by the active mark H3K4me3. The active 
marks histone H3 and H4 acetylation were detected at the ICAM-1 promoter in all cell 
lines, whereas H3K4me1 and H3K36me2 were not or only slightly present on the ICAM-
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Figure 3. DNA methylation levels in ovarian cancer cell panel.
(A) Bisulϐite sequencing results of part of the ICAM-1 promoter surrounding the TSS. Every square represents 
one CpG. Yellow squares depict unmethylated CpGs, blue squares depict methylated CpGs. (B) Bisulϐite 
sequencing results after treating cells with 5 μM 5-aza. (C) Pyrosequencing results of 5 CpGs (see ϐig. 1) after 
treatment with 5-aza.
Transcription factor binding of the ICAM-1 promoter in ovarian cancer cell lines
To determine whether repressive epigenetic marks (DNA methylation and 
H3K27me3) are associated with a lack of transcription factor binding at the TSS region 
of the ICAM-1 promoter in the ICAM-1 negative A2780 cells compared to the ICAM-
1 intermediately positive H134S cells, immunoprecipitation of several transcription 




promoter was predicted in silico (Fig. 1b). By ChIP, occupation of the ICAM-1 promoter 
around the TSS by NF-κB, SP1, E2F4, and p53 (predicted to bind the ICAM-1 promoter) 
was detected in both A2780 and H134S. The average fold enrichment over IgG was 8.6 
in A2780 versus 4.4 in H134S (data not shown). In both cell lines, Lef1, also predicted 
to be binding the investigated part of the promoter, was not observed to bind (data 
not shown). Previously, none of the transcription factors described here were detected 
to bind the EpCAM promoter in the same IPs on these cell lines (both negative for 
EpCAM expression) (21). The folds of enrichment that were observed for ICAM-1 are 
comparable (or even higher) to those observed for EpCAM in e.g. OVCAR3 and CaOV3 
which are highly EpCAM positive (21). So, despite the differences seen in epigenetic 
marks, the negative epigenetic marks are not associated with a lack of TF binding in 
this region.
Biological role of ICAM-1 in ovarian cancer
To explore the cell biological role of ICAM-1 in ovarian cancer, the expression of ICAM-
1 in the ovarian cancer cell line panel was modulated by artiϐicial transcription factors 
(ATFs). Depending on the effector domain fused to the ZF, both up and downregulation 
of ICAM-1 expression on mRNA and protein level was observed when compared to the 
empty vector (Fig. 4). ICAM-1 expression was signiϐicantly upregulated on mRNA level 
by ZF-VP64 in all ϐive cell lines of the panel, ranging from 2.0 + 0.2-fold (p<0.001) in 
intermediately ICAM-1 positive H134S cells to 228 + 36-fold (p<0.001) in weakly ICAM-
1 expressing SKOV3 cells. On protein level, the amount of upregulation ranged from 
1.7 + 0.2-fold (p<0.01) in the ICAM-1 positive CaOV3 cells and 1.8 + 0.6-fold (p<0.01) 
in the intermediately ICAM-1 positive H134S cells to 108 + 29-fold (p<0.05) in the 
weakly ICAM-1 expressing SKOV3 cells. Signiϐicant downregulation was observed on 
mRNA level in all cell lines, ranging from 35 + 13% (p<0.01) in intermediately ICAM-
1 expressing H134S to 94 + 1% (p<0.001) in weakly ICAM-1 expressing SKOV3 cells. 
In the ICAM-1 negative cell line A2780, although downregulation seems to occur on 
mRNA level, the effect is the same as for the zinc ϐinger only, and thus not relevant. 
Indeed, on protein level, all cell lines except for the already ICAM-1 negative cell line 
A2780 showed signiϐicant downregulation, ranging from 37 + 11% (p<0.01) in the 
intermediately ICAM-1 expressing cell line H134S and 47 + 14% (p<0.05) in the weakly 
ICAM-1 expressing cell line SKOV3 to 91 + 2% (p<0.001) in the highly ICAM-1 expressing 
OVCAR3 cells.
To investigate the effect of induction of ICAM-1 expression by ZF-VP64 on the growth 
of ovarian cancer cell lines, MTT assays were performed on four consecutive days after 
plating equal amounts per cell line at day 0 (Fig. 5a). In the ICAM-1 negative A2780 cells 
as well as in the weakly ICAM-1 expressing SKOV3 cells, a reduction in proliferation was 
107
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observed in four days when transduced with ZF-VP64 compared to transduced with the 
empty vector (n=3). Even in the highly ICAM-1 positive OVCAR3 cells, further induction 
of ICAM-1 by ZF-VP64 reduced proliferation, whereas repression of ICAM-1 by ZF-SKD 
did not alter tumor cell growth (n=3). Effects seen in these experiments might very well 
be an underestimation since the cells at day 0 are cells replated 72 hrs. after the ϐinal 







































































































Figure 4. Bidirectional ICAM-1 expression modulation by ATFs.
Top: mRNA expression of ICAM-1 relative to GAPDH after transducing cells with ATFs. The error bars depict 
SD of the experiment performed in triplo. Bottom: Protein expression (MFI) of ICAM-1 after transducing cells 
with ATFs. The error bars depict the SEM of the means of the three experiments. * p<0.05, ** p<0.01, *** 
p<0.001, T-test compared to empty vector.
B
A
To study the role of ICAM-1 expression in (partially) controlling cisplatin sensitivity 
of ovarian cancer cells, cells transduced with ATFs were incubated with different doses 
of cisplatin for 72 hrs. and proliferation was analyzed by MTT assays (Fig. 5b). At a 
concentration of 10 μM cisplatin, 86 + 33% of A2780 cells transduced with ZF-VP64 
survived, compared to 26 + 7% for ZF-SKD and 16 + 11% for the empty vector after 
4 days compared to day 1. For SKOV3, this was 82 + 27% , 25 + 3% and 33 + 11%, 
respectively. In the highly ICAM-1 positive cell lines OVCAR3, the effects of further 
increase of ICAM-1 expression on cisplatin sensitivity were less clear, while in CaOV3 
no changes in cisplatin sensitivity were seen upon transduction with viral constructs.
In order to investigate whether ICAM-1 induction on ovarian cancer cells leads 
to activation of co-cultured monocytes, ICAM-1 expression on Monomac-6 cells was 




Figure 5. Biological role of ICAM-1 in ovarian 
cancer cells in vitro.
(A) Growth curve of ovarian cancer cells after 
transduction with ATFs. Error bars depict the SEM of 
the means of the three experiments. pMX at day 1 was 
set at 1. (B) Survival of ovarian cancer cells transduced 
with ATFs, 72 hrs after treatment with cisplatin. 
The error bars depict the SEM of the means of three 
independent experiments. For every cell type, 0 μM 
cisplatin was set at 100%. (C) As a measure of immune 
activation, ICAM-1 protein expression of Monomac-6 
cells is shown after 24 hrs of co-culture with untreated 
or ATF-transduced ovarian cancer cells.
5c). Whereas LPS could increase ICAM-1 expression on Monomac-6 cells 5.0 + 0.8-fold 
(p<0.01), A2780 transduced with ZF-VP64 increased ICAM-1 expression on Monomac-6 
cells only 1.3 + 0.1-fold (p<0.05) compared to untreated A2780 cells. No signiϐicant 
upregulation of ICAM-1 expression on Monomac-6 cells was observed when co-cultured 
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DISCUSSION
In this study we show, apart from the known tumor suppressive role of ICAM-1 via 
activation of monocytes, which was described before (24, 25), that induction of ICAM-
1 expression in ovarian cancer cells reduces tumor cell proliferation and cisplatin 
sensitivity in vitro. To the best of our knowledge, this is the ϐirst study on the functional 
cell-biological role of ICAM-1 in ovarian cancer.
The beneϐicial role of ICAM-1 in ovarian cancer, shown in the present study by 
using ATFs in vitro, is in line with results obtained upon transfecting ICAM-1 cDNA into 
various cancer cells, where overexpression of the gene was associated with decreased 
tumorigenicity in vivo (26, 27, 28, 29, 30, 31). In more detail, lower proliferation rates 
were observed when cancer cells (other than ovarian) were transfected with ICAM-1 
cDNA and implanted into animal models (28, 29, 31). The reduced growth in vivo has 
been ascribed to increased activation of immune response by the cells upon ICAM-1 
expression. Indeed, when the effect on growth of the cancer cells expressing ICAM-1 
cDNA was studied in vitro, no tumor growth inhibition was observed, for colon and liver 
cancer cells (29, 31). The different outcome between cDNA transfection in colon or liver 
cancer cells and ATF induced ICAM-1 expression in our experiments might be explained 
by the difference in tumor types (colorectal/liver cancer versus ovarian cancer). Actually, 
multiple examples are known of genes displaying cell-context dependent seemingly 
controversial roles, like EpCAM (32) or Maspin (33). In this respect, in breast cancer 
cells, silencing of ICAM-1 expression by siRNA resulted in decreased tumorigenicity in 
vitro (34, 35).
Importantly, in the cDNA studies in colorectal or liver cancer only one isoform of 
ICAM-1 is expressed, whereas the ATFs used in the present study ensure expression of 
all isoforms in their natural ratios, which was previously shown to be of importance for 
the functionality of other genes (36). For ICAM-1, thus far at least seven isoforms have 
been described (37). Thus, our study serves as a good example of the advantage of using 
ATFs to investigate the role of a gene of interest.
Next, we were interested to see whether induction of ICAM-1 expression has a direct 
effect on cisplatin resistance. In literature, cisplatin treatment is reported to increase 
ICAM-1 expression (38). This might be caused by DNA demethylation, since the 
promoter of the ICAM-1 gene is one of the promoters that were found hypomethylated in 
a cisplatin resistant ovarian cancer cell line compared to its cisplatin-sensitive parental 
line (39). Thus, either cisplatin induces ICAM-1 expression (through DNA demethylation 
or indirect) or cisplatin treatment selects for high ICAM-1 expressing cells by killing the 
ICAM-1 low expressing cells. By means of ATF induced ICAM-1 expression, we show that 
it is likely that cisplatin treatment selects for ICAM-1 positive cells, since these are less 




TNF-α target genes was prevented by a TNF-α antagonist, but not the expression of 
ICAM-1 (40). Whether the observed reduction in cisplatin sensitivity upon ATF induced 
ICAM-1 expression in ovarian cancer cells is due to the reduction in cell growth, that 
was observed as well, or an alternative intracellular protection pathway needs further 
investigation.
Previous studies showed that silencing of ICAM-1 in cancer cells, other than ovarian 
cancer, is likely caused by epigenetic parameters (41, 42). However, in contrast to 
genetic mutations, epigenetic mutations are reversible, even by environmental triggers 
(43), indicating that re-expression from the endogenous locus remains possible. Indeed, 
like Arnold et al.(6), we were able to re-express ICAM-1 in ovarian cancer cells using a 
DNA methylation inhibitor. Nevertheless, we only show a slight decrease in methylation 
level in 5 CpGs in the TSS region of the ICAM-1 promoter in A2780 cells upon 5-aza 
treatment. It could be that methylation levels of the promoter did decrease more further 
upstream. However, it seems more likely that the re-expression of ICAM-1 is caused by a 
secondary effect. In line with this, it was shown before that despite the fact that no DNA 
methylation was present at the ICAM-1 promoter in tumor endothelial cells, increased 
expression could be observed upon treatment with 5-aza (41). 
Epigenetic changes are known to play a role in carcinogenesis, also in ovarian cancer 
(44). As many tumor suppressor genes are now known to be epigenetically silenced, 
epigenetic drugs are successfully tested in clinic for various cancer types (45) (and FDA 
approved for hematological malignancies). Indeed, the inhibitors of DNA methylation 
and histone deacetylation are known to affect the expression of genes throughout the 
genome. However, even genes involved in metastasis are upregulated after treating cells 
with epigenetic drugs (46).
In contrast to epigenetic drugs, the ATFs used in this study are engineered to be 
gene-speciϐic and thus uniquely suited to address questions on the biological role of a 
gene and in speciϐic questions on cause or consequence of up- (or down-) regulation of 
any gene that is not genetically mutated. ATFs show the direct consequences of targeted 
gene expression modulation of the gene of interest on various biologically relevant 
processes, whereas current studies (e.g. transcriptomics studies) mainly base their 
associations on circumstantial evidence. In conclusion, this study shows the potency of 
ATFs in validating potential therapeutic targets, thereby fully exploiting the reversibility 
of aberrant epigenetics in cancer
NOTE ADDED IN PROOF
Upon cell line authentication it appeared that the H134S cell line used in this study 
was not clearly recognizable. The proϐile of the H134S cell line was best comparable 
to HeLa cervical cancer cells. Therefore, results obtained with this cell line should be 
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interpreted with caution.
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The role of eppigenetics in the onset and progression of a variety of diseases 
becomes more and more evident. As an example, tumor suppressor genes are 
known to be aberrantly silenced in association with epigenetic marks, including DNA 
hypermethylation and histone modiϐications.  Such silenced genes can be re-expressed 
by epigenetic drugs, but this approach has genome-wide (side) effects.
In this study, fusions of gene-speciϐic DNA binding domains (engineered zinc ϐingers) 
and epigenetic enzymes were expressed in to target epigenetically silenced target genes 
for re-expression. Subsequently their effect on the level of molecular epigenetic marks 
at the target gene and on target gene expression was assessed.
No signiϐicant effects were observed upon targeting putative DNA demethylases, nor 
upon targeting the catalytic domains of UTX, an H3K27 demethylase, or p300, a histone 
acetyltransferase. The epigenetically silenced genes could be re-expressed by zinc 




Targeting epigenetic enzymes to endogenous genes
INTRODUCTION
The contribution of epigenetic mechanisms in development of many diseases becomes 
more and more evident (1). For example, it has been shown that epigenetic silencing of 
tumor suppressor genes can be causative in cancer (2, 3). In fact, DNA methylation is 
currently used as a diagnostic/prognostic marker (4, 5, 6). DNA methylation, especially 
around the transcription start site or exon 1 is of a gene, is associated with repression of 
gene expression (7)(7, 8, 9), whereas posttranslational histone tail modiϐications have 
been associated with active or repressed genes, depending on the type, quantity and 
location of the modiϐication (7, 10).
Epigenetically silenced genes do not generally have genetic mutations (11) allowing 
alternative therapeutic approaches. Furthermore, although both DNA methylation 
and histone methylation were thought to be very stable, it is now known that these 
epigenetic marks are reversible (12, 13). Indeed, re-expression of epigenetically 
silenced genes is possible, as reported for many genes. Interestingly, epigenetically 
silenced genes can also be gene-speciϐically re-expressed by using engineerable DNA 
binding domains (Zinc Fingers; ZFs) fused to activation domains (VP64; four copies of 
the viral protein VP16): Artiϐicial Transcription Factors (ATFs) (14, 15). However, this 
interesting approach is likely to be transient, as VP64 functions through recruitment of 
activators and epigenetic marks silencing the gene are not directly affected (16). 
Since DNA methylation is strongly associated with repressed genes, DNA 
demethylation might facilitate activation of genes. In this respect, while enzymes 
removing certain histone marks (including methylation) have been well identiϐied 
in recent decades, the mechanisms of DNA demethylation are currently largely 
unknown (17, 18). Although passive DNA demethylation is commonly acknowledged 
in mammalian cells, being caused by the lack of inheritance of DNA methylation marks 
upon cell division, active DNA demethylation was not generally accepted until evidence 
started to accumulate (as reviewed in (18)). 
Several proteins and a variety of mechanisms have been proposed to be involved in 
the mammalian active DNA demethylation process, as extensively reviewed (17, 18). Two 
of the proposed proteins are Activation Induced Deaminase (AID) and Apobec1, which 
were suggested to cause DNA demethylation via deamination of the methylated cytosine 
into a thymine base (19). The resulting T/G mismatch might then be recognized by the 
mismatch repair system and the thymine will be exchanged for a cytosine base. Another 
described mechanism for active DNA demethylation is nucleotide excision repair, in which 
Gadd45α was reported to be involved (20). A mechanism proven to play a role in DNA 
demethylation is conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine 
(5hmC), a likely intermediate in active DNA demethylation (21). This process was quite 




Tet2 and Tet3) (22). The formation of 5hmC is suggested to be an intermediate that can 
be changed into an unmethylated cytosine through several mechanisms (23, 24). 5hmC 
might by itself also have a function with respect to gene expression, although this is 
not entirely clear at present (24). Interestingly, targeting Tet1 to a predetermined site 
by fusion to Gal4 caused repression of the reporter gene (25) and promoter 5hmC was 
associated with repression of gene expression in another study as well (26). On the 
other hand, genome-wide hmC sequencing in mouse ES cells showed that the mark is 
present mainly on repressed genes, but also on active genes. Furthermore, the mark is 
primarily enriched at the transcription start site but also within the gene body (25). 
In addition to DNA hypomethylation, several histone modiϐications likely underlie 
the expression of active genes. Also, targeted induction of positive histone modiϐications 
or removal of repressive histone modiϐications resulted in gene expression modulation 
(27). For example, acetylation of histone tail residues is commonly seen at active genes 
(28, 29). This acetylation is performed by histone acetyltransferases (HATs) such as 
p300 (30). Other histone marks, associated with repressed genes, can be removed 
to facilitate expression. An example of this is the action of Ubiquitously transcribed 
tetratricopeptide repeat, X chromosome (UTX), which demethylates H3K27me3, a mark 
associated with repressed genes (31, 32). H3K27me3 is also often present at tumor 
suppressor genes, even when they are expressed. This is because H3K4me3 is also 
present, allowing the gene to be expressed. This bivalent chromatin pattern, however, 
seems to predispose such genes to aberrant DNA hypermethylation in cancer (33, 34). 
In those cases, demethylating H3K27 might relieve this repression.
Identiϐication of effects of before-mentioned putative DNA demethylases and other 
epigenetic enzymes was mainly performed by overexpression or knocking out the 
speciϐic gene. Although these widely used systems can indeed give indications on the 
functions of the proteins, observed effects might be secondary. A more direct tool to 
get indications of answers on fundamental epigenetic questions, like which protein is 
truly responsible for active DNA demethylation, is by exploiting Epigenetic Editing (27). 
Epigenetic Editing, gene-speciϐic rewriting of epigenetic marks, is obtained by the fusion 
of (candidate) epigenetic enzymes to gene-speciϐic DNA binding domains such as ZFs.
In this study, an attempt was made to identify DNA demethylases and to investigate 
whether the known effect of certain histone modifying enzymes can be exploited by 
targeting the enzymes to predetermined endogenous sites. Gene-speciϐic engineered 
ZFs were used that recognize 18 basepair sequences in the promoters of Epithelial Cell 
Adhesion Molecule (EpCAM) or InterCellular Adhesion Molecule-1 (ICAM-1). These 
endogenous, epigenetically silenced model genes have previously been re-expressed 
by targeting ZFs fused to a transient activation domain, VP64 (four copies of the viral 
protein VP16) (35, 36).  In this study, Gadd45α, AID, Apobec1 and truncated versions of 
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Tet1, Tet3, p300 and UTX (including the catalytic domains) were fused to the ZFs. After 
expression of these epigenetic editors, both levels of molecular epigenetic marks and 
target gene expression were analyzed. 
MATERIALS AND METHODS
Plasmids
Gadd45α and p300 CD (aa 1066-1707) were ampliϐied from human cDNA using 
forward and reverse primers comprising AscI and PacI restriction sites in their 5’ end, 
respectively. The forward primer amplifying p300 CD also comprised a MluI restriction 
site to facilitate further cloning. The ampliϐication product of Gadd45α was inserted 
into pMX-Up2-IRES-GFP (36), using AscI and PacI restriction enzymes followed by 
three-point ligation. Murine AID, Apobec1, Tet1 CD (aa 1367-2040) and Tet3 CD (aa 
697-1669) were ampliϐied from plasmids kindly provided by dr. G.L. Xu (Shanghai 
Institutes for Biological Sciences, Shanghai, China) and inserted in the pMX backbone 
using MluI and PacI. 
UTX CD (aa 401-1401) was ampliϐied from plasmid pGvH0064 (37) kindly provided 
by G. van Haaften (NKI-AVL, Amsterdam, the Netherlands). In all constructs, the Up2 
zinc ϐinger (recognizing the EpCAM promoter) was replaced with the CD54 zinc ϐinger 
(38) (recognizing the ICAM-1 promoter; kindly provided by C.F. Barbas III, the Scripps 
Institute, La Jolla, CA, USA) using the SϐiI restriction enzyme to obtain CD54 fusion 
constructs. All PCR-cloned constructs were veriϐied by DNA sequencing.
Cell culture
The packaging human embryonic kidney cell line (HEK293T) and human ovarian 
cancer cell lines (A2780, H134S and Skov3) were cultured in Dulbecco’s Modiϐied 
Eagle’s Medium (DMEM, BioWhittaker), supplemented with 10% Fetal Bovine Serum, 





HEK293T cells were transfected with retroviral vectors encoding the ZF fusion 
constructs, together with the plasmids needed to produce retroviral particles, as 
described before (35). Virus-particle containing supernatant of the transfected cells was 
used to infect the host cells (A2780, H134S and Skov3) and the process was repeated 
after 24 hrs. Transduced cells were harvested 72 hrs after the last infection for western 




Immunoprecipitation and western blotting
Transduced cells were lysed in RIPA buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl; 
1% NP-40; 1% sodium deoxycholate; 0.1% SDS (Thermo Scientiϐic, Waltham, MA, 
USA)) and centrifuged. Protein A magnetic beads (Dynabeads Protein A, Invitrogen, 
Life technologies, Bleiswijk, the Netherlands) were incubated with a rabbit polyclonal 
HA tag antibody (Novus Biologicals via Bio-Connect, Huissen, the Netherlands) at room 
temperature for 30 min. Supernatant of cell lysates was added and the samples were 
rotated at 4°C O/N. Immunoprecipitates were collected and washed four times with 
RIPA buffer. 
Subsequently, western blotting was performed following standard procedures. 
Expression of the ZF fusion constructs was detected by incubating the membrane with 
a mouse monoclonal anti-HA tag antibody (COVANCE, Rotterdam, the Netherlands) at 
4°C O/N, followed by goat anti-mouse IgG conjugated with alkaline phosphatase (DAKO, 
Glostrup, Denmark). Visualization was performed using BCIP/NBT substrate.
RT-PCR
Total RNA was extracted from the transduced cells using an RNeasy Miniprep Kit 
(Qiagen, Hilden, Germany) according to the recommendations of the manufacturer. cDNA 
was obtained using RevertAid Reverse Transcriptase and random hexamer primers 
(Fermentas, Leon-Rot, Germany). p300 containing constructs were ampliϐied with a 
forward primer annealing within the p300 sequence (5’ CTGCTGGATTCGTCTGTGAT 3’) 
and a reverse primer annealing at the HA-tag sequence (5’ ACGTCGTACGGGTAGTTAAT 
3’). UTX containing constructs were ampliϐied with a forward primer annealing within 
the UTX sequence (5’ GGAAGTTGCAGCTACATGAG 3’) and the same HA-tag reverse 
primer. Products were analyzed on an agarose gel.
qRT-PCR 
For ICAM-1 or EpCAM mRNA analysis, qRT-PCR was executed on an AB ViiA7 
Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) with 10 ng of 
cDNA, using Taqman gene expression assays for ICAM-1 (Hs00164932_m1) and 
EpCAM (Hs00158980_m1; both Applied Biosystems). As internal control, RNA 
levels of GAPDH were measured using primers: Fw 5’-CCACATCGCTCAGACACCAT-3’, 
Rev 5’-GCGCCCAATACGACCAAAT-3’ and probe: CGTTGACTCCGACCTTCACCTTCCC 
(Eurogentec, Maastricht, Netherlands). Data was analyzed using the comparative cycle 
threshold method (delta Ct).  Statistic signiϐicance was assessed using paired T-tests.
Flow cytometry
Harvested cells were stained for ICAM-1 or EpCAM protein expression using 
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mouse-anti-ICAM-1 hybridoma supernatant of hu5/3-2.1, kindly provided by Dr. M. A. 
Gimbrone (Harvard Medical School, Boston, MA, USA) or mouse-anti-EpCAM Moc31 
hybridoma supernatant, respectively. Subsequently, cells were incubated with RaM-
F(ab)
2
-PE (DAKO). Fluorescence was measured on a BD FACS Calibur ϐlow cytometer 
(Beckton Dickenson Biosciences, San Jose, CA). The living, GFP positive cells were 
gated to calculate the percentage of living GFP positive cells and the Mean Fluorescene 
Intensity (MFI) of this population for protein levels of ICAM-1 or EpCAM. Statistic 
signiϐicance was assessed using paired T-tests.
Bisulϐite sequencing and pyrosequencing
Genomic DNA was extracted from transduced cells using the Quick-gDNA™ MiniPrep 
kit (D3007, Zymo Research via Baseclear, Leiden, Netherlands) and bisulϐite converted 
using the EZ DNA Methylation-Gold Kit (Zymo Research) following manufacturers’ 
recommendations. For ICAM-1 bisulϐite sequencing, PCR products (Fig. 1a) were 
extracted from gel using the Qiaquick gel extraction kit (Qiagen) and cloned into 
the pCR2.1-TOPO vector (Invitrogen). Individual clones were send for sequencing 
(Baseclear).
For pyrosequencing of the ICAM-1 (Fig. 1a) or EpCAM promoter (Fig. 1b), bisulϐite 
converted DNA was ampliϐied by PCR. Pyrosequencing was performed on the Pyromark 
Q24 MD pyrosequencer (Qiagen) according to the manufacturers’ guidelines. Percentage 
of methylation for each CpG analyzed was determined using Pyromark Q24 Software 
(Qiagen). Statistical signiϐicance was determined using paired T-tests versus untreated 
cells.
Chromatin immunoprecipitation (ChIP)
For ChIP, cells were ϐixated using 1% formaldehyde and subsequently sonicated 
to shear the DNA. Dynabeads (Invitrogen) were loaded with 5 μg of the antibodies as 
indicated at the ϐigures (rIgG, H3/H4Ac and H3K27me3 from Millipore, Amsterdam, 
the Netherlands and H3Core from Abcam, Cambridge, United Kingdom), added to 
the sheared DNA and incubated overnight. Beads were washed and the DNA/protein 
complexes were eluted from the beads. Protein and RNA were removed and the DNA 
was puriϐied and used for PCR, primer positions are indicated in Fig. 1a and 1b.
RESULTS
Expression of ZF fusion constructs
To conϐirm expression of the ZF fusion constructs, immunoprecipitation was 




2a). All constructs comprising putative DNA demethylases were detected at the right 
size. Up2 ZF containing proteins show a little higher molecular weight than the CD54 
ZF containing proteins, explained by the difference in construction (38, 39). Only, a faint 
band was seen for Up2-Tet3, whereas no band was detected for CD54-Tet3. Also the 
control constructs, ZFs without effector domain or ZFs fused to VP64 were detected. 
The band for Up2-VP64 shows a low intensity, which is in line with the toxicity of the 
treatment (36). Also fusion proteins containing AID or the CDs of the Tet-proteins 
resulted in low intensity bands, but here no toxicity was observed. ZFs fused to p300 CD 
or UTX CD were not detected by western blot, but RT-PCR did show expression of these 
constructs in the transduced host cells (Fig. 2b).
TSS
-84 +514
BSS primer FW (-4/+13)
ChIP primer FW (-127/-104)
ZF binding site (+99/+116)
ChIP primer REV (-63/-81)






ZF binding site (-149/-132)
ICAM-1
EpCAM
+93-207 -107 -7-407 -307
Pyroseq. 
(CpG #1-5)
ChIP primer FW (-3/+21) ChIP primer REV (+190/+166)
Figure 1. Promoters of model genes
Schematic representation of part of the ICAM-1 (a) and EpCAM (b) promoter. Indicated are the zinc ϐinger 
binding sites, the primers used for bisulϐite sequencing and/or ChIP and the CpGs analyzed by pyrosequencing.
A
B
Figure 2. Expression of zinc 
ϐinger fusion constructs
In this ϐigure, detection 
of the expression of the 
constructed zinc ϐinger fusion 












































followed by western blot was performed for fusion proteins 
containing putative DNA demethylases, targeting the ICAM-
1 (top) and EpCAM (bottom) gene in A2780 cells. Correct 
bands are surrounded by dashed squares. (B) RT-PCR to detect 
expression of ZF fusions containing p300 in A2780 cells, Up2-
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Gene-speciϐic targeting of putative DNA demethylating enzymes: gene expression
To investigate whether targeted putative DNA demethylases were able to induce 
gene expression, target gene expression was assessed of two model genes in three 
different ovarian cancer cell lines (A2780, H134S and Skov3). In A2780 cells, negative 
for ICAM-1 and EpCAM expression, fusions of the two different ZFs (targeting ICAM-1 or 
EpCAM) to VP64 both induced gene expression on mRNA level compared to expression 
of the ZF only (Fig. 3a and 3b). ICAM-1 expression was induced 495 + 376-fold (p<0.05) 
and EpCAM expression 18 + 11-fold in the surviving cells (not signiϐicant). As described 
by us before (36), the Up2-VP64 fusion protein was highly toxic to the cancer cells used. 
Because of the small amount of cells left after treatment with Up2-VP64, the expression 
of EpCAM on protein level could not be determined upon expression of this construct. 
None of the putative DNA demethylases showed signiϐicant induction of target gene 
expression on mRNA level upon expression of the ZF fusion proteins in A2780 cells 
(Fig. 3a and 3b), nor in H134S or Skov3 cells (data not shown). On protein level, no 
signiϐicant expression differences were observed upon expression of the ZF-DNA 
demethylase fusion proteins in A2780 cells (Fig. 3c and 3d) or H134S or Skov3 cells 






















































































































































































































































Figure 3. Target gene expression upon targeting putative DNA demethylases
Mean expression of ICAM-1 (A and C) and EpCAM (B and D) in A2780 cells after expressing fusion proteins 
comprising ZFs and putative DNA demethylases. Expression was analyzed on mRNA level (A and B) and 
protein level (C and D). MFI is mean ϐluorescence intensity of gated cells. Error bars represent the standard 






Gene-speciϐic targeting of putative DNA demethylating enzymes: DNA methylation 
levels
Despite the fact that no changes in target gene expression were observed upon 
targeting the putative DNA demethylating enzymes, it might be that an effect on DNA 
methylation did occur. To obtain insights in which CpGs are worthwhile to analyze 
for quantiϐication through pyrosequencing, ϐirst bisulϐite sequencing of the ICAM-
1 promoter was performed upon expression of the CD54 ZF alone or fused to VP64 
or Tet1 (Fig 4a). As expected, the CpGs in the ZF binding site and those potentially 
affected by the effector domain (regarding the orientation of the protein) seemed most 
affected. Therefore, CpG #10-14 (see also Fig. 1a) were investigated in more detail by 
pyrosequencing to quantitatively assess the amount of DNA methylation present at 
these speciϐic CpGs. 
Cells treated with the CD54 ZF without effector domain and CD54-VP64 fusion 
protein both showed signiϐicant reduction in the percentage of DNA methylation on 
almost all investigated CpGs in comparison to untreated cells (For CD54 ZF, CpG #10: 
29 + 10 %, p<0.001; CpG #11: 27 + 10%, p<0.01; CpG #12: 6 + 4%, p<0.05; CpG #13: 6 + 
3%, p<0.01; for CD54-VP64, CpG #10: 13 + 3%, p<0.001; CpG #11: 14 + 7%, p<0.01; CpG 
#13: 8 + 4%, p<0.01; CpG #14: 6 + 5%, p<0.05)  (Fig. 4b). Interestingly, expression of 
CD54-Tet1 CD and CD54-Tet3 CD also resulted in signiϐicant reduction in the percentage 
of DNA methylation of CpG #10 (6 + 5% and 4 + 3%, respectively; both p<0.05), although 
the degree of DNA demethylation is comparable to the other domains.
Analyzing CpG methylation in the EpCAM promoter was more challenging, likely due 
to its high CG content. As there is no CpG in the ZF binding site, CpGs directly downstream 
were analyzed (see Fig. 1b). CpG 1 and 2 were relatively well analyzable, whereas CpG 3 
and 4 resulted in more failure of determination, especially for Up2-VP64, Up2-Gadd45α 
and Up2-Apobec1. Methylation levels of CpG 5 resulted in failed determination in almost 
all cases (data not shown). No signiϐicant differences in methylation levels was observed 
in the CpGs in the EpCAM promoter analyzed at least three times upon expression of the 
Up2 fusion proteins (Fig. 4c).
Gene-speciϐic targeting of histone modifying enzymes: gene expression
Towards combining targeted DNA demethylases with targeted histone modifying 
enzymes to obtain more efϐicient and/or prolonged effects, the catalytic domains of a 
HAT (p300) or an H3K27 demethylase (UTX) were fused to the ICAM and EpCAM ZF. 
These speciϐic enzymes are known to change epigenetic marks in a way which might 
facilitate induction of gene expression. In A2780, negative for ICAM-1 expression, again 
CD54-VP64 increased ICAM-1 gene expression (average 157-fold on mRNA level and 
1.7-fold on protein level), but CD54-p300 did not (Fig. 5a). In Skov3, weakly expressing 
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ICAM-1, also CD54-VP64 was able to induce gene expression (average of 88-fold on 
mRNA, 36-fold on protein level), but CD54-p300 and CD54-UTX did not (Fig. 5b). Also 
no changes in EpCAM expression were observed in A2780 or Skov3 upon expression of 
the CD54 ZF only or in fusion to p300 or UTX (data not shown).
In A2780, negative for EpCAM, Up2-VP64 again induced EpCAM expression on 
mRNA level (average of 3-fold) which could not be observed on protein level due to 
a low number of surviving cells (Fig. 5c). Up2-p300 did not have any effect on EpCAM 
expression in A2780. In H134S, negative for EpCAM, Up2-VP64 could not consistently 
induce EpCAM expression on mRNA level (Fig 5d). When ICAM mRNA expression was 
assessed, no differences were seen in A2780 and H134S upon expression of the Up2-ZF 
containing constructs (data not shown).
Gene-speciϐic targeting of histone modifying enzymes: histone modiϐication levels
Although no changes in gene expression were observed for the total cell population, 
it might still be that histone modiϐication levels are altered due to targeting of p300 or 
UTX. Upon expression of CD54-p300 in A2780, the intention was to increase H3 and/
or H4 acetylation levels on the ICAM-1 promoter, but this was not observed. H3K27me3 
levels were slightly decreased at the ICAM-1 promoter in Skov3 cells upon expression of 
CD54-UTX (Fig. 6a), but this was also the case for the untargeted EpCAM promoter (Fig. 
6b). None of the other results were consistent. Upon expression of the Up2 zinc ϐinger 
constructs, H3 acetylation seems to be increased by Up2-p300 in A2780. However, IgG 
is also increased (Fig. 6c). No consistent results were obtained by expressing the other 
constructs, nor for the untargeted ICAM-1 gene (Fig. 6d).
DISCUSSION
In this study, we aimed to induce gene expression of two epigenetically silenced 
endogenous model genes through Epigenetic Editing. ZF fusions to activation domain 
VP64 caused induction of gene expression. Targeting of the ϐive tested candidate DNA 
demethylases did not result in a DNA demethylating effect at the targeted endogenous 
Figure 4. DNA methylation level at target promoter upon targeting putative DNA demethylases
In this ϐigure the DNA methylation levels upon targeting putative DNA demethylases is shown. (A) Bisulϐite 
sequencing to determine CpGs of interest for pyrosequencing of ICAM-1 promoter. Each square represents 
one CpG. Black squares represent methylated CpGs, grey squares represent unmethylated CpGs, white squares 
are undetermined CpGs. At the top the location of the ZF recognition site (ZF) and the direction of the effector 
domain (ED) are indicated. (B) Pyrosequencing of CpG #10-14 of the ICAM-1 promoter, showing the average 
percentage of DNA methylation for each CpG analyzed. Each experiment has been successfully analyzed ϐive 
or six times. Error bars represent the standard error of the mean. * p<0.05, ** p<0.01, *** p<0.001; paired 
T-test. (C) Pyrosequencing of CpG #1-4 (see Fig. 1b) of the EpCAM promoter showing the average percentage 
of methylation. Number of successful analyses per construct are indicated at the top of the graphs. Error bars 
represent the standard error of the main.
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Figure 5. Target gene expression upon targeting catalytic domains of histone modifying enzymes
Expression of ICAM-1 (A, A2780; B, Skov3) or EpCAM (C, A2780; D, H134S) mRNA levels after targeting p300 
and/or UTX are represented in the ϐigures on the left side, protein levels in the ϐigures on the right side. 
































































































































































































































Figure 6. Histone marks with and without targeting catalytic domains of histone modifying enzymes
The percentage of the input of histone modiϐication levels is shown upon targeting catalytic domains of p300 
and UTX. Figures show the histone modiϐication levels at the ICAM-1 (A) or EpCAM (B) promoter in A2780 
or Skov3 cells upon targeting CD54 fusion proteins and at the EpCAM (C) or ICAM-1 (D) promoter in A2780 
or H134S cells upon targeting Up2 fusion proteins. Filled symbols represent one experiment whereas open 
symbols represent another experiment (n=2).
hypermethylated genes. In agreement, there was a lack of upregulation of expression 
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putative DNA demethylases. In addition, targeting of enzymes known to be capable of 
altering histone modiϐications did also not show an effect on molecular level or on gene 
expression.
As reported by others (40), we observed that targeting of VP64 led to signiϐicant 
hypomethylation of target CpGs in the promoter. Although this might be secondary to 
the gene expression activation, hypomethylation was also achieved (even to a higher 
extent) by the ZF only. As both the ZF only and ZF-VP64 construct are highly expressed, 
an alternative explanation for DNA demethylation by VP64 might be sterical hindrance 
by the fusion protein, hampering Dnmt1 in copying the methylation pattern to the 
daughter strand upon cell division. CpGs analyzed in the EpCAM promoter did not show 
any DNA demethylation upon expression of the Up2 constructs. Although the analyzed 
CpGs are not situated within the ZF binding site, like for CpG #10 and #11 of ICAM-1, 
EpCAM CpG #1 and #2 are comparable in distance from the ZF binding site as CpG 
#12 and #13 of the ICAM-1 promoter. The discrepancy might be explained by context 
dependency.
Although no additional targeted DNA demethylation was observed by ZF-Tet1 or 
Tet3 over that observed with ZF only, 5hmC might still have been formed, as bisulϐite 
conversion does not make a distinction between 5mC and 5hmC (41, 42). Therefore, it 
would be of interest to detect 5hmC levels speciϐically at the target site, making use of 
evolving techniques for determining locus-speciϐic 5hmC (43, 44, 45, 46). Previously, 
when Tet1 was targeted to a site integrated in the genome by fusion to Gal4, this 
led to downregulation of reporter gene expression (25). However, in that respective 
study, 5hmC levels were not investigated and the unexpected effect was suggested to 
be independent of the catalytic activity of Tet1. In fact, it might be (partly) due to the 
observed recruitment of Sin3a, part of a co-repressor complex. Moreover, the targeted 
construct was targeted to an active gene which might have caused the lack of detectable 
(further) gene expression activation. Targeting the enzyme to a hypermethylated 
reporter gene is more likely to lead to activation of gene expression through the 
enzymatic activity of Tet1.
No effects of targeted Gadd45α were detected in the current study. Previously, the 
DNA demethylating effect of Gadd45α observed upon overexpression in one study (47) 
could not be reproduced by others (48, 49). Moreover, whereas knockdown of the NER 
machinery, in which Gadd45α is suggested to play a role, resulted in hypermethylation 
(50), Gadd45α knockout mice do not exhibit the expected hypermethylation (49). 
However, we have seen induction of reporter gene expression and indications for DNA 
demethylation by overexpression of Gadd45α or targeting the enzyme to integrated 
repeats of target sites (chapter 3). Thus, it might be that the targeting of one copy of the 




Another suggested mechanism of active DNA demethylation includes deamination 
by AID and Apobec1. Although knock-outs are still viable and fertile (51, 52, 53, 54), 
which might be explained by redundancy, targeting of AID/Apobec1 is expected to 
deaminate methylated cytosine, subsequently recruiting mismatch repair enzymes to 
eventually have the 5-methylcytosine replaced by an unmodiϐied cytosine. However, 
recently it appeared that deamination of cytosine by AID/Apobec1 is sterically favored 
over deamination of 5mC and deamination of 5hmC did not even seem to be induced 
by these enzymes (55). This indicates that the role of AID/Apobec1 in active DNA 
demethylation might be smaller than previously suggested and would explain the 
results obtained by us with these domains.
That targeted DNA demethylation is feasible is proven by the recently studied 
targeting of TDG, a T/G mismatch repair protein (56). This protein, previously 
suggested to be able to demethylate methylated CpGs (57) or at least to play a role in 
the DNA demethylation process (21, 58) was targeted to NFκB target sites by fusing 
it to the NFκB DNA binding domain (56). Indeed, a reduction in methylation levels 
of 5-10% were observed at the CpGs investigated in that study. Moreover, an effect 
on gene expression was achieved despite the few CpGs investigated and shown to be 
demethylated. It might be that DNA demethylation of just one CpG is sufϐicient for gene 
expression activation, as for another gene also DNA methylation of just one CpG showed 
to be sufϐicient for silencing (59). Such high efϐiciency is likely due to methylation 
sensitivity of transcription factors for binding. So, thorough investigation into which 
CpGs to be targeted could be of importance. 
In the TDG study, the targeting construct was delivered via lentiviral transduction 
and transduced cells were selected by detecting the cotransfected LNGFR protein 
(56). In some cases, it might thus be necessary to select for transduced cells before 
analysis. If not all host cells are hit with the virus containing the ZF construct, this might 
cause an underestimation of the effects. However, this was not reϐlected in transfection 
efϐiciencies determined by the percentage of GFP positive cells (e.g. efϐiciencies of >90% 
for the Gadd45α constructs). 
Although no changes in gene expression were observed in the present study, this 
does not necessarily mean that no DNA demethylation has occurred. It is likely that the 
site of action relative to the TSS is of importance for an effect on gene expression (60). 
Alternatively, it has been described before that DNA demethylation can be associated 
with a change in histone modiϐications, resulting in active histone marks even though 
this did not lead to a change in gene expression (61).
Besides the lack of targeted DNA demethylation, also for the catalytic domains of 
histone modifying enzymes no targeted effects were detected in the current study. 
Amino acids 1066-1707, is the domain of the enzyme that was used for fusion to the 
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ZFs in this study, since this is also the commercially available HAT domain of p300 and is 
therefore expected to be able to execute its functions. In other studies, diverse domains 
of p300 have been targeted to various target sites, as reviewed in (27), resulting in 
inconsistent outcomes. Some of these studies show targeting of domains that include 
the one used in this study or are closely similar (62, 63, 64, 65)). From these studies, 
the domain used in this study seems to be successful in half of the cases. One targeted 
domain, aa 964-1922 shows activation in one study (62) but no effect in another study 
(65). In these two studies, the gene expression activating effect that was reported 
seemed to be dependent on the position of the DNA binding domain target site relative 
to the TSS, with a downstream binding site being beneϐicial compared to an upstream 
target site (62, 65). In this study, both a ZF binding upstream (EpCAM) of the TSS and 
one binding downstream (ICAM-1) of the TSS of their respective target genes are used. 
In this regard, the position of the ZF binding site relative to the TSS does not necessarily 
explain the lack of effect seen in the present study. 
UTX, the H3K27 demethylase, has never been reported to be studied in a targeted 
fashion before, but overexpression was shown to result in a decrease in H3K27 
methylation (32). The catalytic activity of the domain used in the present study (aa 
401-1401) was effective in the study by Hong et al., as assessed in a cell-free system. 
Although when targeted to the ICAM-1 or EpCAM promoter no effects were observed, 
the same domain of UTX did show increase of transcription of a target gene upon single 
cell analysis in cells containing a large repeat of DBD recognition sites (chapter 3). For 
UTX, as well as for the other domains, it might be required to target different positions 
within the same promoter simultaneously.
One general consideration for improvement of the experimental set-up of Epigenetic 
Editing might be to reduce the size of the retroviral insert to increase expression 
efϐiciency. For the ZF fusion proteins in this study (containing UTX CD, p300 or Tet3), the 
expression is difϐicult to detect on protein level. Whereas this might be due to technical 
issues of the read-out, these large proteins are probably expressed to a lesser extent. 
Although it has been shown that targeted rewriting of only one epigenetic mark 
at one locus can be sufϐicient to cause modulation of gene expression, as reviewed in 
(27), further improvements to the Epigenetic Editing approach might be made through 
combination treatment with more than one targeted epigenetic enzyme. This would 
diminish chances on remaining repressive marks recruiting silencing machinery to 
regain the repressed state.
Finally, the choice of target gene might inϐluence the likelihood of observing an effect. 
Obviously, the mark affected by the epigenetic enzyme targeted should be present (or 
lacking, when inducing a mark). In addition, it could be that ICAM-1 and EpCAM are 




regions (heterochromatic) are intuitively less accessible for transcription factors than 
active chromatin regions (euchromatin). This could explain why Epigenetic Editing of 
endogenous genes so far only has been reported for repression of gene expression (66, 
67, 68). However, expression of epigenetically silenced genes, including ICAM-1 (35) 
and EpCAM (36), was previously induced by targeting VP64 in fusions to ZFs. Moreover, 
even promoters at the imprinted alleles of genes have been shown to be bound and 
activated by ZF-VP16 fusions (69). Thus, accessibility does not seem to be an issue. 
Likely, remaining epigenetic marks recruit repressive enzymes and/or repressive marks 
are spread. As far as known, no investigation into gene-speciϐic targeting of activating 
epigenetic enzymes to endogenous epigenetically silenced genes has been reported 
before.
In conclusion, further investigation is necessary to exclude the proteins targeted 
in this study as potential candidates. Epigenetic Editing for upregulation of genes 
needs to be further optimized. When successful, Epigenetic Editing can eventually be 
of interest for validation of target genes for therapeutic approaches or perhaps even 
as a therapeutic approach to reactivate epigenetically silenced genes (or to silence 
overexpressed genes) causing disease.
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The ultimate aim of the research described in this thesis was to gene-speciϐically 
induce gene expression of epigenetically silenced genes through Epigenetic Editing. 
This can be broken down into two research questions:
1. How can epigenetic marks be rewritten, speciϐically at the gene of interest?
2. Does this change in epigenetic environment lead to induction of gene expression 
of the target gene?
CHAPTER 2
After a general introduction in chapter 1, chapter 2 is a review of published research 
on actively targeted epigenetic enzymes. In most of the studies described in this review, 
ϐirst a piece of synthetic DNA was integrated in the genome of cells. Next, epigenetic 
enzymes were targeted to this piece of DNA using DNA binding domains recognizing this 
synthetic DNA. Although much information has been derived from this approach, this 
synthetic system, unlike zinc ϐinger, is not able to gene-speciϐically target endogenous 
genes. Interestingly, in many of the studies described a change in epigenetic marks 
at the target site or a change in target gene expression was observed. In some cases 
even both a change in epigenetic marks as gene expression was established. This 
indicates that the change of an epigenetic mark can indeed directly lead to a change 
in gene expression, especially since using an enzymatically inactive epigenetic enzyme 
did not lead to the change in gene expression. Both activation and repression of gene 
expression was established in the studies described in chapter 2. Even though this 
seems promising, there are only a few examples of gene-speciϐic targeting of epigenetic 
enzymes. However, this is of importance to be able to modulate genes of interest and 
also to prevent the modulation of the epigenetic marks of aspeciϐic genes. 
CHAPTER 3
In chapter 3 a study is described in which it was attempted to modulate epigenetic 
marks and/or gene expression. Towards this aim, an artiϐicial system was used, 
consisting of cells that include a large amount of target LacO DNA sites. As a DNA binding 
domain, is this study the LacR protein was used, which can bind LacO DNA. To the LacR 
protein, proposed epigenetic enzymes were fused, supposedly having an effect on 
DNA methylation or histone modiϐications. The epigenetic enzymes used in this thesis 
all were described to either add activating epigenetic marks or to remove repressive 
epigenetic marks. Therefore it is thought that the effect of these epigenetic enzymes 
could lead to activation of gene expression. The usage of a large repeat of target DNA, 
like in chapter 3, could theoretically lead to an enforced effect, since increased numbers 




3, indeed indications were found for some enzymes to be capable of decondensing the 
DNA. So far this did not lead to signiϐicant induction of gene expression when analyzing 
the whole cell population. However, when the effects were analyzed at single cell level, 
some indications of induction of target gene expression were found upon targeting 
Gadd45α (a putative DNA demethylase) and UTX (known as an H3K27 demethylase).
CHAPTER 4
In chapter 3 the effectiveness of certain targeted epigenetic enzymes were examined 
in an artiϐicial system. However, to accomplish Epigenetic Editing, these epigenetic 
enzymes eventually need to be targeted to endogenous target genes. This means that 
the enzymes are targeted to only one target gene instead of to a large repeat of target 
sites, as in chapter 3. 
In chapter 4, the epigenetic environment of a speciϐic gene, EpCAM, was determined 
in ovarian cancer cells. It appeared that EpCAM is differentially expressed in ovarian 
cancer cells and that this agrees with the DNA methylation status of the promoter. 
Also some histone modiϐications associates with active or passive genes were found 
to associate with the EpCAM gene. The pattern of these histone modiϐications, like for 
DNA methylation, agreed with the expression pattern of the gene. Furthermore, we 
could show with epigenetic drugs that the EpCAM gene expression could be modulated. 
Therefore, EpCAM is an interesting model gene for Epigenetic Editing as was attempted 
in chapter 6.
CHAPTER 5
ICAM-1 is another gene that appears to be epigenetically regulated in ovarian cancer 
cells. In chapter 5 we tested whether published ICAM-1 speciϐic zinc ϐingers were still 
able to bind the promoter of this gene when it was epigenetically silenced. Upon fusion 
of the zinc ϐinger to the activating protein VP64, indeed ICAM-1 expression could be 
induced. Thus, also the ICAM-1 gene is an interesting model gene for Epigenetic Editing. 
Not only because it is epigenetically silenced in ovarian cancer cells and we were able to 
induce gene expression using zinc ϐinger fusion proteins, but also because we observed 
in chapter 5 that induction of ICAM-1 expression in ovarian cancer cells reduced cell 
growth.
CHAPTER 6
Just as for ICAM-1, for EpCAM it was previously described that a zinc ϐinger fused 
to VP64 can induce expression from the epigenetically silenced gene. In chapter 6, we 
used this information to apply Epigenetic Editing. The epigenetic enzymes described in 




ϐingers. Upon treating ovarian cancer cells with these fusion proteins, no effect on the 
targeted epigenetic marks nor on gene expression was observed. This might be caused 
by several factors, as will be discussed in chapter 8.






In this thesis, the aim was to induce expression of epigenetically silenced genes 
through gene-speciϐic rewriting of epigenetic marks (Epigenetic Editing). First we 
screened candidate enzymes for potent epigenetic effector domains, capable of removing 
epigenetic marks associated with repressed genes or inducing epigenetic marks 
associated with active genes (chapter 3). We showed that putative DNA demethylase 
Gadd45α and H3K27 demethylase UTX might represent interesting candidates for 
reactivation of gene expression through Epigenetic Editing. Subsequently, endogenous 
model target genes were identiϐied that are epigenetically silenced and could be 
reactivated with epigenetic drugs (chapter 4 and 5). Moreover, as described by us for 
EpCAM (1), ICAM-1  expression could be directly induced using Artiϐicial Transcription 
Factors (ATFs); zinc ϐingers (ZFs) fused to transient effector domains, in this case 
transcription activation domain VP64 (chapter 5). Finally, we attempted to reactivate 
these epigenetically silenced genes using the gene-speciϐic ZFs but in this chapter in 
fusion to potentially gene expression activating epigenetic enzymes (chapter 6). 
Although the gene-speciϐic rewriting of epigenetic marks was not achieved, some pitfalls 
and potentials of Epigenetic Editing become apparent after the performed research and 
will be discussed here. 
PITFALLS
Effective silencing of gene expression has been obtained by targeted DNA 
methylation (2) or by targeted H3K9 methylation (3) through Epigenetic Editing. 
The latter was conϐirmed for another target gene by our lab, using the same delivery 
system as used in chapter 6 (4). However, re-expression of an epigenetically silenced 
gene through Epigenetic Editing (in a gene-speciϐic way) has never been reported. 
Nonetheless, induction of expression of epigenetically silenced genes has been achieved 
through other targeting approaches, where sequence-speciϐic DNA binding domains 
(DBDs) which do not target a speciϐic gene are fused to epigenetic enzymes to enforce 
their presence on the recognition site(s) of the DBD. (see chapter 2). This indicates 
that 1) repressed endogenous genes are accessible 2) Overwriting negative marks r 
inducing positive marks results is associated with an increase in gene expression. Likely, 
spreading of the activating epigenetic mark is necessary for efϐicient activation of gene 
expression. Furthermore, the balance with remaining repressive epigenetic marks, 
which might recruit endogenous enzymes, needs to be tipped over to an expressive 
state. In performing this innovative research, we also identiϐied other issues need to be 
taken into account to improve Epigenetic Editing efforts aiming to achieve induction of 
gene expression of epigenetically silenced genes, as is described here.
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Instructiveness of the edited marks with respect to gene expression 
Genome-wide approaches have resulted in associations of most epigenetic marks 
with either active or repressed genes. The causality of these marks for the associated gene 
expression state, however, is in general unclear. Therefore, the feasibility of modulating 
gene expression by rewriting these marks through Epigenetic Editing is also not clear 
for most epigenetic marks, target genes and/or target contexts. In particular cases of 
research into the effect of epigenetic enzymes in targeted approaches (see chapter 
2) rewriting of one type of mark has been shown to be enough to cause a change in 
gene expression, as the effect of the enzymes was compared with their catalytically 
inactive counterpart. Nonetheless, it is not known whether the observed effects on 
gene expression are actually caused by the epigenetic mark that is changed (Fig. 1a). 




















Induction of gene expression
Figure 1. Epigenetic Editing to induce gene expression –pitfalls and potentials
The action of Epigenetic Editing to induce gene expression is schematically shown in this ϐigure. In the upper 
ϐigure a locus is shown harboring an epigenetically silenced gene. Lollypops represent either unmethylated 
(open) or methylated (ϐilled red) CpGs. Histones (yellow circles) and their tails (orange) are also represented 
and histone tail modiϐications are represented by open or ϐilled black circles (associated with an active or 
repressed chromatin state, respectively). The DNA binding domain (DBD) recognition site is shown as a black 
triangle. Indicated are processes that can affect efϐiciency of Epigenetic Editing: A) Instructiveness of the 
targeted mark; B) Recruitment of/by other proteins; C) Choice of effector domain; D) Context of the target 
gene; E)Linker length; F) Crosstalk between epigenetic marks; G) Spreading of epigenetic marks; H) DNA 




enzymes with an inactive catalytic site (5, 6, 7, 8). It is likely that in these cases the 
targeted protein recruits other proteins (Fig. 1b) that actually perform the effect on 
gene expression, which are thus of more interest as an epigenetic effector domain for 
Epigenetic Editing. 
In this thesis, we adopted several strategies with the ultimate aim of achieving 
sustained gene-speciϐic re-expression of epigenetically silenced genes. In addition to 
targeting candidate DNA demethylases, an H3K27 demethylating enzyme and a histone 
acetyltransferase have been fused to DNA binding domains (DBDs) to perform their 
action at predetermined sites (chapter 3 and chapter 6). However, it might be that the 
speciϐic DNA demethylation, H3K27 demethylation or histone acetylation (alone) is not 
instructive for re-expression of epigenetically silenced genes.
Theoretically, demethylation of DNA is of interest for activation of gene expression 
(9). That is, it is known that DNA methylation, in particular at the transcription start 
site (TSS) and exon 1, is strongly associated with repression of gene expression (10, 
11). In this respect, drugs have been developed that inhibit DNA methylation in order to 
induce gene expression. Such drugs are effective and some are currently used in clinic 
(12, 13, 14). Whereas until recently mainly hematological malignancies were treated 
with these drugs, currently also solid tumours seem to respond to DNA methylation 
inhibitors (15).
However, recently, DNA methylation was reported not to be a stable lock of gene 
expression, but more of importance for gene silencing memory (16). Furthermore, DNA 
demethylation does not always seem to be necessary for activation of gene expression, 
since for some genes (e.g. ICSBP/IRF8 and CAII) promoter methylation (including 
around the TSS) did not hamper expression when activating histone marks were present 
(17, 18). Interestingly, even when DNA is demethylated this is not necessarily sufϐicient 
for induction of gene expression (19), not even if activating histone modiϐications are 
present (which generally seems to coincide) (20).
In addition, there are some indications that DNA demethylation is not instructive 
for induction of gene expression in all cases, as treatment with e.g. DNA methylation 
inhibitor 5-aza-2’-deoxycytidine (5-aza) does not lead to re-expression of all methylated 
genes. In this respect, it was shown that upregulation of genes upon treatment with 
5-aza depends on the CpG content and methylation rates at the speciϐic promoters (21). 
Moreover, treatment with DNA methylation inhibiting drugs was shown to cause as 
many genes to be upregulated as downregulated (22). Furthermore, DNA demethylation, 
through treatment with 5-aza or deletion of the DNA methyltransferases, does not seem 
to be sufϐicient for complete transcriptional (re-)activation, which is suggested to be 
caused for example by a lack of recruitment of Dot1L, responsible for H3K79me2 (23).
However, in another example, demethylation of DNA by inhibiting the DNA 
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methyltransferases resulted in activation of gene expression, followed by a change 
in histone modiϐications to a more permissive chromatin state (24). Importantly, 
endogenous targeting of multiple genes by a candidate DNA demethylase Thymine 
DNA Glycosylase (TDG) upon fusion to the NFκB DBD did result in DNA demethylation 
and, moreover, induction of target gene expression (25). This indicates that, at least in 
particular cases, DNA demethylation can be instructive for reactivation of expression of 
epigenetically silenced genes.
Less is known about the instructiveness of H3K27 demethylation with respect to 
gene expression activation. It is reported that UTX, the H3K27 demethylase used in this 
thesis (chapter 3 and 6), is needed for induction of pluripotency in induced pluripotent 
stem cells, but not so much for maintenance of the feature (26). This could indicate 
that H3K27 demethylation is less suitable for long-term re-expression of epigenetically 
silenced genes by Epigenetic Editing. Another study shows that H3K27 demethylation is 
essential for normal development through the activation of gene expression (27). Also, 
mutations in UTX are associated with cancer and reintroduction of expression of UTX 
not only resulted in reduced proliferation, but also activation of gene expression (28).
Histone acetylation is often associated with active genes. Nonetheless, there are 
indications that histone acetylation is not predictive and thus might not be instructive 
for activation of gene expression (29). Interestingly, in targeted studies, histone 
acetyltransferases seem to effectively induce gene expression. p300, one of the 
previously targeted histone acetyltransferases is, as far as known, the only enzyme of the 
ones used in this thesis (chapter 6) that resulted in targeted induction of reporter gene 
expression before (see Table 2b of chapter 2 (30)). Thus far, only one study exploiting 
targeted histone acetyltransferases investigated and showed both induced histone 
acetylation and gene expression, in the particular case by targeting p300 (31). Although 
this study investigated the effects on plasmid level with cotransfections, it might be 
that the effect can be translated to the instructiveness of targeted histone acetylation 
in the endogenous chromatin context. The other targeting studies all show activation 
of gene expression. Interestingly, two of these targeting studies enforce presence of 
histone acetyltransferases on epigenetically silenced endogenous targets by fusing the 
histone acetyltransferases to the methyl binding domain (MBD) of MeCP2 or to the DNA 
binding domain of MLL. This might indicate that histone acetyltransferases are good 
candidates to use in Epigenetic Editing, although we were not able to show this thus far. 
Nonetheless, more investigation is needed to ensure that the observed targeted effects 
on gene expression are indeed caused by induction of histone acetylation. Also issues 
like heritability of the effect have not been addressed leaving the applicability of these 




Activity of (domains of) epigenetic enzymes
In determining the choice of the epigenetic effector domain (Fig. 1c) for Epigenetic 
Editing, there are other challenges in addition to predicting the instructiveness of its 
actions. In chapter 3 and chapter 6 we attempted to identify true DNA demethylases by 
overexpression and by fusing putative DNA demethylating enzymes or domains thereof 
to DBDs. As far as size limitations allow, it is possible to target full length epigenetic 
enzymes, which is (partially) dependent on the delivery method. However, in some 
sequence-speciϐic targeting studies reviewed in chapter 2, it was shown that certain 
domains of epigenetic enzymes are more active than full length enzymes. Moreover, 
in some cases the full length protein was not active at all. As an example, full length 
Suv39H1 did not result in gene repression upon fusion to a ZF (3). In this particular 
case, the lack of effect was suggested to be caused by capturing of the fusion proteins by 
endogenous proteins like HP1. Evidently, this problem might occur for many DBD-fused 
and also untargeted enzymes. Thus, it seems worthwhile to try out several truncations 
of the enzyme of interest. For true Epigenetic Editing, rewriting the epigenetic mark at 
the target gene, targeting of the catalytic domain of the enzymes should be sufϐicient. In 
this thesis, in chapter 3 and/or 6, the full length of Gadd45α, Aid (murine) and Apobec 
(murine) were fused to DBDs. As such, they might possess domains actively recruited 
by endogenous proteins (like suggested for Suv39H1), hampering the fusion proteins 
from reaching their target site. This, however, does not seem to be the case for Gadd45α 
as it clearly showed decondensation and an increased transcription upon targeting to a 
LacO repeat integrated in cells upon single cell analysis (chapter 3). 
With Epigenetic Editing, theoretically only two copies of DNA need to be targeted 
and thus only two copies of the Epigenetic Editor are expected to be needed per cell. 
However, expression efϐiciency might be of inϐluence on the activity and this could 
also be caused by the (size of) the effector domain fused, as was seen in both chapter 
3 and 6. The larger effector domains (UTX, p300, Tet1 and Tet3) showed little or no 
expression. However, UTX was effective in fusion to LacR, despite the lack of detectable 
protein expression.
Tet proteins
For Tet1 and Tet3 (both murine), truncated domains were used, which are the CXXC 
domains, found to be active for human Tet1 by Tahiliani et al. (32) and for murine 
by He et al. (33). These catalytic domains were previously reported to be active in 
oxidation of 5-methylcytosine (5mC) upon overexpression. In addition, Tet1 was 
previously studied in a targeted fashion, although the exact amino acids used in the 
respective Gal4 targeting study are unclear (34). The targeting of Tet1 in the study 
by Williams et al., interestingly resulted in repression of the targeted reporter gene, 
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but DNA (hydroxy)methylation levels were not investigated and Tet1 was targeted 
to an active reporter gene. Importantly, the Tet proteins facilitate conversion from 
methylated to hydroxymethylated cytosine, and further oxidation to 5-formylctosine 
and 5-carboxylcytosine. Further conversion to unmethylated cytosine is demonstrated 
to be performed by TDG (33, 35). Nevertheless, as hydroxymethylated cytosine levels 
were not determined in this thesis, no conclusions can be drawn about the oxidation 
activity of the targeted Tet domains in chapter 6. Whereas bisulϐite treatment does not 
result in a distinction between 5mC and 5-hydroxymethylcytosine (5hmC), currently 
several assays are reported to investigate hydroxymethylation levels in a locus-speciϐic 
manner. The most interesting assay if the exact target CpG(s) are unknown is an adjusted 
bisulϐite sequencing protocol enabling analysis at the single base level (36, 37). However, 
as 5-hmC antibodies are now available, hMeDIP, the detection of immunoprecipitated 
DNA associated with 5-hmC, might be sensitive enough when the target CpG is known.
Ros1 and Demeter
In contrast to the Tet proteins (of which the catalytic domains used were previously 
reported to be active), for Ros1 (aa 868-1105) and Demeter (DME; aa 1189-1418), 
investigated in chapter 3, truncations of the genes were made based on homology to 
each other and Demeter-like proteins DML-2 and DML-3 (38), which could explain the 
lack of their activity. Since the truncated Ros1 and DME were only investigated upon 
untargeted overexpression, it might be that some essential domains are missing, like 
their DBD, causing the lack of effect. These truncations of Ros1 and DME might however 
still be effective upon fusion to DBDs. Despite the fact that the activity of these plant 
DNA demethylases have not been examined in mammalian cells before (to the best of 
our knowledge), plant Suv39H1 has been successfully targeted to a mammalian gene 
(3). Also the prokaryotic DNA methyltransferases M.SssI and M.HpaII were successful 
in targeted methylation of yeast and mammalian DNA, respectively (39, 40, 41). This 
indicates that certain epigenetic mechanisms are conserved throughout eukaryotes and, 
moreover, the feasibility of using enzymes from other species for Epigenetic Editing in 
mammalian cells. It could be necessary to optimize the codon usage to achieve efϐicient 
expression in mammalian cells.
AID/Apobec1
For the candidate DNA demethylating enzymes used in this thesis, only circumstantial 
evidence indicates that they are indeed able to cause DNA demethylation (42). Increasing 
amounts of evidence indicate that it is likely that the mammalian DNA demethylation 
mechanism is a cascade of events, involving multiple proteins. Several suggestions hint 




(43, 44, 45, 46, 47). Even though direct ‘repair’ of 5meC/G to C/G might be possible, 
it seems more likely that the 5meC is ϐirst converted to another intermediate, such as 
a thymine through deamination or to 5hmC through hydroxylation. Interestingly, Aid 
and Apobec1 (deaminases previously suggested to be part of the DNA demethylation 
process (48, 49, 50)) have recently been shown to be more likely deaminating cytosines 
than 5mC, while deamination of 5hmC was undetectable (51). This indicates that 
if deamination plays a role in active DNA demethylation, it is likely that the pathway 
in which they are involved is independent of the pathway involving oxidation of 5mC 
to 5hmC. Targeting of these deaminases to endogenous genes did not result in DNA 
demethylation or gene-activation (chapter 6), but further investigation is necessary to 
detect whether deamination did take place. 
Gadd45α
The most promising potentially DNA demethylating enzyme in this thesis is Gadd45α. 
We were able to show induction of reporter gene expression in cotransfections where 
Gadd45α was overexpressed (chapter 3). Moreover, LacR-fused Gadd45α appeared 
to be able to induce chromatin decondensation and transcription of a reporter gene 
integrated in mammalian cells (chapter 3). However, no effect of the enzyme was 
observed when targeted gene-speciϐically to endogenous genes by fusion to ZFs 
(chapter 6). This might be explained by the fact that the targeted effect seen upon 
fusion of Gadd45α to LacR was achieved when targeting to a repeat of LacO sites and 
analyzing at single cell level. Thus, it might be necessary to design more than one ZF, 
all binding close to each other in one same region, to obtain signiϐicant effects. Another 
option is to look at single cells for DNA demethylating effects. In addition, there has been 
some debate on whether Gadd45α indeed plays a role in active DNA demethylation or 
not. Whereas in ϐirst instance Gadd45α was thought to induce the ϐirst step of DNA 
demethylation (52), later the protein was suggested to be more of importance for 
the formation of protein complexes, likely consisting of deaminases and DNA repair 
proteins (43, 49). The exact mechanism of DNA demethylation involving Gadd45α 
needs further investigation, which might be achieved through assays like ChIP-reChIP. 
In this way, the proteins recruited by Gadd45α can be determined, potentially leading to 
new interesting candidates for fusing to DBDs in Epigenetic Editing attempts.
UTX
The domain of the H3K27 demethylase UTX (aa 401-1401) that was used in targeted 
efforts in chapter 3 and 6 has not been targeted before. In fact, the activity of this 
truncated domain was only reported upon overexpression after which the nuclear cell 
extracts were incubated with calf core histones (53). Nonetheless, like for Gadd45α, 
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also for UTX effects were observed when analyzing single cells and upon targeting to a 
large repeat of DBD recognition sites (chapter 3). Again, no signiϐicant effects on levels 
of molecular epigenetic marks or on gene expression were observed upon fusion of 
the domain to ZFs and targeting to endogenous epigenetically silenced genes (chapter 
6). It might be that there is more H3K27me3 present in the cells comprising the LacO 
repeats that were analyzed on single cell level, but this has not been assessed. Again, 
also transfection efϐiciency and the fact that only one copy of the enzyme can be targeted 
to the ZF binding site might explain the lack of effects seen in chapter 6.
p300
The HAT domain of histone acetyltransferase p300, chosen for targeted induction of 
histone acetylation in this thesis (chapter 6), consists of the same amino acids as used 
to produce a commercially available variant of the catalytic domain of the enzyme. As 
described above, several domains of the histone acetyltransferase p300 (of which some 
including the domain used in this thesis or are closely similar (54, 55, 56, 57)) have 
previously been targeted to predetermined sites, mainly by fusion to Gal4 (see chapter 
2, Fig. 2). From these studies, the domain used in this thesis seems to be successful 
in half of the cases. One targeted domain, aa 964-1922 shows activation in one study 
(54) but no effect in another study (57). Here it appears that the position relative to the 
TSS is of importance. The study where activation was observed was where the target 
site was downstream of the TSS. Although this is also the case for the ZF binding site 
in the ICAM-1 promoter (chapter 5 and 6), no effect was observed upon expressing 
the ZF fused p300. Importantly, the study showing the activation by targeting p300 to 
a site downstream of the TSS was performed with cotransfections. It might be that the 
position dependency is different in the endogenous chromatin context. Furthermore, the 
chromatin environments targeted in chapter 6 already are occupied by some histone 
acetylation (see chapter 4 and 5), despite the repressed state of gene expression. As 
targeting of p300 could not show a further increase of acetylation levels, no effect on 
gene expression was observed, nor expected. This domain was not investigated upon 
fusion to LacR, which might be of interest as other domains unsuccessful in Epigenetic 
Editing (Gadd45α, UTX CD) to endogenous genes were successful upon single cell 
analysis when targeting to LacO repeats (chapter 3).
The context of the Epigenetic Editing target gene
In chapter 4 and chapter 5 we validated two model genes for induction of gene 
expression through Epigenetic Editing in chapter 6. These genes (Epithelial Cell Adhesion 
Molecule; EpCAM and Intercellular Adhesion Molecule-1; ICAM-1, respectively) showed 




that ZFs targeting these genes were already published. For effective Epigenetic Editing, 
certain factors with regard to the target gene are likely to be of importance and could be 
a pitfall. For example, the chromatin environment of the target gene needs to be able to 
accommodate Epigenetic Editing (Fig. 1d).
Targeting a DNA demethylase to a gene that is not methylated obviously is unlikely 
to cause increase of target gene expression, as could be seen upon targeting of Tet1 to 
an active reporter gene (34). However, the degree of, for example, DNA methylation 
that needs to be demethylated by a DNA demethylase before it exerts an effect on gene 
expression is unknown. Moreover, it might be that the presence of other marks than 
the one addressed hampers the execution of the desired effect. For instance, H3K4 
methylation marks prevent DNA from being methylated (58, 59, 60). Although DNA 
methylation and H3K4 methylation have been detected at the same gene, they were not 
present at the exact same site (61). Furthermore, some marks are mutually exclusive, 
such as methylation and acetylation of lysine residues (62), or methylation of H3K4 
and H3K9 methylation (63). So, for long-term activation of gene expression, it could be 
worthwhile to induce H3K4 methylation in order to prevent repression through DNA 
methylation or to induce histone acetylation to prevent the repressive histone mark 
H3K9 methylation from being induced.
Also DNA methylation and H3K27 methylation have been shown to be mutually 
exclusive at an imprinted gene (64). In another study, the silencing through H3K27 
methylation seems to be independent of DNA methylation (65). Contrastingly, another 
report shows dependence of DNA methylation on H3K27 methylation (66). This 
variability of results can be explained by cell type or gene-speciϐic factors. In the study 
showing that DNA methylation and H3K27 methylation are mutually exclusive at an 
imprinted gene, H3K9 methylation appeared to be a prerequisite for proper induction 
of DNA methylation (64), which has been described more often (67). Although H3K27, 
H3K9 and DNA methylation are all associated with repressed genes, this sort of 
information might also be of importance for achieving induction of gene expression 
through Epigenetic Editing. In those cases where it is known that marks are mutually 
exclusive, it is likely essential to ϐirst remove the hampering epigenetic mark before the 
mark of interest can be inϐluenced.
Noteworthy, it might be that ChIP assays give results on histone tail modiϐications 
more upstream or downstream of the CpGs that were analyzed for methylation. In this 
respect, BisChIP-seq has recently been introduced; a way to simultaneously analyze 
histone modiϐications and DNA methylation at a location of interest (68, 69). This 
technique could also come in handy to analyze the epigenetic context of a certain gene 
before and after intervening via Epigenetic Editing. 
Another issue is the distance of the recognition sequence of the DBD in relation to 
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the mark desired to modulate as was investigated for ZF-VP16 fusion proteins when 
targeted to reporter genes integrated in the genome of plant cells (70). In this study it 
was shown that a ZF-VP16 fusion protein is most effective when targeted to a site as 
close to the TSS as possible. Targeting to a site downstream of the TSS, however, leads 
to blocking of transcription, probably by hampering the activity of RNA polymerase. 
However, in mammalian cells this does not need to be the case, as ZF-VP64 fusion 
proteins were able to induce ICAM-1 expression upon binding to a site downstream 
of the TSS (chapter 5). ZF-fusions to DNA methyltransferases also showed certain 
preferences in the distance between DBD and target of activity (71, 72). Although the 
linker length (Fig. 1e) between ZF and effector domain can be varied, which might 
facilitate ϐlexibility of the targeting construct, increasing ϐlexibility can also lead to an 
unintended effect on physically close parts of DNA. In general, more systemic research 
into such elementary factors as DBD-target distance should be executed.
It is tempting to assume that due to the compact chromatin formation, DBDs can 
not reach epigenetically silenced genes. This would indicate that induction of gene 
expression of epigenetically silenced genes is more challenging than repressing gene 
expression through Epigenetic Editing. Indeed, Epigenetic Editing in order to induce 
gene expression has not been shown before. However, upon fusion of gene-speciϐic 
DBDs to transient transcriptional activators such as VP16/64 or p65, induction of gene-
expression can be observed. Even when imprinted genes are targeted, ZFs are able to 
reach their recognition site within this heterochromatic regions (73). In addition, even 
large macromolecules are able to access condensed chromatin regions (74).
Cross-talk reinforces silencing but prevents activation
As becomes clear from the above, epigenetic marks communicate (Fig. 1f), either 
reinforcing a state of chromatin or preventing a state of chromatin from being induced. 
In this respect, changing one epigenetic mark might be sufϐicient for it to cause a cascade 
of effects eventually resulting in enforced change of gene expression in the desired 
direction. However, upon changing just one mark, this cross-talk of epigenetic marks, 
their writers and readers, might on the other hand cause reinstallment of the original 
epigenetic status after the epigenetic editor is cleared from the system.
Such cross talk can have an effect on the order of events needed to induce or repress 
gene expression. In Arabidopsis, where the mechanism of DNA demethylation is known, 
it was shown that a certain protein (IDM1) binds DNA in a repressive chromatin state, 
containing DNA methylation and lacking H3K4 methylation. By subsequently facilitating 
H3 acetylation, the chromatin state becomes permissive for DNA demethylation to take 
place (75). A similar sequence of events might also occur in the mammalian situation. 




acetylation before DNA methylation marks can be modiϐied. Thus, subsequent targeting 
of e.g. p300 and a DNA demethylase might be successful.
Some reports already give indications on the possible order of events in mammalian 
cells. For example, upon investigation of the silencing of stably integrated transgenes, 
it was observed that H3 and H4 are ϐirst hypoacetylated, together with a reduction of 
H3K4me3 (76). The later observed H3K9 methylation and DNA methylation apparently 
are not the ϐirst steps in such frequent events of gene silencing. To prevent transgene 
silencing, targeting histone deacetylases and/or H3K4 demethylases would likely 
be effective. Indeed, targeting of p300 speciϐically to reporter genes integrated in 
mammalian cells was previously shown to prevent silencing (55).
Crosstalk might occur at several levels. It can be that histone modiϐications 
communicate within a histone tail, within one nucleosome, between two adjacent 
nucleosomes or between two more distant nucleosomes (77).  Various examples 
of crosstalk between epigenetic modiϐications have been described, as extensively 
reviewed in (78). An advantage of crosstalk is that it is also important for the general 
phenomenon of spreading (Fig. 1g) of an epigenetic mark. A well known example 
of this is recruitment of HP1 by H3K9 methylation, subsequently recruiting H3K9 
methyltransferases that spread the mark and can recruit DNA methyltransferases ro 
reinforce the repressed state. An example of crosstalk to spread epigenetic marks is for 
example discussed for the ß-globin locus in (79).
POTENTIALS
Although there are some pitfalls that need to be avoided (as described above), there 
are also many potentials for Epigenetic Editing. Recently, successful efforts have been 
reported (2, 4) and future research can increase efϐiciency, eventually resulting in a 
wide range of applications for the approach.
Gene speciϐicity
Upon ϐinding a good way to perform Epigenetic Editing, no matter what the 
application is, it is detrimental to validate the assumed gene-speciϐicity of the approach. 
In theory, the number of ZFs stitched together has a big inϐluence on the speciϐicity and 
six ZFs, targeting 18 base pairs (bp) is a mathematically unique address in the human 
genome (80). However, increasing the number of ZFs might, in addition to possibly 
increase the speciϐicity, also decrease the efϐiciency. For some genes it could be that ϐive 
(or less) ZFs are enough to target only that speciϐic gene, which will also be dependent 
on other factors such as accessibility of the DNA at the target site compared to potential 
off-target recognition sites. In this regard, clinical trials have been executed with ZF 
proteins comprising three ϐingers, without leading to toxicity (81).
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Recently, ChIP-seq, the genome-wide sequencing of immunoprecipitated chromatin, 
is a technique that is more and more used. As far as known, no ChIP-seq studies were 
reported to prove gene-speciϐic DNA binding of engineered ZFs. One report did show 
ChIP-seq of a naturally occurring ZF with nine ϐingers fused to a repression domain, 
which appeared to bind over 5000 sites (82). Apparently, not all nine ϐingers bound 
in this case. It could be that the off-target effects are caused by binding of different 
combinations of only part of the nine ϐingers. Moreover, it can be that the ZF fusion 
protein was recruited to other sites because of the effector domain (KRAB) fused. 
Although additional ChIP-seq studies on the gene-speciϐicity of ZF binding would be 
interesting, one might argue that relatively little background binding will be lost 
with this assay, as very small peaks will be ϐiltered out with regard to high peaks of 
gene-speciϐic binding. In addition, whereas gene-speciϐic binding is nice and could be 
essential, it is more important to establish a gene-speciϐic effect on gene expression, 
which is the desired ultimate outcome. Indeed, upon targeting a ZF-TF with a repressive 
effector domain, DNA microarrays were performed showing that only the target gene 
was silenced (83). However, with regard to speciϐicity of ZF binding, mainly prediction 
methods have been reported (84, 85). 
In chapter 2 we also touched upon the possibility of creating less active mutants of 
the epigenetic enzymes or using the split enzyme approach (86). Both approaches are 
designed to ensure that the epigenetic enzyme does not exert its effect before reaching 
its intended target site through binding of the DBD. 
Targeting device: Epigenetic Editing is ϐlexible in using DNA binding domains
In this thesis, epigenetic effector domains were targeted to predetermined site 
either in a sequence-speciϐic way, through fusion to LacR (chapter 3), or in a gene-
speciϐic way, through binding to ZFs (chapter 3 and 6). Whereas signiϐicant effects 
were obtained with the LacR DBD, this can not be exploited for use in approaches where 
gene-speciϐicity is needed.
In addition to ZFs (used in chapter 3, 5, 6), other engineerable gene-speciϐic 
DBDs have been reported, which might be of interest for Epigenetic Editing (Fig. 
1h). Polyamides and Triple helix forming oligonucleotides (TFOs) were also used to 
modulate gene expression (87) Disadvantages of these domains in comparison to ZFs 
are that TFOs only efϐiciently bind purine-rich sequences, limiting the choice of target 
sites. TFOs and polyamides thus far primarily showed effects on transcription by 
blocking transcription factor binding sites, causing repression or activation. However, 
a TFO targeting the EpCAM promoter proved to be able to target DNA methylation to 
a predetermined site of a reporter plasmid upon fusion to a methyltransferase (88). 





Recently, increasing attention is focusing on new DBDs; the Transcription 
Activation-Like (TAL) effectors. These domains are derived from plants and have 
already shown their effect on target gene expression upon fusion to VP16 or VP64 
(see (89) and references therein). As opposed to ZFs, the effect of TALes seems to be 
context independent. Where a ZF protein consisting of multiple ϐingers, each potentially 
inϐluencing speciϐicity, this does not seem to be the case for TALes. Like for ZFs, the 
inϐluence of the epigenetic environment at the target site on TALe binding is currently 
still unknown (90). An advantage of TALes is that they appear to be relatively cheap, 
easy and quick to make versus commercially engineered ZFs (91). In comparison to 
ZFs, TALes recognize only one bp whereas ZFs recognize three bp. So in order to target 
a unique address in the human genome, you need to stitch together more TALes, but 
this likely makes the approach more ϐlexible. However, for a TALe to recognize one bp, it 
needs 34 amino acids (92, 93), whereas a ZF consisting of approximately 30 amino acids 
recognizes three bp. As far as current research can show, TALes seem more speciϐic (and 
thus less toxic). This might be due to the fact that one ϐinger in a multimer of ZFs can 
inϐluence speciϐicity whereas TALe monomers do not seem to have this disadvantageous 
property. However, an aspect that might be a major disadvantage of the use of TALes is 
the delivery into (the nucleus of) the cell because of its size (94). 
Heritability 
One of the less recent deϐinitions of epigenetic is: “the study of mitotically and/or 
meiotically heritable changes in gene function that cannot be explained by changes in 
DNA sequence”, as quoted in (95). Thus, one of the great potentials of Epigenetic Editing 
is long-term modulation of gene expression, because epigenetic marks are mitotically 
stable (inherited to daughter cells). Depending on the application of Epigenetic Editing, 
this heritability is of importance (Fig. 1i). Whereas ATFs, combination of ZFs with 
transcription activating or repressing domains such as VP16 and KRAB, respectively, 
have been extensively used to successfully modulate gene expression, this is a transient 
solution as the domains do not have enzymatic activity themselves. However, when 
swapping the effector domains for epigenetic enzymes, this could lead to sustained 
gene expression modulation. 
Although for DNA methylation the mechanism of inheritance is relatively well 
established (96), for histone modiϐications the mechanisms are currently not completely 
clear. Nonetheless, evidence for mitotic inheritance of histone modiϐications is there 
(97, 98, 99, 100, 101) and various models for the mechanism of mitotic inheritance have 
been put forward (97, 98). 
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Delivery
With respect to delivery, ZF fusion proteins have been delivered to cells in different 
ways. Whereas plasmid transfection or retroviral transduction has been used in most 
cases (as also in chapter 3, 5 and 6), other systems are possible (Fig. 1j). Recently, ZF 
fusion proteins were also delivered in RNA (102) and protein forms (103). In addition 
to the form in which the Epigenetic Editors will be forced into the cells, also methods 
should be investigated as to how the Epigenetic Editors can only reach the tissue or cell-
type of interest. If taking cancer as an example, induction of tumor suppressor genes in 
off-target cells or tissues does not necessarily need to be a problem. However, a gene 
that is a tumor suppressor gene in one cell-type might be an oncogene in another type 
of cells. This is nicely exempliϐied by the EpCAM gene, expression of which has different 
effects depending on tumor type (104). Ways to ensure cell-type speciϐic delivery of 
Epigenetic Editors include the use of complexes of antibodies recognizing speciϐic 
cells or tissue and a cationic lipid or liposomes (105). However, such approaches need 
further research.
Applications for Epigenetic Editing
Epigenetic Editing can cause modulation of endogenous gene expression when the 
optimal circumstances are identiϐied. Therefore, in ϐirst instance, Epigenetic Editing is 
useful as a tool to investigate the function of a gene in great detail and with a controllable 
system. That is, in contrast to overexpression of genes, Epigenetic Editing ensures re-
expression of all isoforms of a gene, in natural ratios. When the aim is to repress target 
genes, Epigenetic Editing has as advantage over e.g. siRNA that it only needs to target 
two copies of the gene at DNA level, as opposed to targeting a large amount of constantly 
produced RNA or difϐicult to reach protein molecules. Subsequently, target genes can be 
validated for their potentials as therapeutic targets. In this respect, we showed that 
repression of ICAM-1 expression might play a role in the ovarian cancer tumorigenicity, 
as gene-speciϐic induction resulted in tumor growth inhibition (chapter 5). Importantly, 
Epigenetic Editing is not cell or tissue-type restrained and can thus be deployed in every 
model system of interest.
Furthermore, Epigenetic Editing is a powerful tool to answer fundamental questions 
on the consequence of epigenetic marks on gene expression. Especially upon comparing 
effects of certain targeted epigenetic enzymes with their catalytically dead mutants, 
such answers can be obtained. Also features like the inheritability and spreading of 
epigenetic marks could be investigated in more detail.
Eventually, Epigenetic editing might be of interest as a therapeutic approach. When 
re-expression of epigenetically silenced genes is achieved, treatment of a variety of 




neurological diseases like Alzheimer and Parkinson (106), cardiovascular disease (107) 
and allergic diseases like asthma (108)) known in which aberrant epigenetic silencing 
plays an important (causing) role, most research has been performed in cancer. Here, 
tumor suppressor genes more frequently appear to be aberrantly epigenetically silenced 
than genetically mutated (109). Interestingly, it was shown that silencing through 
DNA methylation of only two tumor suppressor genes is sufϐicient to cause cancer 
formation (110). Interestingly, this might indicate that also the reversal of silencing of 
few tumor suppressor genes might alleviate cancer. Indeed, through siRNA, cDNA or 
ATF treatments it has been shown for numerous genes that silencing or activation of 
one gene already led to a signiϐicant reduction in tumorigenicity ((111), including for 
ICAM-1 in chapter 5).
FUTURE PERSPECTIVES
In conclusion, whereas the general aim of this thesis – Epigenetic Editing to induce 
expression of epigenetically silenced genes - was not fully achieved, possibilities for 
further research into optimizing the Epigenetic Editing protocol are identiϐied. 
It is likely that more than one mammalian active DNA demethylation mechanism 
exists. Moreover, probably more than one targeted protein is needed before activation 
of gene expression is achieved. Thus, it might be necessary to cause co-presence of 
multiple proteins at the target site. In some cases targeting of the enzyme causing 
the ϐirst step in the cascade (like the Tet proteins, hydroxylating 5mC), subsequently 
recruiting endogenous cofactors (such as TDG) to complete the process might be 
sufϐicient. However, it might also be that more than one protein needs to be targeted 
to the same target site for the proteins to ϐind each other, in collaboration leading to 
activation of gene expression. This could be achieved by 1) expressing the DBD in 
fusion to two (or more) different epigenetic effector domains, acting after each other 
2) expressing one DBD with two different enzymes fused (e.g. N- and C-terminally) 3) 
expressing two different DBDs, both binding in the same target region, fused to different 
epigenetic effector domains. In general, the targeting of more than one epigenetic 
enzyme might be beneϐicial, for example the combination of a DNA methyltransferase 
and a histone modifying enzymes. In this regard, also combination therapies of a DNA 
methyltransferase inhibitor and a histone deacetylase inhibitor showed promising 
results (15). 
Importantly, the context of the target gene needs to be taken into account, as the 
effect of several epigenetic effectors is shown to be context dependent. The efϐiciency 
of targeting a particular epigenetic effector domain with respect to induction of gene 
expression might be esteemed by treating cells with epigenetic drugs. Upon induction 
of gene expression in that way, epigenetic marks could be analyzed to observe which 
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effects lead to induction of gene expression.
Furthermore, the detection of effects could be improved for example by sorting or 
selecting transfected cells (as was also performed by e.g. (25)), to make sure all cells that 
are analyzed indeed express the construct, as we show that when analyzing at single cell 
level, effects are more detectable. Another option would be to immunoprecipitate DNA 
associated with the construct (by ChIP of the HA-tagged zinc ϐinger proteins) followed 
by a method to investigate the changes in the epigenetic mark of interest, to ensure 
presence of the epigenetic editor at the target site.
With an epigenetic effector domain that is able to rewrite the epigenetic mark and 
subsequently lead to gene expression modulation, systematic experiments should be 
executed to optimize the approach. In such experiments optimal linker length and/or 
distance between DBD and epigenetic effector domain can be assessed. Also issues like 
heritability and spreading of the epigenetic marks need to be further investigated.
Other domains than the ones used in this thesis might be validated for their efϐiciency 
in rewriting epigenetic marks. Using the review in chapter 2, such domains might be 
fused to ZFs in order to upregulate gene expression. Successful targeted induction of 
gene expression has been achieved with other histone acetyltransferases than p300, 
histone methyltransferases acting on H3K79 or H3K4 and histone demethylases acting 
on H3K9 methylation. 
Repression of gene expression through Epigenetic Editing has already been achieved. 
Furthermore, successful upregulation of gene expression has been achieved with locus-
speciϐic targeting of epigenetic enzymes and by using ATFs. Thus, combining these 
two approaches in Epigenetic Editing is likely to eventually lead to realization of gene-
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Het menselijk lichaam bestaat uit ongeveer 100 biljoen cellen. Het begin van al 
deze cellen ligt bij de bevruchting van een eicel door een zaadcel. Omdat alle cellen 
in het lichaam van die ene bevruchte eicel afstammen bevatten ze dezelfde genetische 
informatie, die bij elke celdeling overgenomen wordt. Ondanks die zelfde genetische 
informatie, verschillen de cellen in het menselijk lichaam behoorlijk van elkaar. Er zijn 
bijvoorbeeld spiercellen, levercellen, huidcellen, en nog veel meer verschillende typen 
cellen. Eén oorzaak van deze verschillen is het verschil in genexpressie. Het DNA dat in 
elke cel gelijk is, bevat ongeveer 25 duizend genen. Elk van deze genen kan tot expressie 
koment of niet (aan of uit staan). Daarnaast zijn er nog tussenvarianten waarin een 
gen zwak tot expressie komt of juist sterk. Dit bepaalt hoeveel van de eiwitten waar 
het gen voor codeert geproduceerd wordt. Deze eiwitten hebben allemaal hun eigen 
belangrijke rol in de cel. Aϐhankelijk van het soort cel (spier/lever/huid enzovoort) zijn 
bepaalde eiwitten nodig of juist niet nodig. Dus het type cel wordt bepaald door welke 
genen tot expressie komen en dus eiwitten produceren. 
Epigenetica
Een van de mechanismen waarmee een cel de expressie van genen (en dus 
de eiwitproductie) reguleert is epigenetica. Dit zijn overerϐbare en reversibele 
veranderingen in genexpressie die niet veroorzaakt worden door een verandering in 
DNA volgorde (genetische informatie). Het DNA van één menselijke cel is ongeveer 2 
meter lang. Dit DNA moet passen in de celkern die gemiddeld slechts een doorsnede van 
6 micrometer heeft. Dit is te vergelijken met een stuk draad van ongeveer 40 kilometer 
lang dat in een tennisbal moet passen. Het is dus voor te stellen dat het DNA ingenieus 
opgevouwen moet worden (gecondenseerd) om in een celkern te passen (Fig. 1). De 
mate van condensatie van het DNA van een gen bepaalt hoe sterk genen tot expressie 
komen.
Histon modiϔicaties
De mate van condensatie hangt af van de nucleosoomdichtheid. Een nucleosoom 
is een cluster van 8 histonen waar DNA omheen gewikkeld is. Elk van de 8 histonen 
heeft een staart die uit de cluster steekt. Deze staart bestaat uit een reeks aminozuren, 
waarvan sommigen een beetje veranderd kunnen worden (histonmodiϐicaties). Er 
bestaan een heleboel verschillende soorten histonmodiϐicaties, die zorgen voor de 
compactheid waarmee DNA wordt opgevouwen en een hoge of lage nucleosoomdichtheid 
veroorzaken. Om ervoor te zorgen dat de genen eiwitten kunnen produceren moet het 
DNA lokaal niet te compact zijn en dus niet teveel nucleosomen bevatten. Er moeten 




Speciϐiek is van belang hoe de situatie is in de buurt van de promoter van het gen. Dit is 









Dit is een schematische weergave van de organisatie van DNA in de celkern. In de kern van een mensenlijke cel 
zitten 23 chromosomen, waarin het DNA opgeslagen ligt. Dit DNA is verpakt in chromatine, een combinatie 
van DNA en histonen. Een chromsoom bestaat uit meerdere genen. Een gen bestaat heeft een promoter die de 
expressie van het gen reguleert. Epigenetische marks als histone modiϐicaties en DNA methylatie beïnvloeden 
de expressie van een gen en daarmee de eiwitproductie zonder de DNA volgorde te veranderen. De gele 
bolletjes zijn histonen, de rode lijnen representeren DNA. De zwarte stokjes met bolletjes stellen CpGs voor 
die gemethyleerd (dicht rood bolletje) of ongemethyleerd (open rood bolletje) zijn. De oranje staarten die uit 
de histonen steken kunnen ook gemodiϐiceerd worden; open zwarte bolletjes representeren genexpressie 
activerende modiϐicaties, dichte zwarte bolletjes representeren genexpressie remmende modiϐicaties.
DNA methylatie
Naast de histonmodiϐicaties kan ook DNA methylatie zorgen voor een verandering 
van eiwitproductie zonder de DNA volgorde te veranderen. DNA bestaat in principe uit 
4 bouwstenen; adenine, thymine, cytosine en guanine. Adenine en thymine vormen een 




baseparen naast elkaar zitten is de genetische informatie die overerft van generatie 
op generatie. Foutjes in de volgorde of de paring van basen (mutaties) die tijdens het 
leven kunnen optreden kunnen allerlei ziektes veroorzaken. Interessant genoeg kunnen 
cytosines daarnaast ook met behulp van celbiologische mechanismen veranderd 
worden. Als een cytosine niet alleen tegenover maar ook náást een guanine zit, in de 
volgorde CG, dan kan de cytosine base gemethyleerd worden (Fig. 1). Dit betekent 
dat er een methylgroep aan de cytosine verbonden wordt die er normaal niet zit. Op 
verschillende manieren kan deze methylatie er voor zorgen dat een bepaald gen niet 
langer zorgt voor eiwitproductie. Dit kan soms erg nuttig zijn en er samen met bepaalde 
histonmodiϐicatie voor zorgen dat niet alle genen aanstaan in alle cellen. 
Epigenetica in gezondheid en ziekte
In het algemeen zijn epigenetische veranderingen zoals histonmodiϐicaties en DNA 
methylatie van belang voor het goed functioneren van het organisme in het geheel en 
de cel in het bijzonder. Net als in de genetische informatie die opgeslagen ligt in de DNA 
volgorde kunnen er echter ook foutjes optreden in de epigenetische informatie. Deze 
onbedoelde veranderingen in epigenetische marks kunnen allerlei ziektes veroorzaken, 
waaronder ook kanker. Dit komt doordat bepaalde belangrijke eiwitten niet meer 
geproduceerd worden of doordat eiwitten die voor de cel niet goed zijn juist wel, of 
méér, geproduceerd worden.
DOEL VAN HET ONDERZOEK
In dit proefschrift staat beschreven hoe we hebben geprobeerd om deze epigenetische 
fouten te repareren. Het ultieme doel van het onderzoek dat beschreven staat in dit 
proefschrift was om voor één speciϐiek gen dat in een bepaalde cel per ongeluk 
uitgeschakeld staat door foute epigenetische informatie te zorgen dat hij weer aan gaat 
en dus weer het bijbehorend eiwit produceert. Als dit speciϐieke eiwit erg belangrijk is 
voor de cel, zou het er zelfs voor kunnen zorgen dat de cel weer normaal wordt en niet 
langer ‘ziek’ is. Dit ultieme doel is geprobeerd te behalen via epigenetische editing.
Epigenetische editing
Epigenetische editing wordt bewerkstelligd door een combinatie van twee factoren 
(Fig. 2). Aan de ene kant wordt gebruik gemaakt van een eiwit dat speciϐiek de DNA 
volgorde kan herkennen van het gen van interesse (Fig. 2a). Eén voorbeeld van zo’n eiwit 
is een zink vinger, die ontworpen kan worden om elk gen van interesse te herkennen. 
Eén zink vinger kan namelijk drie baseparen herkennen. Zink vingers kunnen aan elkaar 
vastgemaakt worden en zo kunnen zes zink vingers aan elkaar dus ongeveer achttien 




In dit proefschrift was het uiteindelijk doel om speciϐiek genen tot expressie te 
brengen. Dit doel is in twee vragen op te breken:
1. Hoe kunnen de epigenetische marks overschreven worden, speciϐiek op het gen 
van interesse om genexpressie te induceren?
2. Resulteert deze verandering in epigenetische informatie tot een verhoogde 
expressie van het gen van interesse?
Aϐhankelijk van de epigenetische informatie die ervoor zorgt dat het gen van interesse 
uit staat zou DNA demethylatie (ervoor zorgen dat een cytosine zonder methylgroep 
de plaats van de gemethyleerde cytosine vervangt) of een bepaalde manier van histon 
modiϐicatie een weg zijn om te zorgen voor activatie van het gen. Een extra uitdaging in 
het activeren van genexpressie door Epigenetische Editing ligt in het demethyleren van 
DNA. Hoewel er bewijs is dat DNA gedemethyleerd kan worden is het nog niet duidelijk 
welk enzym of welke enzymen er voor verantwoordelijk zijn en via welk mechanisme 
dit gebeurt.
Dat het veranderen van epigenetische marks een haalbare kaart is, is gebleken met 
bepaalde medicijnen die al in de kliniek gebruikt worden voor bepaalde kankersoorten. 
Deze medicijnen blokkeren de werking van bepaalde epigenetische enzymen en zorgen 





Aan zo’n gen-speciϐiek DNA bindend domein als een zink vinger wordt dan 
een epigenetisch effector domein gekoppeld (Fig. 2b). Dit is een enzym dat 
histonmodiϐicaties kan toevoegen of verwijderen of DNA methylatie kan veroorzaken of 
opheffen. Aϐhankelijk van hoe de (foute) epigenetische informatie eruit ziet op het gen 
van interesse kan gekozen worden uit een heel assortiment van epigenetische enzymen. 
Figuur 2. Epigenetische Editing
Dit is een schematische weergave van Epigenetische Editing. (A) stelt het gen-speciϐieke DNA bindende 
domein voor (bijvoorbeeld een zink vinger). (B) stelt het epigenetische enzym voor. Met de pijltje wordt de 




de nieuwe cel. Epigenetische editing heeft een aantal voordelen ten opzichte van deze 
epigenetische medicijnen: 
• Waar de epigenetische medicijnen een effect kunnen hebben op alle genen in het 
genoom, wordt bij epigenetische editing het effect gestuurd naar één bepaald 
gen van interesse. Op deze manier is de kans op vervelende bijwerkingen sterk 
gereduceerd.
• Waar het effect van epigenetische enzymen slechts tijdelijk is (omdat het alleen 
maar de enzymen remt en niet daadwerkelijk zelf zorgt voor een verandering 
van de epigenetische marks) is het idee dat epigenetische editing blijvende 
veranderingen in genexpressie teweeg brengt gezien het kenmerk van 
epigenetische marks dat ze overerϐbaar zijn. 
• Waar de epigenetische medicijnen die op dit moment in de kliniek gebruikt 
worden alleen maar kunnen zorgen voor een inductie van genexpressie, kan 
epigenetische editing ook zorgen voor remming van genexpressie, aϐhankelijk 
van het epigenetische enzym dat gebruikt wordt. 
Ook andere benaderingen die momenteel onderzocht worden om genexpressie 
te veranderen hebben nadelen ten opzichte van epigenetische editing. SiRNA is een 
benadering waarbij de tussenvorm van gen naar eiwit (RNA) afgebroken wordt en 
op deze manier de productie van een eiwit wordt verminderd. Het nadeel hier is dat 
er heel veel RNA aanwezig is in een cel en dat het constant geproduceerd wordt. Het 
siRNA moet dus constant toegediend worden. Bij Epigenetische Editing wordt het gen 
zelf getarget, waarvan er maar twee kopieën per cel zijn. cDNA is een kopie van een 
bepaald gen wat ingebracht wordt in een cel om voor een verhoogde eiwitproductie te 
zorgen. Het nadeel hiervan ten opzichte van epigenetische editing is dat het gereguleerd 
wordt door artiϐiciele systemen en dus het eiwit niet in de natuurlijke hoeveelheden 
produceert. Ook zorgt het maar voor de productie van één vorm van een eiwit terwijl er 
in de natuurlijk situatie vaak meerdere vormen geproduceerd worden.
HOOFDSTUK 2
Na een algemene introductie in hoofdstuk 1 is in hoofdstuk 2 een review te vinden 
van het werk van waarbij actief epigenetische enzymen naar een speciϐieke plek zijn 
gebracht. In de meeste van de beschreven studies is eerst een stukje synthetisch DNA 
in het genoom gezet waarna gebruik gemaakt is van DNA bindende domeinen waarvan 
bekend is dat ze dat stukje DNA kunnen herkennen. Deze DNA bindende domeinen zijn 
echter niet aan te passen om een bepaald gewenst stukje DNA te herkennen, zoals dat wel 
het geval is voor zink vingers. Interessant genoeg is in veel van de studies beschreven in 
het review in hoofdstuk 2 een verandering waargenomen in epigenetische marks of in 




informatie als in genexpressie bewerkstelligd, wat een indicatie is dat de verandering 
van epigenetische informatie inderdaad een direct gevolg op genexpressie kan hebben 
aangezien het targeten van inactief gemaakte enzymen niet tot hetzelfde effect leidde. 
Zowel activatie of verhoogde expressie van genen als uitschakeling of verminderde 
genexpressie is bewerkstelligd. Hoewel dit dus veelbelovend lijkt, zijn er slechts een 
paar voorbeelden bekend van gen-speciϐieke targeting van epigenetische enzymen. Dit 
is echter wel van belang om genen van interesse te kunnen beïnvloeden en te voorkomen 
dat de epigenetische marks van andere genen veranderd worden. 
HOOFDSTUK 3
In hoofdstuk 3 is een experimentele studie beschreven waarin we hebben 
geprobeerd om epigenetische informatie en/of genexpressie te veranderen. Hiervoor 
is in dit hoofstuk een modelsysteem gebruikt dat bestaat uit cellen met een heleboel 
kopien van een stukje target DNA erin geïntegreerd. Als DNA bindend domein is in deze 
study een eiwit gebruikt dat aan één zo’n kopie van dat speciϐieke stukje target DNA kan 
binden. Vervolgens zijn aan dat DNA bindende domein verschillende eiwitten gekoppeld 
waarvan beschreven is dat ze een enzymatische werking hebben op histonmodiϐicaties 
of DNA methylatie. De enzymen gebruikt in dit proefschrift zijn allemaal beschreven 
in staat te zijn óf activerende epigenetische marks toe te voegen, óf onderdrukkende 
marks weg te halen. Daarom is het idee dat het effect van deze speciϐieke epigenetische 
enzymen uiteindelijk zou kunnen leiden tot activatie van genexpressie. Het gebruik van 
de vele kopiën van target DNA zou in theorie kunnen leiden tot een versterkt effect 
omdat er meerdere epigenetische enzymen tegelijk aanwezig kunnen zijn op een klein 
gebied. In hoofdstuk 3 hebben we inderdaad aanwijzingen gevonden dat bepaalde 
enzymen in staat zijn om het DNA wat minder gecondenseerd te maken. Dit leidde 
vooralsnog nog niet tot signiϐicante inductie van genexpressie in een hele celpopulatie. 
Wanneer gekeken werd naar een speciϐieke cel werden echter wel indicaties gevonden 
voor inductie van target genexpressie.
HOOFDSTUK 4
In hoofdstuk 3 werd de werkzaamheid van epigenetische enzymen in een artiϐicieel 
systeem onderzocht. Om daadwerkelijk Epigenetische Editing te bewerkstelligen zullen 
deze enzymen echter uiteindelijk naar endogene genen getarget moeten worden. Dit 
betekent dus dat de epigenetische enzymen maar naar één plek worden getarget in 
plaats van naar veel kopiën van target DNA zoals in hoofdstuk 3. 
In hoofdstuk 4 hebben we voor een bepaald gen, EpCAM, bepaald welke epigenetische 
marks het gen heeft in eierstokkankercellen. Het bleek dat er eierstokkankercellen zijn 




laag tot expressie komt. Interessant genoeg bleek deze expressie volledig samen te 
hangen met de hoeveelheid DNA methylatie in het stukje aan het begin van een gen, 
de promoter. Als deze promoter onbereikbaar is voor activerende eiwitten vanwege 
bijvoorbeeld DNA methylatie, kan dit ervoor zorgen dat het gen geen eiwit produceert. 
Naast de DNA methylatie werden ook bepaalde histon modiϐicaties gevonden die 
geassocieerd worden met actieve genen of passieve genen. Hierin bleek ook het patroon 
grotendeels overeen te komen met de expressie van het gen. Bovendien konden we 
aantonen dat met epigenetische medicijnen de genexpressie gemanipuleerd kon 
worden. EpCAM lijkt dus een erg interessant modelgen om te zien of we verandering 
van epigenetische informatie op dat speciϐieke gen kunnen beïnvloeden en of dit een 
verandering in genexpressie tot gevolg heeft. Dit is verder uitgevoerd in hoofdstuk 6.
HOOFDSTUK 5
ICAM-1 is een ander gen dat epigenetisch gereguleerd is in eierstokkanker. In 
hoofdstuk 5 hebben we getest of zink vingers het gen nog steeds konden binden als 
het epigenetisch uitgeschakeld was. Dit hebben we gedaan door eerder beschreven 
zink vingers die binden aan het ICAM-1 gen te fuseren aan eiwitten die genexpressie 
kunnen induceren onaϐhankelijk van de epigenetische informatie op het target gen. 
Inderdaad konden we zien dat deze fusie-eiwitten van zink vingers en activatie-eiwitten 
(VP64) in de eierstokkankercellen waar ICAM-1 uitgeschakeld was door epigenetische 
informatie konden zorgen voor inductie van ICAM-1 genexpressie. Dit gen is dus ook een 
interessant modelgen, niet alleen omdat het epigenetisch uitgeschakeld is in bepaalde 
eierstokkanker cellen maar bovendien omdat het gen weer aan kan worden gezet door 
fusie-eiwitten met zink vingers. Bovendien zagen we dat die reactivatie van ICAM-1 
expressie er voor zorgde dat de kankercellen langzamer gingen groeien.
HOOFDSTUK 6
Net als voor ICAM-1 is eerder voor EpCAM beschreven dat na epigenetische 
silencing van het gen een zink vinger gefuseerd aan VP64 kan zorgen voor inductie 
van genexpressie. Daarom hebben we in hoofdstuk 6 deze informatie gebruikt om 
Epigenetische Editing toe te passen. De epigenetische enzymen die getest zijn in 
hoofdstuk 3 (en andere) werden in hoofdstuk 6 gefuseerd aan de eerder beschreven 
zink vingers voor EpCAM en ICAM-1. Na behandeling van de eierstokkankercellen 
met de zink vinger fusie-eiwitten gebruikt in dit hoofdstuk konden geen verschillen 
gedetecteerd worden in de epigenetische informatie van de beide genen. Ook was er 
geen verschil in de expressie van de genen te zien. Dit kan het gevolg zijn van vele 





Uit het onderzoek wat beschreven is in dit proefschrift valt te concluderen dat er 
nog veel onderzocht moet worden voordat de activatie van onbedoeld uitgeschakelde 
genen via Epigenetische Editing een feit is. Er zijn veel factoren die een rol spelen in 
de expressie van genen en die factoren kunnen elkaar makkelijk en snel beïnvloeden. 
Het is belangrijk dat gezocht gaat worden naar de meest effective modiϐicatie voor 
activatie van genexpressie via Epigenetische Editing. Lastig genoeg is de kans groot 
dat dit niet één modiϐicatie, maar een combinatie van modiϐicaties betreft. Als eenmaal 
genspeciϐieke activatie van genexpressie via Epigenetische Editing is bewerkstelligd zijn 
er nog vele opties om de effectiviteit te vergroten en te optimaliseren. Bijvoorbeeld is het 
waarschijnlijk nodig om te zorgen voor daadwerkelijke genspeciϐiciteit, zodat niet per 
ongeluk andere genen ook beïnvloed worden door het getargete epigenetische enzym. 
Ook moet verzekerd worden dat de enzymen niet al ergens een effect hebben voordat ze 
bij hun speciϐieke target aangekomen zijn. Met de vooruitgang in dit onderzoeksgebied 
(recente publicaties van Epigenetische Editing om genen uit te schakelen en vele 
andersoortige targeting studies die met epigenetische enzymen genen aan zetten) komt 
het gebruik van Epigenetische Editing als een gereedschap voor het onderzoeken van het 
effect van bepaalde epigenetische informatie op speciϐieke genen van interesse binnen 
handbereik. Ook de biologische functie van genen (en de eiwitten die ze produceren) 
kan makkelijker en op een meer natuurlijke manier worden onderzocht door ze via 
Epigenetische Editing aan of uit te zetten vanaf de natuurlijk promoter dan via de 
conventionele weg (siRNA en cDNA). Mocht dit alles uiteindelijk succesvol werken en 
goed geoptimaliseerd zijn, dan zou Epigenetische Editing eventueel zelfs een nieuwe 
therapie voor kanker en andere epigenetisch gereguleerde ziektes worden.
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